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WHO   World Health Organization  
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ZNRF3  Zinc RING finger 3 
ZR   Zona Reticularis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
Abstract 
 
Adrenocortical tumors (ACT) are common neoplasms that are frequently found incidentally.  
Most of the tumors are benign while malignant adrenocortical carcinoma (ACC) is comparably 
more rare but often highly aggressive and with poor prognosis. The two major reasons for the 
clinical outcome of ACC are the difficulty of identifying malignant tumors at earlier stages and 
the non-existence of effective therapies. 
The focus of this dissertation was the identification of the molecular patterns that characterize 
and are specific of adrenal malignancy, which could be useful in the clinical setting for the 
differential diagnosis of adrenocortical tumors. Once characterized the molecular features of 
ACC, our research efforts were then diverted towards the understanding of how the molecular 
fingerprints of ACC could be translated into different biological behaviors looking for insights 
to disclose potential therapeutic targets.  
For that, we evaluated the expression pattern of a high range of molecular markers, involved 
in cell cycle regulation [p53, p21, murine doble minute-2 (MDM2), p27 and cyclin D1], cell 
proliferation (Ki-67), steroidogenesis [steroidogenic acute regulatory protein (StAR), 11β-
hydroxylase (CYP11B1), aldosterone synthase (CYP11B2) and 17α-hydroxylase], cell 
invasion (CD31 and D2-40), cell adhesion (N-, E- and P-cadherin and β-catenin), cell 
immortalization (telomerase) and cell signaling [insulin-like growth factor 2 (IGF2), phospho-
ERK and phospho-p38] in tumor and normal adrenal tissues, to assess their possible 
usefulness for pathological diagnosis. By performing these studies, we showed that Ki-67 and 
p27 were the markers with the highest power to discriminate ACC from adrenocortical 
adenomas (ACA). Ki-67 is a well-stablish marker of malignancy in several cancers that has 
also been reported to be a useful tool for the differential diagnosis of ACT. In contrast, the 
utility of p27 for the pathological diagnosis of ACC had not been previously identified. So, we 
have demonstrated for the first time, that p27 could even be a more powerful diagnostic tool 
than Ki-67, since it is able to exclude all ACA and diagnose more ACC when compared to Ki-
67. Besides that our results suggested that p27 could possibly have an unknown role in 
adrenocortical tumorigenesis and thus represent a potential treatment target. 
In addition, CYP11B1 was demonstrated to be very accurate for the distinction between ACC 
and adrenocortical adenomas with Cushing syndrome (ACAc), while CYP11B1 and CYP11B2 
dual negativity was shown to be very specific for malignancy. Moreover, the incomplete pattern 
of the CYP11B1, CYP11B2 and 17α-hydroxylase expression in ACC can justify the increased 
secretion of steroid metabolites precursors witnessed in ACC which was observed in previous 
studies. 
2 
IGF2 also proved to be very useful to differentiate ACC from non-functioning adrenocortical 
adenomas (ACAn). Besides that, the incubation of the adrenocortical carcinoma cell line 
H295R, with IGF2 dose-dependently increased cell proliferation and viability, while IGF2 at 
different concentrations also modulates cell metabolism. So, we demonstrated that different 
IGF2 concentrations in ACC could be responsible for different biological behaviors of ACC and 
influence the response to treatment. 
Another molecular fingerprint that was identified as potentially useful to distinguish different 
ACT is the pattern of expression of the adhesion molecule N-cadherin, due to the fact that the 
majority of the ACC depict a loss of N-cadherin membrane expression while all ACA retain N-
cadherin membrane expression. Besides that, a positive correlation between the loss of the N-
cadherin expression and the absence of telomerase expression was observed, suggesting the 
existence of a telomerase reverse transcriptase (TERT) non-canonical function in cell 
adhesion. We also found that TERT promoter mutations are infrequent in ACC and nuclear 
telomerase expression is only present in a minority of cases. 
As ACC are often metastasized when first diagnosed, we decided to assess whether blood 
and lymph vessel density within ACT was correlated with malignancy or tumor functionality. 
Angiogenesis was shown to be increased in ACC, suggesting that this phenomenon may have 
an important role in ACT biological behavior, while lymph vascular density seems to be more 
closely related to the tumor functional status than malignancy.  
Finally, once MAPK/MEK/ERK pathway activation is frequently dysregulated in the majority of 
human cancers, we decided to analyze the status of this pathway and to explore the potential 
of its inhibition as a therapeutic target in ACC. For that, we incubated H295R ACC cell line with 
different concentrations of a specific MAPK/MEK/ERK pathway inhibitor (PD184352). This 
inhibition lead to a significant decrease in cell proliferation as well as in steroidogenesis, 
besides increasing the redox state of the H295R cells. Overall, these findings suggest that 
MEK/MAPK/ERK signaling has a role in adrenocortical tumorigenesis that can be potentially 
targeted for ACC treatment, which if successfully achieved could lead to better clinical 
outcomes than the currently available therapy. 
In summary, the results presented in this thesis are key to improve the pathological diagnosis 
of adrenocortical tumors and for driving the future development of novel anti-tumor therapies. 
 
  
3 
Resumo 
 
Os tumores adrenocorticais (ACT) são neoplasias comuns que frequentemente são detetados 
por acidente. A maioria destes tumores são benignos, enquanto que os tumores 
adrenocorticais malignos (ACC) são raros mas extremamente agressivos e com mau 
prognóstico. As duas principais razões para o desfecho clínico dos ACC são a dificuldade em 
identificar estes tumores malignos em fases precoces e a atual inexistência de terapias 
eficazes. 
O objetivo desta dissertação foi a identificação de padrões moleculares que possam 
caracterizar e serem específicos da malignidade do ACT, e que possam ser úteis no cenário 
clinico para o diagnóstico dos tumores do córtex da suprarrenal. Uma vez identificados esses 
padrões moleculares nos ACC, focamos a nossa investigação na compreensão de como é 
que essas características moleculares poderiam ser traduzidas em diferentes 
comportamentos biológicos, levando à descoberta de potências alvos terapêuticos.  
Para isso, avaliamos o padrão de expressão de uma variedade de marcadores moleculares 
envolvidos na regulação do ciclo celular (p53, p21, murine doble minute-2 (MDM2), p27 e 
ciclina D1), proliferação celular (Ki-67), esteroidogénese [steroidogenic acute regulatory 
protein (StAR), 11β-hydroxylase (CYP11B1), aldosterone synthase (CYP11B2) and 17α-
hidroxilase], invasão celular (CD-31 e D2-40), adesão celular (N-, E- e P-Caderina e β-
catenina), imortalização celular (telomerase) e sinalização celular [insulin-like growth factor 2 
(IGF2), fosfo-ERK and fosfo-p38] em tecido adrenocortical tumoral e normal, de modo a 
verificarmos a sua potencial utilidade no diagnóstico desta patologia. Realizando estes 
estudos, demonstramos que o Ki-67 e o p27 foram os marcadores com maior poder 
discriminativo no diagnóstico de ACC em relação aos adenomas adrenocorticais (ACA). O Ki-
67 é um marcador de malignidade já bem estabelecido em vários cancros e já reportado 
anteriormente como útil no diagnóstico diferencial de ACT. Pelo contrário, a utilidade do p27 
no diagnóstico patológico de ACC nunca tinha sido identificada. Assim, demonstramos pela 
primeira vez que o p27 pode ser uma ferramenta de diagnóstico mais poderosa que o Ki-67, 
uma vez que consegue excluir todos os adenomas e diagnosticar mais carcinomas do que o 
Ki-67. Além disso, os nossos resultados sugerem que o p27 tem possivelmente, um papel 
ainda desconhecido na tumorigénese de ACC e pode representar um potencial alvo 
terapêutico. 
O CYP11B1 também demonstrou ser um marcador muito preciso na diferenciação entre ACC 
e adenomas adrenocorticais com síndrome de Cushing (ACAc). No que se refere à 
inexistência de marcação para ambos os CYP11B1 e o CYP11B2, esta demonstrou ser muito 
específico para definir malignidade. Adicionalmente, a baixa expressão do CYP11B1, 
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CYP11B2 and 17α-hidroxilase nos ACC pode justificar a elevada secreção de metabolitos dos 
percussores de esteroides pelos ACC reportada em estudos anteriores. 
O IGF2 também provou ser muito útil a distinguir ACC de adenomas adrenocorticais não 
funcionantes (ACAn). Por outro lado, a incubação da linha celular de carcinoma 
adrenocortical, H295R, com diferentes concentrações de IGF2, levou a um aumento dose-
dependente da proliferação celular e viabilidade, ao tempo que diferentes concentrações de 
IGF2 modularam o metabolismo celular. Assim, demonstramos que diferentes concentrações 
de IGF2 nos ACC podem ser responsáveis por diferentes comportamentos biológicos e 
influenciar a resposta aos tratamentos.  
Outra impressão molecular que foi identificada como potencialmente útil para o diagnóstico 
diferencial de ACT é a expressão da molécula de adesão N-caderina, devido ao facto da 
maioria dos ACC apresentar perda da expressão membranar da N-caderina ao passo que 
todos os ACA mantiveram essa expressão. Também foi observada uma correlação positiva 
entre a perda de expressão membranar da N-caderina e a ausência da expressão nuclear da 
telomerase, sugerindo a existência de uma função não canónica da telomerase reverse 
transcriptase (TERT) na adesão celular. Também observámos que as mutações no promotor 
da TERT são raras nos ACC e que a expressão nuclear da telomerase está presente apenas 
numa minoria dos casos. 
Como a maioria dos ACC já metastizaram aquando do diagnóstico, decidimos avaliar a 
densidade de vasos sanguíneos e linfáticos dentro dos ACT e correlacionar essa densidade 
com a malignidade e com a funcionalidade tumoral. Observamos que a angiogénese estava 
aumentada nos tumores malignos enquanto que a densidade de vasos linfáticos parece estar 
mais associada com a funcionalidade dos tumores do que com a sua malignidade. 
Finalmente como a via de sinalização MAPK/MEK/ERK se encontra frequentemente 
desregulada na maioria dos tumores humanos, nós decidimos avaliar a ativação desta via 
ACC e explorar o seu potencial como um alvo terapêutico. Para isso, incubamos a linha celular 
H295R com diferentes concentrações de um inibidor específico da via MAPK/MEK/ERK 
(PD184352). Esta inibição levou a uma diminuição significativa da proliferação celular bem 
como da esteroidogénese. Por outro lado, aumentou o estado redox das células H295R. No 
general, os nossos resultados sugerem que esta via tem um papel na tumorigénese 
adrenocortical e que pode ser um alvo potencial no tratamento de ACC, que pode levar a 
melhores resultados clínicos do que a terapia atualmente disponível. 
Em sumário, os resultados presentes nesta tese são importantes tanto para a melhoria do 
diagnóstico patológico dos tumores adrenocorticais como também para impulsionar o 
desenvolvimento futuro de novas terapias anti-tumorais.
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1.1 Adrenal gland 
 
The adrenal glands are endocrine organs located above the superior pole of each kidney. Each 
gland has two distinct parts: an outer region, near the adrenal capsule, designated adrenal 
cortex that comprises 80% of the adrenal mass, and an inner region, so called adrenal medulla 
(Nussey and Whitehead 2001).  
The adrenal cortex is responsible for adrenal steroid secretion and it is divided into three 
distinct morphological layers with different functionality, which are the glomerulosa, the 
fasciculata and the reticularis layers (Figure 1). These three layers present specific enzymatic 
features that are needed for the production of different steroids (Nussey and Whitehead 2001).   
 
 
Figure 1 - Human adrenal gland stained by Masson tricromium (10x). Costa MM (not published): Ca- 
capsule; ZG- zona glomerulosa; ZF- Zona fasciculata; ZR-Zona reticularis; M- medulla. 
 
The outer layer is the glomerulosa layer that is responsible for mineralocorticoids production, 
predominantly aldosterone. Mineralocorticoid secretion is mainly regulated by angiotensin II 
but it can also be influenced by adrenocorticotropic hormone (ACTH) and potassium. The 
intermediate layer is fasciculata that produces glucocorticoids, mainly cortisol, having ACTH 
as the major regulator. The inner layer is reticularis that produces adrenal androgens, namely 
dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEA-S), which can 
be converted into testosterone or aromatized to estrogens in peripheral organs, such as the 
adipose tissue (Figure 2) (Mulrow and Franco-Saenz 1996, Nussey and Whitehead 2001). 
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The adrenal medulla, located in the center of the adrenal gland, is considered to be a modified 
sympathetic ganglion, as it produces catecholamines, such as norepinephrine and epinephrine 
(McCorry 2007). 
Adrenal tumors can arise both from the adrenal cortex or medulla. Tumors originating from the 
cortex are named adrenocortical tumors, while those originating from the medulla are 
designated pheochromocytomas (Lee and Duh 2009). 
 
 
 
 
Figure 2 - Steroidogenesis in the different layers of the adrenal cortex. In red are represented the 
enzymes located in the mitochondria and at blue the enzymes located in the smooth endoplasmic 
reticulum. 
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1.2 Adrenocortical tumors  
 
Adrenocortical tumors (ACT) are common tumors of the adrenal cortex, affecting 3% to 10% 
of the human population (Else, Kim et al. 2014). These can be classified according to their 
biological behavior in benign or malignant, and according their functionality in non-functioning 
or functioning tumors (Lee and Duh 2009). The majority of the ACT are benign, non-functioning 
and discovered incidentally during imaging for unrelated clinical reasons (Pignatelli 2011).  
The detection of non-functioning adrenocortical tumors (both benign and malignant) increased 
significantly over the last years, due the widespread use of computed tomography (CT), 
magnetic resonance imaging (MRI) and abdominal ultrasonography (Low, Dhliwayo et al. 
2012, Audenet, Mejean et al. 2013).  
Functioning ACT can secrete steroids autonomously and independently of ACTH or renin-
angiotensin system regulation, leading to various clinical syndromes depending on the 
secreted steroids, namely Conn’s syndrome when aldosterone secreting, Cushing’s syndrome 
for cortisol secreting or virilizing syndrome in result of androgen production (Audenet, Mejean 
et al. 2013, Else, Kim et al. 2014). Some malignant tumors are able to secrete precursor 
steroids or even inactive steroids and hence in spite of being hormonally functioning do not 
produce a clinical syndrome (Arlt, Biehl et al. 2011). The symptoms related with excessive 
hormone secretion can occasionally accelerate the adrenal tumor finding. Thus, due to the 
elevated possibility of apparently asymptomatic patients harboring functional tumors, 
according to the European Network for the Study of Adrenal Tumors (ENSAT), all patients with 
identified adrenal masses should undergo endocrine function tests for glucocorticoid (minimum 
3 of 4 tests), sexual steroids and steroid precursors production, mineralocorticoid excess and 
catecholamine excess (Fassnacht, Johanssen et al. 2009, Berruti, Baudin et al. 2012). 
The prognosis of adrenocortical carcinomas is very different from adrenocortical adenomas 
which stresses the importance of differential diagnosis between the two entities (Soon, 
McDonald et al. 2008, Lafemina and Brennan 2012). However, distinguishing benign from 
malignant adrenocortical tumors is not always simple. So far, the size of the lesion on the 
imaging studies are the strongest predictor of the adrenocortical malignancy and according to 
recent guidelines, ACT with more than 4 cm should be treated surgically. (Nieman 2010, 
Kapoor, Morris et al. 2011). Although the tumors size needs to be taken into account, it should 
not be used alone in order to avoid disregarding small sized malignant tumor masses at a 
stage where these could have a better prognosis (Lafemina and Brennan 2012). In addition to 
size, a threshold value of 10 Hounsfield units (HU) of unenhanced CT scan was shown to have 
a high specificity and sensibility for the differential diagnosis of adrenocortical malignant 
lesions, particularly when associated with decreased contrast washout (Allolio and Fassnacht 
2006, Mazzuco, Durand et al. 2012).  
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After surgical removal, the pathological diagnosis is based on the tumor macroscopic 
characteristics, such as size, presence of an intact capsule, areas of necrosis or hemorrhage, 
adjacent organ invasion and lymph node metastasis. At the microscopic level, there are 
several morphological features used to assess malignancy whenever metastasis have not 
been identified. The most widely used method for pathological diagnosis is the Weiss scoring 
system that relies in criteria such as, nuclear grade, mitotic rate, abnormal mitosis, proportion 
of clear cells, necrosis, diffuse architecture, invasion of the tumor capsule, sinusoid  and 
venous invasion (Weiss 1984, Allolio and Fassnacht 2006, Lafemina and Brennan 2012). More 
recently, a modified Weiss scoring system has been proposed, based on the five strongest 
and more reliable criteria (mitotic rate, abnormal mitosis, proportion of clear cells, necrosis, 
and capsular invasion), thus eliminating the parameters that were considered to be subjective 
or difficult to interpret in the original Weiss system (Table 1) (Lau and Weiss 2009, Tissier 
2010). 
 
Table 1- Modified Weiss system used for establishing differential diagnosis between adrenocortical 
adenoma and adrenocortical carcinoma [adapted from (Lau and Weiss 2009)]. 
Histological Criteria 0 1 
Mitotic rate <5 per 50 high-power fields (HPF) >5 per 50 HPF 
Abnormal mitoses Absent 
Presence of abnormal 
distribution of chromosomes or 
excessive number of mitotic 
spindles 
Necrosis Absent Present 
Clear Cells 
 
Clear cells comprising > 25% of 
the tumor 
Clear cells comprising 25% or 
less of the tumor 
Capsular invasion Absence of capsular invasion 
Nests or cords of tumor 
extending into or through tumor 
capsule 
Weiss score calculation: 2x mitotic rate criterion + 2x clear cells criterion + abnormal mitoses + necrosis + 
capsular invasion (score of 3 or more suggests malignancy) 
 
1.2.1 Adrenocortical carcinomas 
 
Adrenocortical carcinomas (ACC) are rare tumors with an annual incidence of 1 to 2 cases per 
million persons worldwide (Roman 2006, Fassnacht, Libe et al. 2011, Chagpar, Siperstein et 
al. 2014, Else, Kim et al. 2014, Libe, Borget et al. 2015). ACC present two peaks of incidence, 
in children under 5 years old and in adults between 40 and 50 years of age, with a female/male 
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ratio of 1.5:1 (Roman 2006, Low, Dhliwayo et al. 2012, Chagpar, Siperstein et al. 2014). The 
tumors are even rarer in children although there is a region in South Brazil where their 
incidence is ten times higher than the rest of the world (Ribeiro, Michalkiewicz et al. 2000).  
The majority of the ACC are functional (50-60%), with Cushing’s syndrome alone being the 
most frequent presentation among adults (45%), followed by Cushing’s syndrome in 
association with a virilization syndrome (25%) (Ng and Libertino 2003, Allolio and Fassnacht 
2006, Pignatelli 2011).  
ACC may be also associated with hereditary syndromes (Table 2) such as Li-Fraumeni 
syndrome, Beckwith-Wiedemann syndrome, and multiple endocrine neoplasia type 1, Lynch 
syndrome, familial polyposis coli syndrome or more rarely even with congenital adrenal 
hyperplasia or Carney complex (Else, Kim et al. 2014). It must be stressed however, that the 
majority of ACC are in fact sporadic (Else 2012, Mazzuco, Durand et al. 2012, Chagpar, 
Siperstein et al. 2014). 
 
Table 2 - Hereditary Tumor syndromes associated to ACT [adapted from (Soon, McDonald et al. 2008)]. 
 
Hereditary tumor 
syndrome 
Gene (locus) Prevalence of ACT 
Li-Fraumeni syndrome 
TP53 (ch17p13), 
hCHK2 (ch22q12.1) 
ACC: 3%–4% 
Beckwith-Wiedemann syndrome 
IGF2, H19, CDKN1C, 
KCNQ1 (ch11p15) 
ACC: 5% 
Multiple endocrine neoplasia 1 MEN1 (ch11q13) ACA: 55%; ACC: rare 
Congenital adrenal hyperplasia CYP21B (ch6p21.3) 
ACA: 82%; hyperplasia: 100%; 
ACC: rare 
ACA: adrenocortical adenoma; ACC: adrenocortical carcinoma; ACT: adrenocortical tumor 
 
Adrenocortical carcinoma staging  
The disease stage and margin-free resection are the majors’ prognostic factors in ACC 
(Fassnacht, Johanssen et al. 2009, Berruti, Baudin et al. 2012). There are two main tumor–
node–metastasis (TNM) classifications to evaluate ACC, the one proposed by the International 
Union Against Cancer (UICC) in 2004 and more recently the TNM classification proposed by 
the ENSAT that seems to have an improved prognostic accuracy (Table 3) (Fassnacht, 
Johanssen et al. 2009, Fassnacht, Libe et al. 2011). 
According the ENSAT classification, the 5-year disease-specific survival rate is approximately 
82% for stage I, 61% for stage II, 50% for stage III, and 13% for stage IV (Fassnacht, 
Johanssen et al. 2009). The majority of the ACC are diagnosed in an advanced stage leading 
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to a poor prognosis (Else, Kim et al. 2014). The most common metastatic sites of the ACC are 
lung (46-79%), liver (44-93%), lymph nodes (18-73%) and peritoneum (16-79%) (Allolio, 
Hahner et al. 2004). 
 
Table 3 - World Health Organization (WHO)/ International Union Against Cancer (UICC) and European 
Network for the Study of Adrenal Tumors (ENSAT) classification of adrenocortical carcinoma [adapted 
from (Fassnacht, Johanssen et al. 2009) and (Lacroix 2016)]. 
Stage WHO/UICC (2004) ENSAT (2008) 
I T1; N0; M0 
II T2; N0; M0 
III 
T3; N0; M0 T3-4; N0; M0 
T1-2; N1; M0 T1-4; N1; M0 
IV 
T3; N1; M0 
Any M1 T4; N0-1; M0 
Any M1 
T1: tumor ≤5 cm; T2: tumor >5 cm; T3: tumor infiltration in surrounding tissue; T4: tumor invasion in adjacent organs;  
N0: no positive lymph nodes; M0: no distance metastases;  N1: positive lymph nodes;  M1: presence of distant 
metastasis 
 
Adrenocortical carcinoma treatment 
Surgery is the most important treatment for ACC, while complete surgical resection (R0) is the 
only potential curative approach (Figure 3) (Fassnacht, Johanssen et al. 2009, Libe 2015). 
Even though there is a high rate of ACC recurrence after R0 surgery, thus adjuvant therapy is 
mandatory (Libe 2015). Open adrenalectomy is the most consensual operation type, since 
laparoscopy carries a greater risk of malignant cell dissemination (Leboulleux, Deandreis et al. 
2010, Libe 2015). In addition, Reibentanz et al reported a significantly reduced risk for tumor 
recurrence and disease related death if the lymph nodes were resected during the 
adrenalectomy (Reibetanz, Jurowich et al. 2012).  
In patients with incomplete resection (R1) or undefined resection (Rx), adjuvant mitotane 
therapy is recommended to reduce the risk of recurrence and control the hormone excess, 
which can be conjugated with tumor irradiation (Allolio and Fassnacht 2006, Terzolo, Angeli et 
al. 2007, Fassnacht, Libe et al. 2011, Berruti, Baudin et al. 2012). However, the benefits of 
mitotane as adjuvant therapy have been questioned due to the lack of data from controlled 
clinical trials or from large prospective studies with consistent assessments of mitotane dosing 
(Kopf, Goretzki et al. 2001, Pignatelli 2011, Berruti, Baudin et al. 2012). Furthermore, the 
mitotate mechanisms of action and pharmacokinetics are still poorly understood, as there is a 
high variability of individual plasma levels that can be reached by a same given dosage 
(Hermsen, Fassnacht et al. 2011, Libe 2015).  
Chapter 1  
 
13 
Mitotane is also associated with significant toxicity, such as, adrenal insufficiency requiring 
compensation with hydrocortisone; vertigo; central nervous system disorders and gastro-
intestinal side effects (Kroiss, Quinkler et al. 2011, Libe 2015). 
 
 
 
Figure 3 - Flow chart for Adrenocortical carcinoma therapy [adapted from (Fassnacht, Libe et al. 2011, 
Else, Kim et al. 2014)]. 
 
In metastatic ACC when total resection is not technically possible, surgery can only be 
recommended to control excess hormone production, in slow progressing tumors or in tumors 
where 80% of their mass can be resected (Libe 2015). Still, the first line therapy for advanced 
ACC is mitotane alone or in the combination with other drugs, such as etoposide, doxorubicin, 
cisplatin (EDP) or with streptozotocin (Sz) (Fassnacht, Libe et al. 2011, Berruti, Baudin et al. 
2012). Mitotane in combination with EDP is associated with a better progression-free survival 
as compared to the mitotane with Sz combination, however no difference was observed on 
overall survival (Fassnacht, Libe et al. 2011, Libe 2015). 
 
 
Similarly to what is routinely used for other types of tumors, molecular and 
immunohistochemistry markers are now being considered of great potential as diagnostic and 
prognostic tools in adrenocortical tumors (Wachenfeld, Beuschlein et al. 2001, Allolio and 
Fassnacht 2006, Tissier 2010). Overexpression of Ki-67 proliferation marker and Insulin-like 
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growth factor 2 (IGF2) has been repeatedly demonstrated to be good predictors of malignancy 
and prognosis (Wachenfeld, Beuschlein et al. 2001, Tissier 2010, Lafemina and Brennan 
2012). However, no single or combination of molecular markers has yet been validated for use 
in the clinical practice. While more recently, the Helsinki Score has been proposed as diagnosis 
and staging tool for adrenocortical carcinomas, based not only on morphological features, such 
as the Weiss system, but also on the Ki-67 index (Helsinki Score: 3 × mitotic rate +5 × necrosis 
+ Ki-67 index). Duregon et al, verified that this score was better compared to the Weiss system 
in predicting ACC prognosis (Duregon, Cappellesso et al. 2016). 
 
1.3 Pathophysiology of Adrenocortical carcinoma 
 
The key molecular mechanisms that seem to be involved in the ACC pathophysiology are the 
activation of the Wnt pathway, IGF2 system and cell cycle alterations, which include those 
occurring in the well-studied tumor gene suppressor, p53. 
 
1.3.1 Wnt Signaling pathway  
 
Wnt signaling pathway is a highly conserved molecular cascade that requires glycoproteic 
extracellular ligands of the Wingless family (Wnts) for activation, which regulates a diversity of 
cellular processes essential for embryonic development and homeostatic systems (Komiya 
and Habas 2008). 
The majority of the early studies on the Wnt signaling pathway focused on the canonical β-
catenin-dependent pathway. However, in the past few years, other Wnt pathways have been 
disclosed including the non-canonical planar cell polarity pathway involved in ciliogenesis and 
the non-canonical Wnt/calcium pathway involved in cell movement (Komiya and Habas 2008). 
The β-catenin-dependent Wnt signaling role in the normal adrenocortical tissue development, 
homeostasis and tumorigenesis is well-stablished (Berthon, Martinez et al. 2012), and thus 
described here in further detail. 
 
Canonical Wnt signaling pathway 
β-catenin is a molecule associated with cadherin membrane proteins, which plays a structural 
role in the cell adhesion, as well as in the Wnt signaling pathway (Wijnhoven, Dinjens et al. 
2000, Komiya and Habas 2008) (Figure 4).  
In the absence of Wnt ligands, β-catenin is rapidly phosphorylated at critical NH2-terminal 
residues by glycogen synthase kinase 3β (GSK3-β), a member of a regulatory complex 
composed by proteins that also includes Axin, adenomatous polyposis coli (APC), casein 
kinase 1α (CK1α) and others. β-catenin phosphorylation results in its ubiquitination and then 
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targeted for degradation by the proteasome (Figure 4) (Komiya and Habas 2008). The bind of 
Wnt ligands to Frizzled (Fz) receptors with low-density lipoprotein receptor-related protein 
(LPR) coreceptor, results in the inhibition of the regulatory complex Axin-APC-GSK3-β, leading 
to β-catenin accumulation in the cytoplasm and nuclear translocation. In the nucleus, β-catenin 
regulates target gene expression by binding to the T cell-specific transcription factor/lymphoid 
enhancer-binding factor 1(TCF/LEF) (Figure 4) (Komiya and Habas 2008). 
In normal adrenal gland development, Wnt signaling activity is restricted to the zona 
glomerulosa and it is involved in cortex zonation (Berthon, Drelon et al. 2014, Walczak, Kuick 
et al. 2014). Besides that, β-catenin activation is associated with an upregulation of 
Angiotensin II receptor type 1 (AT1R) and aldosterone synthase (Berthon, Sahut-Barnola et 
al. 2010, Berthon, Drelon et al. 2014). 
 
β-catenin in adrenocortical carcinomas 
Tissier et al was the first author to demonstrate that Wnt signaling activation was frequent in 
adrenocortical tumors. Cytoplasmic and/or nuclear accumulation of β-catenin was found in the 
majority of the analyzed adrenocortical tumors, being higher in ACC (77%). Activating somatic 
mutation in CTNNB1, the gene that encodes β-catenin, was shown in a similar percentage of 
adrenocortical adenomas (ACA) (27%) and ACC (31%) and these mutations were observed 
only in ACT with abnormal β-catenin accumulation and most were point mutations on exon 3 
that corresponds to a GSK3-β/CK1 phosphorylation site. These mutations prevent β-catenin 
phosphorylation and induce accumulation of the protein. In ACA, β-catenin alterations were 
more frequent in nonfunctioning ACA, suggesting that β-catenin pathway activation might be 
involved in the development of non-functioning ACT adrenocortical adenomas and 
adrenocortical carcinomas (Figure 4) (Tissier, Cavard et al. 2005). 
This study was soon followed by others that showed CTNNB1 mutation to be present with 
equal prevalence in benign and malignant ACT, as well as associated steroidogenesis 
dysfunction and thus more prevalent in non-functioning tumors (Masi, Lavezzo et al. 2009, 
Bonnet, Gaujoux et al. 2011, Parviainen, Schrade et al. 2013, Kovach, Nucera et al. 2015). 
Through the comparison of ACC with different outcomes, CTNNB1 mutation and abnormal β-
catenin immunostaining was shown to be present predominantly in ACC with poor-outcome 
and ENSAT stages III and IV, thus with locally advanced or metastatic disease (Ragazzon, 
Libe et al. 2010, Gaujoux, Grabar et al. 2011). The presence of β-catenin nuclear staining was 
positively correlated with the presence of tumor necrosis and high mitotic count (Gaujoux, 
Grabar et al. 2011) 
Non-functioning ACA harboring CTNNB1 mutations were found to be significantly larger and 
heavier than those ACA without these mutations (Bonnet, Gaujoux et al. 2011). Durand et al, 
using microarray analysis identified the genes that are differentially expressed in ACT with 
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CTNNB1 mutations and high nuclear β-catenin immunostaining compared with wild-type 
CTNNB1 ACT without nuclear accumulation of β-catenin. Isthmin1, zebrafish homolog (ISM1), 
RalA-binding protein 1 (RALBP1), phosphodiesterase 2A cGMP-stimulated (PDE2A) and 
ectodermal-neural cortex 1 (ENC1) were found to be overexpressed in the mutated tumors, 
while phytanoyl-CoA 2-hydroxylase-interacting protein (PHYHIP) was found to 
underexpressed (Durand, Lampron et al. 2011). 
Using a transgenic mouse model with constitutive β-catenin activation in the adrenal cortex 
(ΔCat), Berthon et al observed a progressive sub-capsular cell hyperplasia of steroidogenic 
cells due to proliferation and ectopic expansion of sub-capsular cell populations resulting in 
cortical and medullary dysplasia. 10-month-old mice developed primary hyperaldosteronism 
and over a 17 months’ time course, ΔCat mice adrenal glands developed malignant 
characteristics such as neovascularization and local invasion, demonstrating β-catenin role as 
an adrenal oncogene, leading to the development of benign aldosterone-secreting ACT and 
promoting malignancy (Berthon, Sahut-Barnola et al. 2010). 
H295R is a human adrenocortical cancer cell line that harbors an activating CTNNB1 mutation 
on the GSK3β phosphorylation site. Gaijoux et al silenced the CTNNB1 gene in H295R cells 
leading to a specific Wnt signaling pathway inactivation with significant reduction of CTNNB1 
and AXIN2 expression, which was responsible for a decrease in cell proliferation, accumulation 
of cells in the G1 phase and increased apoptosis in vitro. CTNNB1 gene silenced H295R cell 
xenografts in athymic nude mice completely prevented tumor cells growth as compared to 
what was observed using unsilenced H295R cells of the control group (Gaujoux, Hantel et al. 
2013). 
 
Alterations of other components of the canonical Wnt pathway found in ACT 
Since abnormal β-catenin immunostaining is more frequent in ACC than in ACA, despite the 
similar rate of CTNNB1 mutations, it has been hypothesized that other components of Wnt 
signaling pathway could also be involved.  
Wnt pathway co-receptors LRP5 and LRP6 expression is more frequently observed in ACA 
that in ACC, with LPR5 expression being more frequent in virilizing ACT, while LRP6 
expression is similar regardless ACT subtype (Parviainen, Schrade et al. 2013).  
WNT-4 is one of the Wnt ligands that is a critical component of the reproductive system. WNT-
4 gene expression was found to be significantly higher in aldosterone producing ACA, and 
lower in cortisol secreting ACA with Cushing syndrome and virilizing ACC as compared to 
normal adrenal glands, ACC with Cushing syndrome and virilizing ACA (Kuulasmaa, 
Jaaskelainen et al. 2008). 
Axin and APC are negative regulators of Wnt signaling, as they belong to the regulatory 
complex that leads to β-catenin phosphorylation and posterior degradation. Chapman et al 
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observed 12-bp deletion in exon 7 of AXIN2 gene in 7% of ACA and 17% of ACC (Chapman, 
Durand et al. 2011). Guimier et al observed this AXIN2 genetic change only in 2% of ACC 
analyzed and no AXIN1 alterations were found in ACC (Figure 4) (Guimier, Ragazzon et al. 
2013). APC mutations were found in 2-3.3% of ACC cases (Gaujoux, Grabar et al. 2011, Assie, 
Letouze et al. 2014, Zheng, Cherniack et al. 2016).   
Zinc RING finger 3 (ZNRF3) is also associated with the Wnt receptor complex that inhibits Wnt 
signaling by promoting Fz and LRP6 receptors degradation (Hao, Xie et al. 2012). Assié et al 
reported the finding of ZNRF3 gene somatic alterations in 21% of ACC, which included 
homozygous deletions and mutations. In their ACC series, CTNNB1 and ZNRF3 alterations 
were found to be mutually exclusive. ACC with altered ZNRF3 presented β-catenin gene 
targets activation, but it was weaker than in ACC with CTNNB1 mutations (Assie, Letouze et 
al. 2014). Another research group has only observed ZNRF3 gene alterations to be present in 
12.2% of the analyzed ACC cases (Juhlin, Goh et al. 2015). The Cancer Genome Atlas (TCGA) 
study found ZNRF3 homozygous deletion (chr22q12.1) and non-silent mutations of this gene 
in 16% and 19.3% of  ACC, respectively (Zheng, Cherniack et al. 2016). ZNRF3 role as tumor 
suppressor gene in ACC has been confirmed by Hanin et al  after observing that ZNRF3 
overexpressing H295R cells showed decreased cell proliferation and an increased apoptosis, 
while ZNRF3 silenced H295R cells were protected against apoptosis (Figure 4) (Hanin, Marthe 
et al. 2016).  
 
Wnt pathway as a treatment target for ACC 
The accumulated evidence supporting the role of the Wnt pathway in ACT tumorigenesis, 
compounds that inhibit β-catenin transcription, such as PKF115-584 and PNU74654, were 
tested in vitro to evaluate their therapeutic potential for ACC.  
PKF115–584 dose-dependently inhibited H295R proliferation, even in the presence of 
increased steroidogenic factor-1 levels, a protein well-known to be involved in this cell line  
proliferation; while it also decreased the percentage of H295R cells in S-phase and increased 
apoptosis (Doghman, Cazareth et al. 2008). PNU-74654 also decreased H295R proliferation 
and increased early and late apoptosis. Besides that PNU-74654 inhibited the H295R 
steroidogenesis, decreasing cortisol, testosterone, androstenedione production levels, SF1 
and CYP21A2 gene expression and protein levels of steroidogenic acute regulatory protein 
(StAR) and aldosterone synthase. This study confirmed the role of Wnt pathway in the control 
of initial and late steps of steroidogenesis (Leal, Bueno et al. 2015). Therefore, this data 
supports that these inhibitors may become useful for treatment of tumors with activated Wnt 
signaling pathway. 
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Figure 4 - Schematic representation of the canonical Wnt signaling pathway. In the absence of Wnt 
ligands, β-catenin is rapidly phosphorylated by GSK3-β, a member of a regulatory complex composed 
by Axin, APC and CK1α. β-catenin phosphorylation results in its ubiquitination and degradation. ZNRF3 
is associated with the Fz receptor complex that inhibits Wnt signaling pathway by promoting Fz receptor 
degradation. Binding of Wnt ligands to Fz receptors with the correceptor LPR, activates dishevelled 
(DVL) that inhibits the regulatory complex Axin-APC-GSK3-β leading to β-catenin accumulation in the 
cytoplasm and nuclear translocation. In the nucleus, β-catenin regulates target gene expression by 
binding to TCF/LEF. Gene and proteins alterations already described in the ACC are indicated. 
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1.3.2 IGF2 System  
 
IGF2 is a growth factor secreted mainly in the liver but also in the majority of the tissues where 
it can act in an autocrine or a paracrine way. IGF2 is described to regulate the cell growth, 
differentiation and metabolism that is mostly expressed during embryogenesis to promote fetal 
growth (Livingstone 2013).  
IGF2 gene is located at chr11p15 and it is only expressed from the paternal allele, while the 
maternal one is imprinted by promoter methylation (DeChiara, Robertson et al. 1991). The 
chr11p15 region is organized in two different clusters: a telomeric domain that includes the 
IGF2 gene and the H19 gene and a centromeric domain that includes the CDKN1C gene 
(Figure 5) (DeChiara, Robertson et al. 1991, Ribeiro and Latronico 2012). The CDKN1C 
encodes a cyclin dependent kinase inhibitor that regulates the G1-S phase of the cell cycle 
and its role in the ACT that will be further detailed under the “Cell Cycle” topic of this Thesis.  
 
IGF2 overexpression in adrenocortical tumors 
Loss of the maternal allele or loss of the imprinting with the duplication of the paternal allele 
leads to increased IGF2 expression and decreased H19 and CDKN1C expression. Alterations 
in the chr11p15 region are frequently observed in sporadic ACT (Gicquel, Raffin-Sanson et al. 
1997, Ribeiro and Latronico 2012) (Figure 5).  
 
 
Figure 5 - Alterations of chr11p15 in normal and malignant adrenocortical tissue. The imprinted 
chr11p15 locus contains the genes CDKN1C, IGF2, and H19. In normal adrenocortical tissue, only the 
paternal allele of the IGF2 gene is expressed and the maternal alleles of CDKN1C and H19 are 
expressed. In adrenocortical carcinoma, paternal isodisomy with loss of the maternal allele is frequently 
observed, which leads to IGF2 overexpression.  
 
Gicquel et al described that loss of heterozygosity (LOH) in chr11p15, characterized by the 
loss of the maternal allele and duplication of paternal one, and/or IGF2 gene overexpression 
were found in 93.1% of ACC and in only 8.6% of ACA (Gicquel, Raffin-Sanson et al. 1997). 
LOH in chr11p15 was correlated with an increase of the Weiss score and associated with 
higher risk of ACC recurrence. It also showed to be a strong predictor of shorter disease-free 
survival (Gicquel, Bertagna et al. 2001).  
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Many studies have demonstrated that IGF2 gene expression was 10 to 20 fold higher in ACC 
when compared to ACA and normal adrenal glands (Ilvesmaki, Kahri et al. 1993, Gicquel, 
Raffin-Sanson et al. 1997, Boulle, Logie et al. 1998, Gicquel, Bertagna et al. 2001, de Fraipont, 
El Atifi et al. 2005, Giordano, Kuick et al. 2009, Soon, Gill et al. 2009, Ragazzon, Assie et al. 
2011, Guillaud-Bataille, Ragazzon et al. 2014, Nielsen, How-Kit et al. 2015). Higher IGF2 
expression levels were associated with more aggressive phenotype and risk of ACC 
recurrence (Boulle, Logie et al. 1998, Gicquel, Bertagna et al. 2001). Chr11p15 LOH was found 
to have a greater prognostic value when compared to IGF2 overexpression, suggesting that 
the loss of genes expressed from the maternal allele are important for ACC tumorigenesis 
(Gicquel, Bertagna et al. 2001) 
The IGF2 protein expression has also been reported to be 8 to 80 fold higher in ACC than in 
ACA or normal adrenal glands (Ilvesmaki, Kahri et al. 1993, Boulle, Logie et al. 1998, Erickson, 
Jin et al. 2001, Schmitt, Saremaslani et al. 2006, Soon, Gill et al. 2009), although no differences 
in IGF2 plasma levels have been described between patients with ACA, ACC or healthy 
volunteers (Patel, Ellis et al. 2014). The utility of IGF2 combined with Ki-67 for the differential 
diagnosis between ACC and ACA was found to be highly sensitive (96-100%) as well as 
specific (95.5-100%) (Schmitt, Saremaslani et al. 2006, Soon, Gill et al. 2009).  
When Guillaud-Bataille et al compared ACC with high and low mRNA IGF2 levels, these were 
found to present similar Weiss scores, Ki-67 indexes, ENSAT stages, overall and event-free 
survival rates and occurrence of metastasis, thus the authors concluded that IGF2 status 
correlates with malignancy but it is not a good prognosis marker (Guillaud-Bataille, Ragazzon 
et al. 2014). 
Transgenic mice overexpressing human IGF2, despite having increased IGF2 serum levels 
and moderate expression in the adrenal cortex, only depict mild adrenocortical hyperplasia 
due to the increased fasciculata volume and do not develop ACT (Weber, Fottner et al. 1999).  
In addition, in another study using two different transgenic mouse models, one overexpressing 
IGF2 specifically in the adrenal cortex and other overexpressing IGF2 and constitutively active 
β-catenin in the adrenal cortex, have shown that IGF2 was able to recruit adrenal progenitor 
cells but not to induce adrenocortical tumor development. In mice with constitutive β-catenin 
expression, IGF2 overexpression did not seem to influence benign β-catenin-induced tumors, 
although a mild increase of Weiss score and tumor proliferation was observed for ACC in a 
late stage (Drelon, Berthon et al. 2012). These studies suggest that IGF2 overexpression does 
not has a role in adrenocortical tumor development but could be involved in malignant 
progression (Weber, Fottner et al. 1999, Drelon, Berthon et al. 2012). 
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IGF receptors in adrenocortical tumors 
IGF2 actions are mediated by the IGF1 receptor (IGF1R), insulin receptor (IR) and IGF2 
receptor (IGF2R) (Alberini and Chen 2012, Iams and Lovly 2015). IR and IGF1R are tyrosine 
kinase receptors that when activated lead to phosphorylation of adaptor proteins belonging to 
the IR substrate (IRS) family or Src homology 2 domain-containing transforming protein (SHC). 
Phosphorylation of these proteins then leads to the activation of the mitogen-activated protein 
kinase (MAPK) pathway and the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. In turn, 
activated Akt triggers the subsequent activation of the mammalian target of rapamycin (mTOR) 
pathway (Figure 6). MAPK, PI3K/Akt and mTOR pathways are described to stimulate cancer 
cells proliferation, survival and metastasis (Livingstone 2013, Iams and Lovly 2015). IGF2R is 
structurally distinct from IR and IGF1R, being a mannose 6-phosphate receptor and not a 
tyrosine kinase receptor. IGF2 binding to IGF2R induces endocytosis, lysosomal trafficking 
and ligand clearance (Alberini and Chen 2012, Iams and Lovly 2015).  
In the adrenocortical tumorigenesis, IGF1R is thought to mediate most of the relevant 
biological effects of IGF2 (Ribeiro and Latronico 2012). IGF1R is present in normal adult 
human adrenocortical tissue and its expression is similar in ACA and normal tissue but higher 
in ACC (Kamio, Shigematsu et al. 1991, Weber, Auernhammer et al. 1997). Among ACA, those 
presenting with Cushing’s syndrome also seem to have higher IR expression when compared 
with ACA presenting with Conn’s syndrome (Kamio, Shigematsu et al. 1991). 
More recent studies have showed that in pediatric ACC, IGF1R expression was significantly 
higher in ACC than in ACA, and its expression was higher in ACC with metastases. Besides 
that two microRNAs (99a and 100) were demonstrated to be involved in the regulation of 
IGF1R expression in pediatric ACC (Almeida, Fragoso et al. 2008, Doghman, El Wakil et al. 
2010). Whereas in adults, IGF1R expression was similar in ACC and ACA and IGF1R 
amplification and overexpression were observed only in 1 of 69 ACT, suggesting that these 
events are infrequent (Ribeiro, Jorge et al. 2014).  
LOH at the IGF2R locus was found to occurs in 26% of ACT, which was higher in malignant 
(58%) as compared with benign tumors (9%), although it was not correlated with tumor 
expansion or hormonal secretion pattern (Leboulleux, Gaston et al. 2001). 
 
IGFBPs in adrenocortical tumors 
The bioavailability of IGF2 is modulated by a family of six high-affinity IGF binding proteins 
(IGFBPs). The IGFBPs -1 to -6 are secreted proteins that can also be found intracellularly. The 
major functions of these proteins are IGFs transportation, IGFs protection from proteolytic 
degradation when coupled to IGFBPs; and inhibition of the interaction between IGF2 and 
IGF1R, since IGF2 affinity for IGFBPs is higher than IGF1R (Ribeiro and Latronico 2012, 
Baxter 2014). In serum, IGF2 is mainly present in ternary complexes with acid labile subunit 
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(ALS) and IGFBP-3 and -5, which do not allow the interaction of IGF2 with the target tissues 
since these ternary complexes cannot pass the vascular epithelial layer. The other IGFBPs 
(IGFBP-1, -2, -4, -6) are also present in serum, being IGFBP-2 the most abundant. These 
IGFBPs, form with IGF2, binary complexes that can across the vascular epithelial layer 
(Forbes, McCarthy et al. 2012). 
IGFBP-3 gene expression was shown to be upregulated in ACC (Ilvesmaki, Liu et al. 1998, 
Soon, Gill et al. 2009) while IGFBP-5 was found to be decreased in ACC when compared to 
ACA (de Reynies, Assie et al. 2009). IGFBP-2, -4, -5 and -6 gene expression was lower in 
functioning ACC that in non-functioning ACC. Furthermore, lower IGFBPs expression in 
hormone-producing carcinomas was associated with higher IGF2 expression, in contrast with 
Cushing and Conn syndrome adenomas that had higher expression of IGFBPs when 
compared with non-functioning ACA (Ilvesmaki, Liu et al. 1998). 
Boulle et al noticed that overexpression of IGFBP-2 in ACC together with high levels of IGF2 
expression, suggesting that the malignant phenotype is associated with high expression of 
IGF2 and IGFBP-2. In addition, IGFBP-2 proteolytic fragments were present in ACC 
suggesting that IGFBP-2 proteolysis may increase IGF2 bioavailability and enhance its 
proliferative effects on adrenocortical tumor cells (Boulle, Logie et al. 1998).  
IGFBP-2 plasma levels of patients with ACA, ACC and healthy controls were compared and 
no significant difference was observed between patients with ACA or ACC complete remission 
and healthy controls. However, patients with metastatic disease had significantly higher 
IGFBP-2 plasma levels that were also inversely correlated with patient’s survival (Boulle, 
Baudin et al. 2001, Patel, Ellis et al. 2014). Besides that, other study showed that IGFBP-2 
levels were not correlated with the tumor weight, histological grade, tumor secretion or 
response to mitotane treatment (Boulle, Baudin et al. 2001). 
Therefore, despite the IGFBP-2 plasma levels have a poor sensitivity for ACC diagnosis, it can 
be a marker of tumor progression in patients with progressive metastatic disease. 
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Figure 6 - IGF2 signaling. The binding of IGF1 or IGF2 to IGF1R activates two distinct signal 
transduction pathways: MAPK responsible for cell proliferation and PI3-AKT that promotes anti- 
apoptotic effects. The binding of IGF2 to IGF2R targets IGF2 to induces lysosomal degradation of the 
ligand. Gene and proteins alteration already described in the ACC are indicated. (Due the similarity of 
the signaling mediated by IR and IGF1R, the IR initiated signaling is not shown). 
 
IGF system as a treatment target for ACC 
The fact that IGF1R was found to be deregulated in ACT and IGF2 overexpressed in ACC 
provided the rationale that IGF1R could be an important target to treat these tumors. Therefore, 
the therapeutic efficacy of IGF1R inhibition was tested in in vitro, in vivo and in clinical trials 
(Costa, Carneiro et al. 2016).  
NVP-AEW541, a small IGF1R inhibitor molecule, tested in ACC cell lines was able to decrease 
the cell proliferation in a dose- and time-dependent manner, as well as to induce apoptosis 
rate (Almeida, Fragoso et al. 2008). Barlaskar et al using a dual IGF1R antagonist approach 
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with NVP-AEW541 and a human monoclonal antibody (IMC-A12) in ACC tumor cells, also 
resulted in a dose-dependent decrease of cell proliferation.  
IGF1R inhibition also reduced ACC tumor xenografts growth in athymic nude mice in a more 
effective way than mitotane treatment. Furthermore, IGF1R inhibition and mitotane 
combination resulted in a greater suppression of tumor proliferation (Barlaskar, Spalding et al. 
2009).  
Figitumumab, a human monoclonal antibody that targets the IGF1R, was tested in a phase I 
dose-escalation study in patients with advanced solid tumors. No responses were observed in 
the 14 patients with previous treated metastatic ACC and no patients had stable disease for 
more than 6 months (Cohen, Baker et al. 2005, Haluska, Worden et al. 2010). Cixutumumab 
(IMC-A12), another antibody that targets IGF1R, was evaluated in combination with mitotane 
in 20 patients with metastatic ACC and a partial response was observed only in one patient 
(Lerario, Worden et al. 2014). Cixutumumab was also tested in combination with the mTOR 
inhibitor temsirolimus for the treatment of 42 patients with advanced solid tumors. Four of the 
10 patients with ACC had stable disease for longer than 8 months. More 26 patients were 
included in this cohort but no responses were observed except for the stable disease, where 
42% of the ACC patients achieved stable disease for at least 6 months (Naing, Kurzrock et al. 
2011). Linsitinib, an oral small molecule inhibitor of both IGF1R and IR was tested in clinical 
trials. In phase I, 15 patients with refractory ACC were treated with linsitinib and a partial 
response was showed only in two ACC patients (Jones, Kim et al. 2015). A double-blind, 
placebo-controlled phase III clinical trial evaluated the efficacy of linsitinib in 139 previously 
treated patients with advanced ACC, however linsitinib failed to improve the  progression-free 
survival  and the overall survival (Fassnacht, Berruti et al. 2015). 
So, despite the well-known influence of IGF2 system in the ACC pathophysiology, the clinical 
trials that used inhibitors of the IGF1R failed to produce satisfactory results in order to be used 
as therapeutic tools. 
 
 
1.3.3 Cell Cycle  
 
The cell cycle is a complex process that results in the cell division. It includes four distinct 
phases going from the cell growth, DNA replication, partition and distribution of the duplicated 
chromosomes and cell division (Figure 7) (Cooper 2000). This process is regulated by complex 
intracellular and extracellular signaling cascades that coordinate the different phases of the 
cell cycle to ensure a successful cell division (Cooper 2000, Lim and Kaldis 2013).  
Deregulation of the cell cycle is one of the most frequent events in tumor development. 
Therefore the understanding of its underlying mechanisms is essential to the knowledge of 
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tumorigenesis occurs and it allows the emergence of new possible therapeutic targets (Park 
and Lee 2003, Asghar, Witkiewicz et al. 2015).  
Cell cycle regulation is generally grouped in three waves that correspond to the transition 
points of the cell cycle: G1 to S; G2 to M and M to G1 (Figure 7) (Bertoli, Skotheim et al. 2013). 
The majority of the cell cycle regulation alterations in ACC was found to be present in the G1 
to S and G2 to M transitions (Appendix 1 of this Thesis) (Szabo, Tamasi et al. 2010).   
 
 
Figure 7- Schematic representation of the mammalian cell cycle. Cell cycle is mainly regulated by cyclin-
dependent kinase (CDK): CDK2, CDK4, CDK6 and Cdc2; cyclins (cyclin A, B, D and E) and CDK 
inhibitors (p15Ink4B, p16Ink4A, p18Ink4C, p19Ink4D, p21Cip1, p27kip1, p57Kip2. In red are 
represented the overexpressed cell cycle regulators and in green the underexpressed regulators in 
ACC. 
 
G1-to-S phase transition in adrenocortical carcinomas 
Cell cycle progression from G1 to S phase is mainly regulated by the cyclin-dependent kinases 
(CDK) (CDK-2, -4 and -6); cyclins (D and E), CDK inhibitors (p15, p16, p21, p27 and p57), the 
retinoblastoma protein (pRb), the c-myc, and the E2F transcription factor family (Bartek, 
Bartkova et al. 1996, Sherr 2000, Zajac-Kaye 2001). 
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CDK4 encodes the most important cyclin-dependent kinase protein CDK4 that plays a crucial 
role in the cell cycle G1-S phase transition. In ACC CDK4 was found to be amplified in 7% to 
17.9 % of the ACC (De Martino, Al Ghuzlan et al. 2013, Ross, Wang et al. 2014, Zheng, 
Cherniack et al. 2016). The CDK6 gene has also been described to be amplified in ACC 
although only in the more aggressive forms (de Reynies, Assie et al. 2009).Overexpression of 
CDK2 and CDK4 has also been reported in ACC (Ragazzon, Assie et al. 2011). 
One of the most frequent DNA copy number changes in ACC confirmed by several studies has 
been gains in chromosome (chr)12, combined with the amplification of CDK4 and CDK2 
(located at chr12q13) (Zhao, Speel et al. 1999, Dohna, Reincke et al. 2000, Zhao, Roth et al. 
2002, Stephan, Chung et al. 2008, Barreau, de Reynies et al. 2012). In particular, gains in 
chr12q13.2 has also been associated with ACC poor survival rates (Stephan, Chung et al. 
2008).  
CDK4 and CDK2 proteins overexpression was detected in the human ACC cell line (H295R) 
and in the majority of the ACC (Bourcigaux, Gaston et al. 2000). Schmitt et al verified that all 
the ACC studied presented CDK4 positive staining, but the same occurred in the majority of 
ACA. ACA had a very weak positivity when compared to ACC (Schmitt, Saremaslani et al. 
2006).  
Cyclin E is the regulatory subunit of the cyclin E–CDK2 complex, together they control the 
progression through G1 phase (Hwang and Clurman 2005, Caldon and Musgrove 2010, Lim 
and Kaldis 2013). Cyclin E dysregulation is often observed in several tumor cells, it is thought 
to be involved in the tumorigenesis process and to be an important prognosis marker for some 
tumors (Tissier, Louvel et al. 2004, Hwang and Clurman 2005, Berrebi, Leclerc et al. 2008). 
There are two subtypes of cyclin E, the cyclin E1 and the cyclin E2, encoded by the genes: 
CCNE1 at chr19q12, and CCNE2 at chr8q22.1, respectively (Caldon and Musgrove 2010).  
CCNE1 and CCNE2 overexpression and amplification in ACC has been reported by several 
authors (Giordano, Thomas et al. 2003, de Reynies, Assie et al. 2009, Giordano, Kuick et al. 
2009, Tombol, Szabo et al. 2009, Ragazzon, Assie et al. 2011, Zheng, Cherniack et al. 2016), 
in particular gains in chr19q12, where CCNE1 is located (Szabo, Tamasi et al. 2010, Barreau, 
de Reynies et al. 2012). Overexpression of the cyclin E protein was observed in ACC and 
found to be significantly associated with the histologic grade and with shorter disease-free 
survival (Bourcigaux, Gaston et al. 2000, Tissier, Louvel et al. 2004, Giordano, Kuick et al. 
2009).  
Cyclin D1 expression was also found to be increased in ACC when compared to  ACA and/or 
normal adrenal cortex by several authors (Lombardi, Raffaelli et al. 2006, Mitsui, Yasumoto et 
al. 2014), whereas Stojadinovic et al did not detect cyclin D1 overexpression in both ACC and 
ACA (Stojadinovic, Brennan et al. 2003). Cyclin D2 protein levels were also studied in the 
adrenocortical tumors (ACT) but no significant differences were found between the different 
Chapter 1  
 
27 
ACT tumors (Bourcigaux, Gaston et al. 2000). The amplification of CCND1 and CCND2 genes 
that encode cyclin D1 and D2, respectively, has  not been observed in ACC (Zhao, Roth et al. 
2002).  
The ataxia telangiectasia mutated (ATM) and ATR (ATM and Rad3-related) protein kinases 
are members of the Phosphoinositide 3 (PI3) family of serine-threonine kinases involved in 
activation of the DNA damage checkpoint. DNA double-strand breaks activate p53 primarily 
via ATM- and ATR-dependent pathways (Figure 8) (Abraham 2001, Jazayeri, Falck et al. 
2006). ATM regulates p53 accumulation by checkpoint kinase 2-mediated phosphorylation and 
directly by phosphorylating MDM2, while ATR influence p53 phosphorylation through activation 
of Checkpoint kinase 1 (Chk1) (Abraham 2001). The protein p53 presents various cellular 
functions including induction of apoptosis and cell cycle arrest in the G1 and G2 phases of the 
cell cycle (Figure 8) (Agarwal, Agarwal et al. 1995, Chen, Ko et al. 1996). 
p53 upregulates the endogenous p21 mRNA and protein levels in G1 phase (el-Deiry, Tokino 
et al. 1993). Overexpression of p21 blocks the phosphorylation of pRb by cyclin E/CDK2, 
preventing the E2F mediated gene  expression induction required for cells to entry S phase 
(Adams, Sellers et al. 1996). The TP53 gene, located at chr17p13, is frequently found to be 
genetically altered in tumors (Soussi 2007). The wild-type TP53 is considered a tumor 
suppressor gene and the majority of mutated of TP53 are considered to be oncogenes, since 
TP53 mutations can result in loss of protein function leading the accumulation of dysfunctional 
p53 in the nucleus, genetic instability and facilitation of tumor progression (Kim and Deppert 
2004). 
Germline mutations in the TP53 are present in approximately 71% of families with Li–Fraumeni 
syndrome (Hisada, Garber et al. 1998). This syndrome confers susceptibility to several tumors 
including ACC (Table 2) (McBride, Ballinger et al. 2014).  
Although germline TP53 mutations are rare in adult patients with ACC, somatic TP53 
mutations are more common (Ohgaki, Kleihues et al. 1993, Barzon, Chilosi et al. 2001, Libe, 
Groussin et al. 2007, Herrmann, Heinze et al. 2012, Waldmann, Patsalis et al. 2012). In a large 
cohort of adult Caucasian patients with ACC, they observed a 3.9% prevalence of TP53 
germline mutation (Herrmann, Heinze et al. 2012); in contrast 13% of the patients younger 
than 40 years old, carried a TP53 germline mutations (Herrmann, Heinze et al. 2012). Germline 
mutations in TP53 were observed in 50%-80% of children with sporadic ACC (Wagner, 
Portwine et al. 1994, Varley, McGown et al. 1999, Wasserman, Novokmet et al. 2015).  
Many studies analyzed the presence of somatic TP53 mutation in ACC and verified that its 
prevalence varies from 20 to 30% in sporadic ACC (Barzon, Chilosi et al. 2001, Ragazzon, 
Libe et al. 2010, Waldmann, Patsalis et al. 2012).  The majority of patients with ACC and 
mutated TP53 had a poor outcome (Ragazzon, Libe et al. 2010).  
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Chr17p13 LOH has been demonstrated to be present in approximately 80% of ACC, although 
not always associated with the presence of TP53 mutations (Gicquel, Bertagna et al. 2001, 
Libe, Groussin et al. 2007). A minimal region loss on 17p13 has been identified in ACC, 
compared with ACA where no region of loss was observed (Soon, McDonald et al. 2008). 
Underexpression of ATR gene, related to chromosome (chr3q23) loss, was also observed in 
adrenocortical carcinomas and was associated with poor survival (Stephan, Chung et al. 2008, 
Szabo, Tamasi et al. 2010). Mutations in ATM gene were also described in ACC by some 
authors (De Martino, Al Ghuzlan et al. 2013, Ross, Wang et al. 2014). 
 
Figure 8 - Schematic representation of p53 regulation. p53 transcriptional activity is inhibited by MDM2 
that promote p53 ubiquititation. DNA damage leads to p53 phosphorylation via ATM/ATR, preventing is 
association with MDM2. Besides that, p19ARF also inhibit MDM2 preventing p53 ubiquitination. Stabilized 
p53 goes to the nucleus where is able to transcriptionally upregulate genes involved in Apoptosis and 
Cell cycle Arrest. Gene and proteins alteration already described in the ACC are indicated. 
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p53 expression was evaluated in ACT and it was demonstrated to be absent  in the majority 
of ACA (Arola, Salmenkivi et al. 2000, Stojadinovic, Brennan et al. 2003). Among ACC, p53 
expression has been found to be highly variable between 5 to 52%, denoting the inadequacy 
of this marker to identify malignancy in ACT (Reincke, Karl et al. 1994, McNicol, Struthers et 
al. 1997, Arola, Salmenkivi et al. 2000, Stojadinovic, Brennan et al. 2003). In childhood ACC, 
p53 expression demonstrated no prognostic significance (Sbragia, Oliveira-Filho et al. 2005). 
The CDK inhibitor, p57 is encoded by the CDKN1C gene located at chr11p15, where IGF2 is 
also located (Figure 5) (Borriello, Caldarelli et al. 2011, Fassnacht, Libe et al. 2011). In the G1 
phase of the cell cycle, p57 is able to inhibit the activity of CDK2-cyclin E, CDK2-cyclin A and 
CDK4-cyclin D1 leading to cell cycle arrest (Figure 7) (Pateras, Apostolopoulou et al. 2009, 
Borriello, Caldarelli et al. 2011).    
The majority of ACC and virilizing ACA present low p57 and H19 expression and high IGF2 
expression (Liu, Kahri et al. 1997). In contrast  to  normal adrenal glands and most ACA where 
the p57 mRNA is highly expressed, suggesting that p57 has a physiological role in normal 
adrenal cortex growth, the combination of low p57 and H19 expression and high IGF2 
expression seems to be involved in ACT malignancy (Liu, Kahri et al. 1997). 
Low expression of CDKN1C gene and p57 protein has been found in adult and childhood ACC. 
This was not due to mutations since no CDKN1C mutations were detected, suggesting that 
other mechanisms, such abnormalities of imprinting or methylation, could be responsible for 
its low expression (Bourcigaux, Gaston et al. 2000, Barzon, Chilosi et al. 2001, West, Neale et 
al. 2007, Soon, McDonald et al. 2008, Tombol, Szabo et al. 2009). Downregulation of p57 in 
ACC was found to be associated with CDK2 increased activity (Bourcigaux, Gaston et al. 
2000). 
CDKN2A can encode, by alternative splicing, for p16, a CDK4/6 inhibitor, and p14, a p53 
stabilizer, whereas, CDKN2B encodes another CDK4/6 inhibitor, the p15 (Dominguez-Brauer, 
Brauer et al. 2010, De Martino, Al Ghuzlan et al. 2013). Alterations in both genes, namely the 
deletion of CDKN2A and CDKN2B were observed in 14.3% and 10.7% of the analyzed ACC, 
respectively. The samples with the CDKN2B deletion, frequently also presented deletion in the 
CDKN2A (De Martino, Al Ghuzlan et al. 2013). Allelic losses on chr9p21, where CDKN2A and 
CDKN2B are harbored, were observed (Pilon, Pistorello et al. 1999, Zheng, Cherniack et al. 
2016). Furthermore, they reported the loss of nuclear immunostaining for p16 in three of the 
seven ACC analyzed (Pilon, Pistorello et al. 1999).   
p21 and p27 are CDK inhibitors (CDKi) involved in the regulation of cyclin E-CDK2 and  cyclin 
D-CDK4/6 complexes in the G1-S transition (Figure 7) (Lloyd, Erickson et al. 1999, Warfel and 
El-Deiry 2013). p21 is encoded by CDKN1A gene and p27 is encoded by CDKN1B gene, a 
gene that is rarely mutated in the context of cancer (Lloyd, Erickson et al. 1999, Nickeleit, 
Zender et al. 2007, Warfel and El-Deiry 2013).  
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The p21 protein expression was observed in both benign and malignant ACT, although a 
significantly higher proportion ACC presented positive expression (Stojadinovic, Brennan et al. 
2003). Babinska et al, also found an increased expression of p21 in ACC when compared with 
ACA and a significant correlation between its expression and the occurrence of metastasis 
(Babinska, Sworczak et al. 2008).  Other author did not find significant differences between 
benign and malignant ACT and there is evidence that its expression is inconsistent regardless 
of molecular abnormalities, similarly to the p53 expression (Barzon, Chilosi et al. 2001). 
Nakazumi et al observed p27 expression to be decreased in the ACC when compared with 
ACA (Nakazumi, Sasano et al. 1998). However, other authors have found opposite results, 
with increased p27 expression in ACC when compared to ACA (Stojadinovic, Brennan et al. 
2003) 
CDK2 phosphorylation of Thr160 is required for its activity and for G1 to S transition (Poon and 
Hunter 1995). The Cdk-associated protein phosphatase (KAP), encoded by the CDKN3 gene, 
is responsible for the dephosphorylation of Cdk2 on Thr160 and cell cycle arrest (Poon and 
Hunter 1995). Despite that, CDKN3 upregulation has been observed in ACC, when compared 
with ACA and normal adrenal glands (Giordano, Thomas et al. 2003, de Reynies, Assie et al. 
2009, Giordano, Kuick et al. 2009, Soon, Gill et al. 2009). Cyclin A binding  to Cdk2 inhibits 
dephosphorylation of CDK2 by KAP, allowing the G1-S transition (Poon and Hunter 1995). 
Overexpression of CCNA2 gene that encodes cyclin A2 is also observed in ACC when 
compared with ACA and normal adrenal glands and its expression is even higher in the more 
aggressive ACC (de Reynies, Assie et al. 2009) 
In G1 phase, in order to allow the transition to S phase, CDK-cyclin complexes are responsible 
for the inactivation of the pRb through phosphorylation (Giacinti and Giordano 2006). Activated 
pRb binds to the transactivation domain of E2F to form a  pRB- E2F complex that changes the 
chromatin structure at the E2F-responsive promoter by recruiting histone deacetylase (HDAC) 
to the pRB–E2F complex (Figure 9) (Takaki, Fukasawa et al. 2004, Giacinti and Giordano 
2006). Then, this complex binds to the promoter of some genes such as DNA polymerase 
subunits, cyclin A and cyclin E, which are required for S phase entry, leading to the 
transcription repression of those genes, and cell cycle arrest in phase G1 (Giacinti and 
Giordano 2006, Sun, Bagella et al. 2007).  
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Figure 9 - Schematic representation of Rb regulation. Hyperphosphorylation of Rb by the CDK/Cyclin 
complexes prevents the binding of RB to the transcription factor E2F, allowing the transcription of genes 
required for S phase entry. Gene and proteins alteration already described in the ACC are indicated. 
 
Upregulation of genes with binding sites for E2F seems to be a common event in many tumor 
types and has been also observed in ACC (Rhodes, Kalyana-Sundaram et al. 2005, Giordano, 
Kuick et al. 2009). Few studies have found a significant overexpression of E2F genes in ACC 
(Tombol, Szabo et al. 2009, Szabo, Tamasi et al. 2010). While, gains in the chr20, namely 
chr20q and chr20q11, where E2F1 is harbored have been reported as a common event in 
ACC (Zhao, Speel et al. 1999, Zhao, Roth et al. 2002, Barreau, de Reynies et al. 2012), while 
other authors have not detected gains in chr20 as a common occurrence in ACC (Kjellman, 
Kallioniemi et al. 1996, Sidhu, Marsh et al. 2002). HDCA-3 overexpression associated with 
chromosome gain (chr5q31) was found in ACC (Szabo, Racz et al. 2011). 
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Inactivating mutations, deletions and allelic losses of RB gene were observed in several tumors 
and seem to be associated with an increase in cancer susceptibility (Giacinti and Giordano 
2006, Di Fiore, D'Anneo et al. 2013). Ragazzon et al after using a prognosis predictor based 
on the combination of the genes:  MCM5, VEPH1, PINK1, and SLC2A1, verified that the 10% 
of the ACC with poorer prognosis presented RB1 mutations. The loss of pRB was exclusively 
found in the subgroup of aggressive tumors, suggesting that the RB1 has an important role in 
the last events of the ACC and could be used as a prognostic marker (Ragazzon, Libe et al. 
2014). Among the ACC with pRB loss, the majority presented an allelic loss at the RB1 locus 
(Ragazzon, Libe et al. 2014). Zheng et al also reported deletions of RB1 as a frequent event 
(Zheng, Cherniack et al. 2016). de Fraipont et al confirmed that mRNA expression of RB1 was 
reduced in the malignant ACT (de Fraipont, El Atifi et al. 2005). Gupta et al also reported 
differences in the pRB1 staining between benign and malignant ACT whereas, among the ACT 
studied by Vargas et al, both benign and malignant ACT, were positive for pRB1, with no 
differences between these two groups (Vargas, Vargas et al. 1997, Gupta, Shidham et al. 
2001).  
c-Myc is a pivotal regulator of the cell cycle being able to activate and repress pathways 
affecting G1 to S phase progression in mammalian cells. c-Myc overexpression leads to loss 
of CDK inhibitors resulting in the inactivation of pRb through phosphorylation, release of E2F 
and cell cycle progression to S phase. Furthermore, c-Myc induces the activity of E2F, and 
subsequent transcriptional activation of DNA synthetic enzymes (Zajac-Kaye 2001, Dang 
2013).  
The transcriptional functionality of c-Myc is only possible after heterodimerization with its 
obligate partner MYC-associated protein X (Max) (Grandori, Cowley et al. 2000, Jung, Wang 
et al. 2015). Absence of Max protein and loss of heterozygosity have been found to be frequent 
in adrenal medulla tumors (Comino-Mendez, Gracia-Aznarez et al. 2011); in ACC, a significant 
underexpression of Max was observed (Szabo, Tamasi et al. 2010). Amplification of 
protooncogene c-myc is frequently observed in a wide variety of human neoplasms through a 
variety of mechanisms (Nesbit, Tersak et al. 1999, Dang 2013).  
In contrast to the observation in the majority of tumors, several studies revealed that c-myc is 
underexpressed in ACC compared to ACA and to the normal adrenal cortex (Liu, Voutilainen 
et al. 1997, de Reynies, Assie et al. 2009, Giordano, Kuick et al. 2009, Tombol, Szabo et al. 
2009, Szabo, Racz et al. 2011). Giordano et al found that c-myc expression was independent 
of the ACC functionality (Giordano, Kuick et al. 2009). However Liu et al reported that c-myc 
gene expression was lower in virilizing ACA and in hormonally active ACC (Liu, Voutilainen et 
al. 1997). Myc amplification was also observed in two out of twenty five childhood ACT 
(Letouze, Rosati et al. 2012).  
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Chromosome loss in the chr8q24 region, corresponding to the region where c-myc is harbored 
was also found to be present in ACC (Stephan, Chung et al. 2008). 
The location of c-myc protein has also been correlated with ACT malignancy, since ACC 
express c-myc both in the cell cytoplasm and nuclei while ACA only express it in the cell nuclei 
(Suzuki, Sasano et al. 1992). 
Since overexpression of c-myc induces cell proliferation and ACC are rapidly proliferating 
tumors, c-myc was expected to be overexpressed in ACC, however the opposite was found to 
occur in this type of tumor (Szabo, Racz et al. 2011, Dang 2013). Szabó et al suggested that 
c-myc expression is not a necessary condition for proliferation in all types of tissues and that 
c-myc underexpression can be compensated by the overexpression of another myc family 
member (n-myc or l-myc), nevertheless this has not been documented so far (Szabo, Racz et 
al. 2011).  
The Smad proteins are components of the transforming growth factor β (TGF-β) signaling 
pathway. Phosphorylation activated Smad complexes enables their translocation to the 
nucleus where in collaboration with other cofactors, modulate the down-regulation of c-myc 
expression and up-regulation of CDK inhibitors, suppressing cyclin D/E and the progression to 
S phase (Massague, Blain et al. 2000, Denicourt and Dowdy 2003).  Smad family members 
decreased expression are observed in some human cancers. Inactivation of Smad4 encoding 
genes by loss of the entire chromosome segment (chr18q), small deletions or inactivating 
somatic mutations are able to contribute to the progression of several types of tumors 
(Samanta and Datta 2012). Low Smad4 protein expression was observed in 92% of the ACC 
compared to 40% of ACA, suggesting that downregulation of Smad4 expression may be 
involved in the carcinogenesis of ACC (Wang, Sun et al. 2014). In a microarray study, a 
significant SMAD3 gene overexpression was also described in ACC (Szabo, Tamasi et al. 
2010). However, Parviainen et al found that the expression of the SMAD3 protein was inversely 
correlated with the Weiss score thus more benign ACT (Parviainen, Schrade et al. 2013).  
Skp, Cullin, F-box containing (SCF) complex is an E3 ubiquitin ligase complex responsible for 
the ubiquitination of proteins destined for proteasomal degradation (Nakayama and Nakayama 
2005, Bochis, Fetica et al. 2015). The SCF complex controls the G1/S and the G2/M transitions 
by controlling the abundance of cell cycle regulators, such as Cyclins, CDKi, c-Myc and cell 
division cycle 25 (Cdc25) (Nakayama and Nakayama 2005). 
The SCF complex consists of four components: the invariable subunits Skp1, Cul1 and Rbx1 
and a variable F-box protein (Skp2, Fbw7 and β-TrCP) that determines target specificity 
(Nakayama and Nakayama 2005).  
Some of the components of the SCF complex were studied in the ACC and gene 
overexpression of the SKP1, SKP2 and CUL1, mainly related with chromosome gain, was 
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observed by some authors (Sidhu, Marsh et al. 2002, Tombol, Szabo et al. 2009, Szabo, 
Tamasi et al. 2010). 
The importance of an ErbB3 binding protein (Ebp1) in the regulation of the cell cycle has also 
been demonstrated (Zhang, Woodford et al. 2003, Zhang, Lu et al. 2008), as Ebp1 inhibits the 
transcription of E2F1 regulated cell cycle genes such as Cyclin D1, cyclin E and E2F1 (Zhang, 
Woodford et al. 2003). Furthermore, EBP1 overexpression associated with chromosome gain 
was found to be present in ACC (Szabo, Tamasi et al. 2010).  
 
G2-to-M phase transition in adrenocortical carcinomas 
The most important role of the G2 phase is to ensure that the chromosomes have been 
accurately replicated without mistakes or damages, in order to allow the cycle to progress to 
mitosis (DiPaola 2002).  
G2 to M transition is mainly regulated by the cyclin-dependent kinase, Cdc2, also known as 
CDK1 (Kaldis and Aleem 2005, Nakayama and Yamaguchi 2013). Cdc2 is able to form a 
complex with either Cyclin B or Cyclin A (Figure 7) (Desai, Wessling et al. 1995, Kaldis and 
Aleem 2005). 
Cdc2 is activated by a combination of some required steps: the phosphorylation of Thr161 by 
the Cdk-activating kinase (CAK) in order to open the catalytic region of Cdc2; the nuclear 
translocation of Cdc2/cyclin B1 complex by the polo-like kinase 1 (Plk1) phosphorylation of 
Ser147 on Cdc2 and the dephosphorylation of Thr14 and Tyr15 by the Cdc25 phosphatase family, 
Cdc25A, Cdc25B, and Cdc25C (Toyoshima-Morimoto, Taniguchi et al. 2002, Porter and 
Donoghue 2003, Schmit and Ahmad 2007, Lindqvist, Rodriguez-Bravo et al. 2009). Activation 
of Cdc25C is achieved by phosphorylation of Ser198 by Plk1, leading to nuclear export of the 
Cdc25C (Toyoshima-Morimoto, Taniguchi et al. 2002). After that, Cdc25C is 
hyperphosphorilated by the complex Cdc2-cyclinB1, leading to a positive feedback loop, 
increasing the Cdc2-cyclinB1 activity (Figure 10A) (Schmit and Ahmad 2007).  
Cdc25 is a dual-specificity phosphatase that not only activates the complexes cyclin B-Cdc2, 
but also the cyclin A-CDK2 and cyclin E-CDK2 at key cell cycle transitions: the isoform Cdc25A 
regulates the G1/S transition whereas the isoforms Cdc25B and Cdc25C act at G2/M, 
controlling the entry into mitosis (Karlsson-Rosenthal and Millar 2006, Frazer and Young 
2012).  
Inactivation of Cdc25C is reached through phosphorylation of Ser216, creating a binding site for 
the 14-3-3 protein. Then the Cdc25C goes to the cytoplasm preventing Cdc25C and Cdc2 
interaction (Figure 10B) (Abraham 2001, Schmit and Ahmad 2007). This phosphorylation is 
mediated by Chk1, Chk2, C-TAK1 and Plk3 and also through the complexes formation Cyclin 
B-cdc2 or Cyclin A-cdc2 (Schmit and Ahmad 2007). 
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Therefore, Cdc2 is also able to bind to cyclin E, as well CDK2 and regulate the G1/S phase in 
parallel or in absence of the CDK2 (Kaldis and Aleem 2005).  
The overexpression of CDC2 was reported in the ACC, with a higher expression in more 
aggressive cases (Giordano, Thomas et al. 2003, de Reynies, Assie et al. 2009, Giordano, 
Kuick et al. 2009, Soon, Gill et al. 2009, Tombol, Szabo et al. 2009). In ACC, CHEK1 gene 
encoding Chk1 protein and YWHAZ gene encoding 14-3-3ζ were also   overexpressed in ACC, 
in a microarray study (Szabo, Tamasi et al. 2010). Overexpression of the gene that encodes 
the 14-3-3β protein (YWHAB), associated with chromosome gain (chr20q13.1) was also 
observed (Szabo, Tamasi et al. 2010). 
 
 
Figure 10 - Schematic representation of CDC2/cyclin B regulation. In unstressed cells, Plk1 
phosphorylates Cdc25C, Wee1 and Myt1, leading to Cdc2/cyclin B activation and entries in the mitosis 
(A). In the presence of DNA damage, Chk1/2 are phosphorylated via ATM/ATR and are able to induce 
Cdc25C nuclear exclusion and to activate Wee1, leading to the inactivation of Cdc2/cyclin B and cell 
cycle arrest (B). Gene and proteins alteration already described in the ACC are indicated. 
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Inactivation of the Cdc2-cyclin B complexes, responsible for mitosis is a pre-requisite to exit 
mitosis (Figure 7) (Kaldis and Aleem 2005, Nakayama and Yamaguchi 2013). 
Cyclin B presents various isoforms: Cyclin B1 that is encoded by CCNB1, cyclin B2 that is 
encoded by CCNB2 and cyclin B3, that is the less well characterized cyclin B, encoded by 
CCNB3 (Lozano, Perret et al. 2002, Nieduszynski, Murray et al. 2002). 
Cyclins B1 and B2 are expressed in the majority of proliferating cells. Cdc2/cyclin B1 
complexes promote nuclear envelope breakdown, chromosome condensation, and mitotic 
spindle assembly while, cytoplasmic Cdc2/cyclin B2 complexes are essential for the mitotic 
reorganization of the Golgi apparatus (Satyanarayana and Kaldis 2009). Cyclin B3 seems to 
share some properties of the others Cyclin B (Satyanarayana and Kaldis 2009).  
Overexpression of CCNB1 or the correspondent chromosome gains were described in ACC 
comparing to  ACA and normal adrenal glands (Fernandez-Ranvier, Weng et al. 2008, de 
Reynies, Assie et al. 2009, Soon, Gill et al. 2009, Tombol, Szabo et al. 2009, Szabo, Tamasi 
et al. 2010). Cyclin B1 protein expression was also found to be increased in ACC but it had a 
high specificity (100%) and a low sensitivity (43%) for predicting malignancy. In consequence, 
Cyclin B1 is only useful for confirming a malignancy but is not helpful for excluding it when it is 
negative (Soon, Gill et al. 2009). 
CCNB2 overexpression was also found in ACC, particularly in the more aggressive forms. 
However the correspondent chromosomal alterations were not observed (Fernandez-Ranvier, 
Weng et al. 2008, de Reynies, Assie et al. 2009, Tombol, Szabo et al. 2009, Szabo, Tamasi 
et al. 2010). 
Deregulation of Cdc25 isoforms expression and activity, leading to unrestrained proliferation, 
has been found in some tumors (Karlsson-Rosenthal and Millar 2006, Frazer and Young 
2012). In ACC, CDC25 isoforms gene overexpression has already been described (de 
Reynies, Assie et al. 2009, Tombol, Szabo et al. 2009, Szabo, Tamasi et al. 2010), in parallel 
with  the gain of chromosome region ch5q31.2, where CDC25C is harbored (Lai, Godley et al. 
2001, Goh, Scholl et al. 2014). 
Overexpression of Plk1, the kinase responsible for Cdc2/cyclin B1 complex nuclear 
translocation and Cdc25c phosphorylation, has been associated with tumor development and 
considered a possible prognostic marker for some tumors (Wolf, Elez et al. 1997, Knecht, Elez 
et al. 1999, Tokumitsu, Mori et al. 1999, Takahashi, Sano et al. 2003, Ito, Miyoshi et al. 2004, 
Weichert, Denkert et al. 2004). Furthermore, Plk1 inhibitors are in preliminary tests for tumor 
treatment (Nogawa, Yuasa et al. 2005, McInnes, Mazumdar et al. 2006, Mross, Frost et al. 
2008). 
Overexpression of PLK1 has been found in ACC when compared with the non-functioning 
ACA, cortisol-producing ACA and with the normal adrenal glands (Tombol, Szabo et al. 2009).  
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Plk1 inhibitors, such as the small molecule BI-2536, have been tested in adrenocortical 
carcinoma cell lines, SW-13 and H295R, and found to significantly reduce the tumor cell 
growth, suggesting that Plk1 inhibitors deserve to be further investigated as a potential 
therapeutic approach in ACC (Linnehan, Coan et al. 2012, Bussey, Bapat et al. 2016). 
In G2 phase, p53 increases the Growth Arrest and DNA Damage-inducible 45 (Gadd45) 
expression that binds to Cdc2, preventing the formation of CyclinB-Cdc2 complex; additionally 
it increases 14-3-3δ expression that removes CyclinB-Cdc2 complex from the nucleus (Zhan, 
Antinore et al. 1999). 
Reprimo (RPRM) is a highly glycosylated protein, involved in the regulation of Cyclin B1-Cdc2 
pathway, also controlled by p53 (Ohki, Nemoto et al. 2000). When ectopically expressed in the 
cytoplasm it represses Cdc2 activity and the nuclear translocation of cyclin B1, leading to the 
cell cycle arrest (Ohki, Nemoto et al. 2000, Saavedra, Valbuena et al. 2015).  
RPRM gene has been described to be significantly downregulated in ACC compared with ACA, 
while GADD45 in contrast was significantly upregulated (Soon, Gill et al. 2009, Szabo, Tamasi 
et al. 2010). Tombol et al confirmed the same deregulation of these genes but not at a 
significant level (Tombol, Szabo et al. 2009). 
p53 and MDM2 (Mous double minute 2) form an auto regulatory negative feedback loop 
allowing the maintenance of low cellular p53 levels in the absence of stress (Moll and Petrenko 
2003). p53 stimulates the expression of MDM2 and MDM2 inhibits p53 activity by promoting 
its degradation, blocking its transcriptional activity, and promoting its nuclear export (Moll and 
Petrenko 2003, Shi and Gu 2012). DNA damage promotes phosphorylation of p53 and MDM2 
and avoid their interaction, thus stabilizing p53 (Figure 8) (Moll and Petrenko 2003). Protein 
p19ARF also stabilizes p53 by inhibiting the nuclear export of Mdm2 by tethering Mdm2 in the 
nucleolus (Tao and Levine 1999). Using microarray gene expression profiling, CDKN2D, the 
gene that encodes the p19ARF, was significantly upregulated in ACC (Szabo, Tamasi et al. 
2010). 
The co-amplification of sarcoma amplified sequence (SAS)/CDK4 and MDM2 was observed 
in advanced ACC by Zhao et al, and it was pointed out as having an important role in ACC 
progression (Zhao, Roth et al. 2002). More recently Giordano et al found an increased 
expression of both SAS and CDK4 in one ACC, in which no MDM2 expression was observed 
(Giordano, Thomas et al. 2003). Others authors, observed that the amplification of the MDM2 
gene and of the chromosomal region where MDM2 is located (12q14.3-q15), was observed in 
a minority of the human ACC, including those occurring in childhood (Stephan, Chung et al. 
2008, Letouze, Rosati et al. 2012, De Martino, Al Ghuzlan et al. 2013, Ross, Wang et al. 2014). 
Curiously, using immunohistochemistry, MDM2 protein expression showed no differences 
between ACA and ACC (Stojadinovic, Brennan et al. 2003). 
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The Myelin Transcription Factor 1 (Myt1) and Wee1 are proteins able to inhibit the Cdc2, 
through inhibitory phosphorylation at Thr14 and Tyr15 (Figure 10) (Liu, Stanton et al. 1997, Liu, 
Rothblum-Oviatt et al. 1999, DiPaola 2002, Karlsson-Rosenthal and Millar 2006).  
Once activated, cyclin B–Cdc2 complexes phosphorylate Wee1 and Myt1 to promote their 
inactivation, allowing an even larger amplification of Cdc2 activation (Lindqvist, Rodriguez-
Bravo et al. 2009). Wee1 is predominantly a nuclear protein that has been found to associate 
with centrosomes, whereas Myt1 is present in the cytoplasm bound to membrane structures 
(Baldin and Ducommun 1995, Liu, Stanton et al. 1997).  
WEE1 gene overexpression has been found in ACC when compared with ACA and normal 
adrenal glands (Giordano, Thomas et al. 2003), but there was no MYT1 gene overexpression 
in ACC (Tombol, Szabo et al. 2009). 
Cdk7 is known for exerting a dual role in cell cycle regulation as well as transcriptional control 
(Fisher 2005, Satyanarayana and Kaldis 2009). Cdk7 together with cyclin H and the assembly 
factor MAT1 (ménage à trois-1) forms the CAK complex, that are responsible for 
phosphorylation and activation of Cdc2, Cdk2, Cdk4 and Cdk6, allowing the cell cycle to 
progress (Satyanarayana and Kaldis 2009). 
Zhao et al identified amplifications of three different loci on chromosome 5 in ACC, such as at 
the chr5q13 position, where the CDK7 is harbored (Zhao, Speel et al. 1999, Zhao, Roth et al. 
2002). CDK7 expression has also been described to be increased in ACC (de Reynies, Assie 
et al. 2009). 
Topoisomerases (TOP) are enzymes that are involved in the biological processes that require 
strand unwinding, such as replication, transcription, and maintenance of genome stability, 
since they are able to introduce transient breaks in DNA (Wang 1996, Nitiss 2009). The TOP1 
introduces single strand breaks in the DNA and TOP2 introduces double strand breaks. Type 
III topoisomerases are required to segregate replicated chromosomes (Nitiss 2009, Wendorff, 
Schmidt et al. 2012). TOP2A, is a TOP2 isoform, present only in the S, G2, and M phases of 
the cell cycle of proliferating tissues (Nitiss 2009, Wendorff, Schmidt et al. 2012). 
Several authors confirmed  TOP2A  overexpression in ACC (Giordano, Thomas et al. 2003, 
Fernandez-Ranvier, Weng et al. 2008, de Reynies, Assie et al. 2009, Giordano, Kuick et al. 
2009, Tombol, Szabo et al. 2009, Ragazzon, Assie et al. 2011) which was associated with 
higher  ACC aggressiveness (de Reynies, Assie et al. 2009). 
TOP2A protein is overexpressed in ACC, being even higher in tumors with metastases. Its 
expression was associated with significantly poorer overall and disease-free survival (Iino, 
Sasano et al. 1997, Gupta, Shidham et al. 2001, Jain, Zhang et al. 2013, Ip, Pang et al. 2015). 
Iino et al have also suggested that TOP2A could be an even better proliferation marker than 
Ki-67, since some cells expressing TOP2A failed to express Ki-67 (Iino, Sasano et al. 1997).  
Chapter 1  
 
39 
Chromosomal gains at chr17, where TOP2A is harbored, were also found in ACA, suggesting 
that it may be an early event in the tumorigenesis of ACT (Zhao, Speel et al. 1999). 
TOP1 expression was also increased  in ACC compared to ACA (Lombardi, Raffaelli et al. 
2006). 
 
 
Spindle assembly checkpoint regulation 
The mitotic spindle assembly checkpoint (SAC) is highly regulated in order to ensure a high 
conformity of chromosomes segregation. It suspends the initiation of the anaphase until all 
chromosomes are correctly oriented in the mitotic spindle (Lara-Gonzalez, Westhorpe et al. 
2012). The SAC is composed of important signaling proteins that are able to avoid 
chromosome missegregation: Aurora kinase family (AURK A, B and C), budding unhibited by 
benzimidalozes (BUB1, BUB2 and BUB3), BUB1 homologue beta (BUB1B or BUBR1), mitotic 
arrest deficient proteins (MAD1 and MAD2) and monopolar spindle 1 (MPS1) (Bolanos-Garcia 
and Blundell 2011, Lara-Gonzalez, Westhorpe et al. 2012, Borges, Moreno et al. 2013). Cells 
with an unsatisfactory result in the checkpoint, recruit these proteins to the kinetochores, which 
leads to a formation of a mitotic checkpoint complex (MCC) composed by BUBR1, BUB3, 
MAD2 and Cdc20 that inactivates the anaphase-promoting complex/cyclosome (APC/C) 
(Figure 11A)  (Bolanos-Garcia and Blundell 2011, Lara-Gonzalez, Westhorpe et al. 2012). 
Otherwise, in cells with a satisfied checkpoint, the APC/C is responsible for the ubiquitylation 
and degradation of securin and cyclin B1. The securin degradation allows the release and 
activation of separase, leading to the cleavage of mitotic cohesin at centromeres allowing 
chromosome separation and mitotic progression. In contrast, cyclin B1 degradation by APC/C, 
inactivates Cdc2 leading to mitotic withdrawal (Figure 11B) (Bolanos-Garcia and Blundell 
2011, Lara-Gonzalez, Westhorpe et al. 2012).  
Defects in the SAC regulation, leading to aneuploidy were found to be present and to facilitate 
tumorigenesis of some cancers (Kops, Weaver et al. 2005, Schvartzman, Sotillo et al. 2010, 
de Voer, Geurts van Kessel et al. 2013).  
ACC are known for having a high frequency of chromosomal instability (Dohna, Reincke et al. 
2000, Stephan, Chung et al. 2008). BUB1 and BUB1B are upregulated/overexpressed in ACC, 
while BUB1B in combination with PTEN-induced putative kinase 1 (PINK1), were identified by 
two groups as important predictors of overall survival although in adult patients only (de 
Reynies, Assie et al. 2009, Fragoso, Almeida et al. 2012). In pediatric patients, BUB1B was 
not found to be useful as an outcome discriminator (Fragoso, Almeida et al. 2012). Instead, 
AURKA and AURKB were overexpressed in ACC and associated with more aggressive 
disease and death risk in childhood (Borges, Moreno et al. 2013). Moreover, the AURK 
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inhibitors inhibited cell proliferation and reduced clonogenic capacity of a childhood ACT 
primary cell line, suggesting a potential therapeutic tool in childhood ACT (Borges, Moreno et 
al. 2013). Finally the majority of ACC were found to present positive immunohistochemistry 
staining for Mitotic Arrest Deficient-Like 1 (MAD2L1) protein that was described to be absent 
in normal adrenal glands and in the majority of the ACA (Soon, Gill et al. 2009). 
 
 
Figure 11 - Schematic representation of SAC regulation. Unattached kinetochores catalyzes the 
formation of MCC leading to the inhibition of APC/C (A). When all chromosomes are aligned and the 
kinetochores attached, there are no formation of MCC allowing the Cdc20 activation. Cdc20 Activates 
APC/C that leads to the ubiquitination of Cyclin B and Securin. Separase is now able to cleave the 
mitotic cohesin at centromeres allowing chromosome separation and mitotic progression. While the 
Cyclin B ubiquitination, certificates the Cdc2 inhibition and Mitotic exit (B). Gene and proteins alteration 
described previously in ACC are indicated. 
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Cell Cycle regulators as a treatment target for ACC 
Cell cycle regulators are promising not only diagnostic markers but also treatment targets for 
ACC. The fact that the completed clinical trials in ACC patients produced insufficient outcomes, 
highlights that there is still much to be learned about the molecular pathology of these tumors, 
thus in addition to these and ongoing clinical trials, other pharmacological targets based on the 
recent molecular findings related to the cell cycle alterations found in ACC are likely to be 
tested in the near future.  
TOP2A, whose protein expression is associated with poor overall and disease-free survival 
(Iino, Sasano et al. 1997, Gupta, Shidham et al. 2001, Jain, Zhang et al. 2013, Ip, Pang et al. 
2015) is particularly interesting. TOP2A inhibition has already been tested in in vitro and in 
clinical trials with some promising results. In vitro anti-cancer activity of 14 different agents 
targeting TOP2A were evaluated. Among these agents the one that demonstrated to have the 
highest anticancer activity was aclarubicin and this compound will probably be tested in future 
clinical trials for the treatment of locally advanced and metastatic ACC (Jain, Zhang et al. 
2013). Moreover, clinical trials including etoposide and doxorubicin, topoisomerase 2 enzyme 
inhibitors, in combination with cisplatin (EDP) used in advanced ACC resulted in a better 
progression-free survival when compared to the mitotane and streptozotocin combination 
(NCT00094497) (Fassnacht, Libe et al. 2011, Fassnacht, Terzolo et al. 2012, Libe 2015). 
PLK1 regulates multiple steps of cell division and DNA stability/repair. PLK1 expression levels 
are positively correlated with a poor survival in ACC patients, suggesting PLK1 as a good 
prognostic marker that could also be a good candidate for targeted therapy (Liu 2015, Bussey, 
Bapat et al. 2016). TKM-080301 is a lipid nanoparticle formulation of a siRNA targeting PLK1. 
It was tested in 4 ACC patients (NCT01262235) with a good response in stabilizing disease 
including a 13% reduction of tumor size in one patient, thus suggesting that the role of PLK1 
inhibition for ACC treatment should be further investigated.  
The CDK/cyclin complexes have a critical role in the regulation of cell cycle transition that if 
disrupted can ultimately lead to uncontrolled proliferation. Thus, these are certainly molecular 
attractive targets for cancer treatment (Asghar, Witkiewicz et al. 2015). The overexpression of 
CDK4/6/2 and 1, as well as the overexpression of cyclins involved in the G1-S transition 
(CCNE1/2) and in the G2-M (CCNB1/2) were recurrently observed in ACC (Zhao, Speel et al. 
1999, Dohna, Reincke et al. 2000, Zhao, Roth et al. 2002, Giordano, Thomas et al. 2003, 
Stephan, Chung et al. 2008, de Reynies, Assie et al. 2009, Giordano, Kuick et al. 2009, Soon, 
Gill et al. 2009, Tombol, Szabo et al. 2009, Barreau, de Reynies et al. 2012). Moreover CDK 
inhibitors are being tested for several advanced solid tumors, but there are no registered 
clinical trials aiming to assess their efficacy in ACC. Besides, despite the results of the initial 
clinical trials using CDK inhibitors being disappointing, the recent use of highly selective CDK 
inhibitors, specifically targeting CDK4 and CDK6, combined with patient stratification, showed 
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a more substantial and promising clinical activity (Asghar, Witkiewicz et al. 2015). Indeed, a 
small molecule that is a selective CDK4/6 inhibitor (SHR6390) is in clinical trial for advanced 
solid tumors, currently in a recruiting phase and thus could represent an opportunity to include 
patients with ACC (NCT02684266).  
Altered expression of CDC25 gene isoforms, repeatedly described in ACC, could represent a 
potential treatment target for these tumors (de Reynies, Assie et al. 2009, Tombol, Szabo et 
al. 2009, Szabo, Tamasi et al. 2010). However, despite the fact that several natural and 
synthetic molecules with distinct structural features targeting CDC25 with good pre-clinical 
results have been identified (Brezak, Kasprzyk et al. 2008, Brenner, Reikvam et al. 2014), no 
registered clinical trials using CDC25 inhibitors for ACC are ongoing. 
In addition, the recovery of p53 tumor suppressor gene function, using MDM2 antagonist (such 
as RO5503781) and the reactivation of mutant TP53, using PRIMA-1MET, already tested for 
other malignancies (Khoo, Verma et al. 2014), also have the potential in to be used in ACC 
that have TP53 inactivated. 
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Adrenocortical carcinomas are usually very aggressive malignant tumors with a poor clinical 
prognosis. The striking difference between adrenocortical adenomas and carcinomas 
biological behavior renders the identification of accurate molecular markers that could be used 
for differential diagnosis beyond classical histological morphology analysis extremely 
important. Such molecular markers if available could prove useful not only as tools for 
diagnosis at earlier disease stages but could also enhance the understanding of adrenocortical 
tumor biology and unravel unpredicted therapeutic targets thus leading to innovative drugs 
development. To test this hypothesis, the following aims have been established: 
 
1- To characterize the expression pattern of molecular markers involved in the cell cycle 
and proliferation in different subsets of adrenocortical tumors; 
2- To characterize the expression pattern of key enzymes/proteins involved in the adrenal 
steroidogenesis in different subsets of adrenocortical tumors; 
3- To investigate the blood and lymph vessel density within adrenocortical tumors and 
how did it correlate with the tumors biological behavior and functional status; 
4- To evaluate the role of telomerase in adrenocortical tumors biology by analyzing the 
presence of telomerase promoter mutations and telomerase nuclear expression, and 
how does these correlate with cadherins and β-catenin expression; 
5- To understand the contribution of IGF2 for adrenocortical cancer hallmarks, including 
cell proliferation, viability, invasion and metabolism;  
6- To characterize the putative role of MAPK-MEK-ERK pathway activation in tumor 
progression and the potential its inhibition for adrenocortical carcinomas treatment. 
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3.1 Abstract 
 
Adrenocortical carcinomas are rare malignant tumors that tend to be highly aggressive, while 
benign adrenocortical tumors are more common and frequently found incidentally. Currently, 
the use of molecular markers for the differential diagnosis of adrenocortical tumors is still 
controversial. Our aim was to analyze the molecular profile of different adrenocortical tumors 
with the purpose of identifying markers that could be useful for the pathological diagnosis of 
adrenocortical tumors.  
The adrenocortical tumors studied included non-functioning adenomas (n=15), functioning 
adenomas with Cushing syndrome (n=10), and carcinomas (n=13); while normal adrenal 
glands (n=14) were used as controls. For each sample, the percentage of the stained area for 
the biomarkers involved in cell cycle regulation (p53, p21, MDM2, p27 and cyclin D1) and cell 
proliferation (Ki-67) were quantified using the morphometric computerized tool ImageJ.  
Among the molecular markers studied, only p27 and Ki-67 were found to be significantly 
different between adrenocortical adenomas (ACA) and adrenocortical carcinomas (ACC). 
Considering the cut-off values of 0.50% for Ki-67 and 7.23% for p27, all adenomas presented 
lower levels of these markers.  
Despite Ki-67 being a well-stablish marker of malignancy that was also previously reported to 
be a useful tool for the differential diagnosis of ACT, p27 had never been identified as a suitable 
indicator for this purpose. Thus, with this research work we demonstrated for the first time that 
p27 is a powerful diagnostic tool even superior to Ki-67, as it is able to exclude all the ACA 
and identify more ACC than Ki-67. Furthermore, our results suggest that p27 could possibly 
have an unknown role in adrenocortical tumorigenesis and represent a potential treatment 
target. 
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3.2 Introduction 
 
In spite of ACC generally having rather larger tumor sizes and different histological 
characteristics, the differential diagnosis between adrenocortical adenomas (ACA) and 
adrenocortical carcinomas (ACC) is not always easy. The most widely used method for 
pathological diagnosis of ACT is the Weiss score system is based on 9 histopathological 
characteristics, or more recently the modified Weiss score based on the 5 most reliable 
histological criteria of the classical Weiss score (mitotic rate, abnormal mitosis, proportion of 
clear cells, necrosis and capsular invasion), eliminating those criteria considered more 
subjective or difficult to interpret (Lau and Weiss 2009, Tissier 2010). Nevertheless, these 
parameters are still difficult to assess, subjective and may be insufficient to define or exclude 
malignancy in every ACT. As a consequence, it is well recognized that additional tools for 
differential diagnosis of ACT are still needed (Tissier 2010, Fassnacht, Libe et al. 2011), while 
the identification of specific molecular markers to classify ambiguous ACT and understand 
their biological behavior, would be particularly welcomed. 
Previous studies have suggested that some molecular markers involved in cell cycle regulation 
could be useful to define malignancy in ACT. However, the reliability and accuracy of studies 
that suggested the use of such markers has been questioned in result of the usage of 
subjective quantification methods yielding contradictory reports.  
 
Chapter 3 
51 
3.3 Aim 
 
The main goal of the current study was to identify molecular markers that could improve the 
differential diagnosis of ACT. For that we have chosen to evaluate biomarkers involved in cell 
cycle regulation (p53, p21, murine doble minute-2 (MDM2), p27 and cyclin D1) and cell 
proliferation (Ki-67) immunohistochemically labelled using a computerized morphometric 
method to avoid subjectivity in a sample of significant size in order to test the accuracy of the 
molecular marker in the diagnosis of ACT.  
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3.4 Material and Methods  
 
Case Selection 
Paraffin-embedded adrenal samples from a total of 52 patients were used. These 
encompassed adrenocortical adenomas (ACA) (n=25), including non-functioning adenomas 
(ACAn) (n=15) and adenomas with Cushing syndrome (ACAc) (n=10), and adrenocortical 
carcinomas (ACC) (n=13). In addition, 14 normal adrenal glands (N-AG), obtained as part of 
nephrectomy procedures performed for the treatment of kidney tumors, were used as controls. 
 
Immunohistochemistry (IHC) 
IHC was performed on formalin-fixed paraffin embedded tissue sections mounted on adhesive 
microscope slides (HistoBond, Marienfeld, Germany). Sections were successively 
deparaffinized, rehydrated in graded alcohols, and processed using the avidin-biotin 
immunoperoxidase method.  
For antigen retrieval of MDM2, the sections underwent microwave treatment for 15 minutes in 
0.01 M-citrate buffer at pH 6.0 with 0.05% Tween 20. The endogenous peroxidase was blocked 
with 3% hydrogen peroxide in methanol, followed by incubation in normal serum for 30 
minutes. Then the samples were incubated overnight at 4° C in the primary antibody to MDM2 
(ab15471;1:100; Abcam). Samples were then incubated with secondary antibodies at 1:200 
dilution (Polyclonal swine anti-rabbit, Dako Denmark) for 30 minutes, followed by avidin-biotin 
peroxidase complex (1:100, Vector Laboratories, Inc.) for an additional 30 minutes. 
Diaminobenzidine was used as chromogen and hematoxylin as nuclear counterstaining.  
For the other markers, IHC was performed using the Kit Novolink Polymer Detection System 
(Leica). For p53 and p27, antigen recuperation was performed by pressure cooker boiling for 
3 minutes and for cyclin D1 and ki-67 by incubation in 0.01 M-citrate buffer at pH 6.0 with 
0.05% Tween 20 for 5 minutes. For p21 antigen retrieval was performed by microwaving at 
900W for 15 minutes. The endogenous peroxidase was blocked with 3% hydrogen peroxide 
in methanol. The sections were incubated overnight at 4°C in the appropriate diluted primary 
antibody: rabbit anti-human monoclonal antibodies to p53 (453M-94; 1:100; Cell Marque), p21 
(421M-14; 1:50; Cell Marque), p27 (427M-94; 1:500; Cell Marque), cyclin D1 (271R-14; 1:500; 
Cell Marque) and Ki-67 (27R-14; 1:100; Cell Marque). Diaminobenzidine was used as 
chromogen, and hematoxylin as the nuclear counterstain. The following tissues were used for 
positive control: colon carcinoma for p53 and Ki-67; breast cancer for MDM2 and Cyclin D1 
and tonsil for p21 and p27. 
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Immunofluorescence (IF) 
IF for Ki-67 and p27 was performed using a similar procedure. Antigen retrieval was performed 
by pressure cooker boiling for 3 minutes and then Sudan black B 0.5% in 70% of alcohol was 
used during 3 minutes in order to decrease tissue auto fluorescence. The incubation was 
followed with normal serum (1:5) for 30 minutes and afterwards incubated with primary 
antibodies anti-p27 (1:50) and anti-Ki-67 (1:250). For p27/Ki-67 detection slides were 
incubated for 2 hours with a cocktail containing a fluorescent secondary antibody goat anti-
rabbit (1:1000; Ref. 4413; Cell Signaling Technology) and goat anti-mouse (1:750; Ref. 4408; 
Cell Signaling Technology). The slides were then mounted and counterstained with DAPI hard-
set. 
 
Computerized Image analysis 
Using the camera AxioCam MRC Zeiss, 10 photos were taken from each sample and antibody 
at 400x magnification using the image acquisition software AxioVs40 v4.8.2.0 Zeiss for 
Windows, always under the same magnification, illumination and by the same researcher. IHC 
images were analyzed using the image processing software, ImageJ (originated at the National 
Institutes of Health, USA) with color deconvolution plugin which can separate the stained area 
from the initial image and then quantify the percentage of the stained area. The “percentage 
of the stained area” was compared between the different groups. 
 
Statistical analysis 
Statistical analysis was performed with GraphPad Prism (version 5.00) for Windows and a 
p<0.05 was considered significant. All results are presented as Mean ± Standard Error (SE). 
D’Agostinho & Pearson test was used to evaluate variables normality. For continuous variables 
that passed this test, one-way ANOVA test with the post-hoc Tukey was used to compare the 
means of three groups. For the variables that did not pass the normality test, the Kruskal Wallis 
with a Post-hoc Dunn’s was used. The area under the receiver operating characteristic (ROC) 
curve was used to determine diagnostic accuracy of the markers with significant results. Based 
on the area under the ROC curve (AUC), the test was considered excellent for values ranging 
between 0.90 to 1.00; good when between 0.80 to 0.90; fair if between 0.70 to 0.80; poor for 
values between 0.60 to 0.70 and fail if below 0.60 (Fan, Upadhye et al. 2006). The analysis of 
ROC curves also allowed to obtain the best cut-off values for the differential diagnosis. 
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3.5 Results 
 
p27 is an excellent marker for the differential diagnosis between ACC and ACA 
Among the 5 molecular markers related to the cell cycle that were studied, only p27 labeling 
was found to be significantly different between ACA and ACC (Figure 12 and 17).  
ACC presented a significantly higher percentage of stained area for p27 (9.49 ± 1.22%) when 
compared to ACAn (3.59 ± 0.28%) (Figure 17) with an AUC of 0.93 (Figure 18A); as well as 
when compared to ACAc (3.81 ± 0.42%) with an AUC of 0.94 (Figure 18B). Besides that an 
excellent AUC was also obtained when comparing ACC with total ACA (ACAt) (AUC=0.92) 
(Figure 18C). Despite no other significant differences were observed for the other markers, 
MDM2 was found to be significantly lower in ACC (0.81 ± 0.41%) when compared with N-AG 
(3.37 ± 0.74%), while p21 was significantly higher in ACC (1.97 ± 0.53%) when compared with 
N-AG (0.53 ± 0.15%) (Figure 13, 14, 15, 16, 17).  
 
 
Figure 12 - Immunohistochemistry staining of p27 (Scale = 50 µm). A- Adrenocortical carcinoma; B- 
Adrenocortical adenoma with Cushing syndrome; C- Non-functioning adrenocortical adenoma and D- 
Normal adrenal gland. 
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Figure 13- Immunohistochemistry staining of p53 (Scale = 50 µm). A- Adrenocortical carcinoma; B- 
Adrenocortical adenoma with Cushing syndrome; C- Non-functioning adrenocortical adenoma and D- 
Normal adrenal gland. 
 
 
 
Figure 14 - Immunohistochemistry staining of MDM2 (Scale = 50 µm). A- Adrenocortical carcinoma; B- 
Adrenocortical adenoma with Cushing syndrome; C- Non-functioning adrenocortical adenoma and D- 
Normal adrenal gland. 
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Figure 15 - Immunohistochemistry staining of p21 (Scale = 50 µm). A- Adrenocortical carcinoma; B- 
Adrenocortical adenoma with Cushing syndrome; C- Non-functioning adrenocortical adenoma and D- 
Normal adrenal gland. 
 
 
 
Figure 16 - Immunohistochemistry staining of cyclin D1 (Scale = 50 µm). A- Adrenocortical carcinoma; 
B- Adrenocortical adenoma with Cushing syndrome; C- Non-functioning adrenocortical adenoma and 
D- Normal adrenal gland. 
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Figure 17 - Graphic representation of the percentage of p53, MDM2, p21, p27 and Cyclin D1 in the 
studied groups, (ANOVA: * p<0.05; ** p<0.01;*** p<0.001). 
 
 
 
Figure 18 - ROC curves to assess the ability of the different molecular markers to distinguish between 
adrenocortical carcinomas (ACC) from non-functioning adrenocortical adenomas (A); ACC from 
adenomas with Cushing syndrome (B) and ACC from total adenomas (C) with the respective area under 
the curve (AUC). 
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Ki-67 is increased in ACC 
The nuclear expression of the proliferation marker Ki-67 was significantly higher in ACC (2.15 
± 0.65%) compared with ACAn (0.08 ± 0.03%), ACAc (0.13 ± 0.02%) and N-AG (0.05 ± 0.02%) 
(Figure 19).  
 
Figure 19 - Immunohistochemistry staining of Ki-67 (Scale = 50 µm). A- Adrenocortical carcinoma; B- 
Adrenocortical adenoma with Cushing syndrome; C- Non-functioning adrenocortical adenoma; D- 
Normal adrenal gland, and E- Graphic representation of the percentage of the Ki-67 in the studied 
groups (ANOVA: *** p<0.001). 
 
Ki-67 has shown to be a good marker for the differential diagnosis between ACC and ACAc 
(AUC=0.83) and between ACC and ACAt (AUC=0.89). Besides that, an excellent AUC was 
obtained comparing ACC with ACAn (AUC=0.92) (Figure 20). 
 
Figure 20 - ROC curves to assess the ability of Ki-67 to distinguish adrenocortical carcinomas (ACC) 
from non-functioning adrenocortical adenomas (ACAn), adenomas with Cushing syndrome (ACAc) and 
total adenomas (ACAt) with the respective area under the curve (AUC). 
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No co-localization was observed between Ki-67 and p27 
IF staining for was performed in order to understand whether Ki-67 and p27 expression in ACC 
were related markers. No co-localization was observed between of two molecular markers in 
the same cell in all the ACC analyzed (Figure 21). 
 
 
Figure 21 - Immunofluorescence staining for Ki-67 and p27 in an ACC (400x). Dapi was used as a 
nuclear counterstaining. 
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3.6 Discussion 
  
The differential diagnosis between benign and malignant tumors of the adrenal cortex is 
currently based on several histological parameters according to the Weiss scoring system, in 
which a tumor scoring equal or below 2 is classified as benign and a tumor with a score equal 
or above 4 is considered malignant. A Weiss score of 3 gives rise to a category of tumors for 
which the Weiss scoring system has an insufficient capacity to differentiate ACC from ACA to 
achieve a definite diagnosis (Tissier 2010). Therefore, there is a common agreement that more 
accurate molecular markers are need to improve the differential diagnosis of ACT and to allow 
an earlier identification of those with malignant potential. 
To meet this aim we have performed an immunohistochemistry characterization of the 
expression pattern of molecular markers involved in the cell cycle in a large collection of normal 
and pathologic adrenal glands. Most of these individual molecular markers had been 
previously suggested to be potentially useful for the differential diagnosis of adrenal cortex 
tumors by several groups. However, the reliability and accuracy of such data has been 
questioned in result of the use of subjective quantification methods at the observers discretion 
yielding contradictory reports (Stojadinovic, Ghossein et al. 2002, Stojadinovic, Brennan et al. 
2003, Schmitt, Saremaslani et al. 2006, Tissier 2010). One of the main strengths of the present 
study was the use of a computerized morphometric analysis that not only allows to remove the 
subjectivity of the observer, but also holds the promise of being potentially useful to validate 
the clinical utility of other molecular markers recently disclosed by genomic studies (Giordano, 
Kuick et al. 2009, Fragoso, Almeida et al. 2012). Besides that, this automatic analysis is also 
feasible, easily accessible and implementable in the clinical setting, being less subjective and 
time consuming than the traditional manual cell counting method that is currently used. 
The limitation of this study is the limited number of tumors included, which given the relative 
rarity of the pathology renders representativeness to this series; nevertheless this research 
should still to be considered a pilot study on the usefulness of an objective quantification 
method to evaluate the diagnostic potential of molecular markers in ACT. 
No significant differences in the expression of the cell cycle molecular markers p53, MDM2, 
p21 and Cyclin D1 were found between ACA and ACC. Tp53 is a tumor suppressor gene, 
which the resultant protein promotes DNA repair (He, Siddik et al. 2005, Fassnacht, Libe et al. 
2011); MDM2 is a protein that inactivates p53 by binding to both wild type p53 as well as the 
mutated p53 protein (Moll and Petrenko 2003, Manfredi 2010); and p21 is a cyclin-dependent 
kinase inhibitor (CDKi) induced by p53 that when over expressed triggers cell cycle arrest in 
proliferating cells (He, Siddik et al. 2005). Although no significant differences in p53 protein 
were found between ACC and ACA, this resulted mostly from the heterogeneity of the p53 
staining found in the ACC, as some tumors depicted a high p53 expression suggesting the 
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presence of p53 mutations, while others had low p53 expression. The expression of cyclin D1 
was higher in ACC when compared with ACA, but no significant differences were observed. 
Cyclin D1 is a regulator of the G1 to S transition phase of the cell cycle (Ewen and Lamb 2004). 
Using ROC curves for analyzing the differential diagnosis between total ACA and ACC, we 
found an AUC lower than 0.80, suggesting that this molecular marker is unlikely to be useful 
for the differential diagnosis of ACT. Previous studies using a 5% cut-off to consider cyclin D1 
immunostaining as positive also failed to demonstrate the usefulness of this molecular marker 
to confirm the diagnosis of adrenal malignancy (Stojadinovic, Ghossein et al. 2002, 
Stojadinovic, Brennan et al. 2003). 
Ki-67 protein expression was significantly higher in ACC when compared with ACA and normal 
adrenal glands. The analysis of the ROC curve for the differential diagnosis between ACC and 
total ACA, demonstrated an AUC of 0.89 and the value of 0.50% as the best cut-off for the 
differential diagnosis of ACT. Increased Ki-67 expression in ACC has been confirmed in 
several previous reports, thus its clinical usefulness is now well established and consensual 
(Stojadinovic, Ghossein et al. 2002, Stojadinovic, Brennan et al. 2003, Schmitt, Saremaslani 
et al. 2006, Soon, Gill et al. 2009).  
The p27 immunostaining was the most positive finding of this study, allowing a clear distinction 
between ACC and all other groups. The p27 protein, is a CDKi that regulates cell cycle 
progression from G1 to S phase of the cell cycle, while p27 up-regulation results in cell cycle 
arrest and apoptosis (Lee and Duh 2009). The percentage of p27 stained area was significantly 
higher in ACC when compared to all the other studied groups. The analysis of the area under 
the ROC curve suggested that p27 has an excellent accuracy for the differential diagnosis 
between ACC and both functioning and non-functioning ACA using a cut-off value of 7.23% as 
the best discriminator. Moreover, p27 has demonstrated to be a better marker of malignancy 
when compared to Ki-67 in result of presenting a higher specificity and sensitivity. In a 
previously study, the presence of p27 in most ACC and in a substantial percentage of ACA 
had also been shown, but failed to recognize its potential as a diagnosis biomarker 
(Stojadinovic, Brennan et al. 2003). Our study, using an assessment method that is far less 
subjective and defining a cut-off value through the ROC analysis makes the use of p27 for the 
distinction between ACC and ACA very relevant. The high specificity of p27 for the ACC could 
probably have been found in the previous study if an objective method of assessment and 
higher cut-off value had been chosen, as similar results have also been previously described 
for breast tumors and melanomas (Fredersdorf, Burns et al. 1997, Bales, Dietrich et al. 1999, 
Nickeleit, Zender et al. 2007).  
Indeed, p27 was recently described as a multifunctional protein involved in the regulation of 
several cellular processes in a CDK-independent manner that involves the nuclear export 
and/or cytoplasmic retention (Chu, Hengst et al. 2008). Cytoplasmic p27 is described to confer 
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a pro-tumorigenic advantage since it is implicated in the control of cell migration, transcriptional 
repression, autophagy, stem cell specification and differentiation and apoptosis (Chu, Hengst 
et al. 2008, Serres, Zlotek-Zlotkiewicz et al. 2011, Jeannot, Nowosad et al. 2017). The multi-
functionality could justify the high p27 expression in ACC. Once only nuclear expression was 
observed in ACC it suggests that nuclear p27 may have an unknown function in ACC 
tumorigenesis, such that cancer cells could eventually develop tolerance to cell cycle 
progression inhibition mediated by p27 or develop the ability to repress p27 activity, as an 
important step in tumor progression. Thus, despite the nuclear expression of p27, it would be 
unable to arrest the cell cycle. The fact that no co-localization of p27 and Ki-67 was found in 
the same cell, suggests that nuclear p27 might have an additional unknown role unrelated to 
proliferation in the adrenocortical tumorigenesis. 
 
In conclusion, p27 and Ki-67 were among the studied molecular markers the ones that 
demonstrated the highest discriminative power for the differential diagnosis between ACC and 
ACA. In addition, p27 seems to be a better specificity than Ki-67 for the ACC diagnosis and a 
higher sensitivity for the exclusion of ACA. One of the main contributions of this study was the 
demonstration of the usefulness and convenience of an automatic method of analysis not only 
to assess and validate the accuracy of molecular markers for the differential diagnosis of ACT, 
but also to be implemented in the clinical setting. At last but not the least, the finding that p27 
is overexpressed in ACC, suggests that this CDKi could possibly have an unknown role in 
adrenocortical tumorigenesis and represent a potential treatment target. 
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4.1 Abstract 
 
Autonomous steroid secretion is a common feature of adrenocortical carcinomas (ACC), 
although not always clinically evident owing to an inefficient steroidogenesis with increased 
release of steroid precursors.  
Expression of proteins involved in steroidogenesis, namely steroidogenic acute regulatory 
protein (StAR), 11β-hydroxylase (CYP11B1), aldosterone synthase (CYP11B2) and 17α-
hydroxylase, were analyzed by immunohistochemistry in ACC (n=14), adenomas presenting 
with Cushing syndrome (ACAc) (n=11) and clinically non-functioning adenomas (ACAn) 
(n=15). The percentage of the stained area for each protein was analyzed using the ImageJ 
software for computerized morphometric quantification. 
CYP11B1, StAR and 17α-hydroxylase expression was significantly lower in ACC when 
compared to ACAc. CYP11B2 was found to be poorly expressed in all the tumors analyzed. 
CYP11B1 was the steroidogenic enzyme with the most discriminative power to distinguish 
ACC from ACAc with a sensitivity of 100% and specificity of 92%, with an expression higher 
than 4.44% indicating the presence of a cortisol secreting adenoma. CYP11B1 and CYP11B2 
dual negativity presented a specificity of 100% for the differential diagnosis between ACC and 
ACAc.  
ACC depict an incomplete pattern of steroidogenic protein expression, with decreased 
CYP11B1 and 17 α-hydroxylase, which could explain the predominant secretion of steroid 
precursors. In cortisol secreting tumors, CYP11B1 positivity alone is highly specific for benign 
lesions, while CYP11B1 and CYP11B2 dual negativity allows to identify malignancy. 
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4.2 Introduction 
 
The majority of adrenocortical carcinomas (ACC) are able of autonomous steroid  production 
presenting as clinically functioning tumors (50-60%), frequently exhibiting Cushing syndrome 
alone (45%) or a combination of virilizing and Cushing’s syndromes (25%) (Ng and Libertino 
2003, Allolio and Fassnacht 2006, Pignatelli 2011). However, despite being able of steroid 
production in some ACC this do not result in any clinically apparent hormonal syndrome due 
to inefficient steroidogenesis with increased secretion and release of steroid precursors. 
Urinary steroid profile of patients harboring ACC revealed that these tumors secrete and 
release predominantly intermediate metabolites (Grondal, Eriksson et al. 1990, Kikuchi, 
Yanaihara et al. 2000, Arlt, Biehl et al. 2011, Kerkhofs, Kerstens et al. 2015). This steroid 
secretion pattern could be attributed to the underdifferentiated status of the tumor cells 
expressing an incomplete pattern of enzymes involved in the steroidogenic cascade.  
StAR is a mitochondrial protein that is responsible for the translocation of the cholesterol from 
the outer to the inner mitochondrial membrane in steroidogenic cells (Miller 2007). Once in the 
mitochondria, cholesterol is hydroxylated twice and cleaved by the cholesterol side chain 
cleavage enzyme (CYP11A1) to generate pregnenolone (Figure 2 of Introduction chapter). 
After leaving the mitochondria, pregnenolone is oxidized and isomerized to form progesterone, 
which is then converted to 11-deoxycorticosterone by CYP21A2 enzyme. From this step of the 
steroidogenic cascade, due to zone-specific enzyme expression, steroidogenesis differs 
among the different adrenal cortex zones. At the glomerulosa, 11-deoxycorticosterone is 
transferred back into the mitochondria and is successively hydroxylated by CYP11B2 enzyme 
to originate aldosterone. At the fasciculata, 17α-Hydroxylase converts pregnenolone into 17α-
hydroxypregnenolone, which is then oxidized to 17α-hydroxyprogesterone and afterwards 
hydroxylated by CYP21A2 to originate 11-deoxycortisol. At this point, 11-deoxycortisol 
reenters into the mitochondria to be converted by CYP11B1 into cortisol. At the zona 
reticularis, pregnenolone is hydroxylated by 17α-Hydroxylase to yield 17-
hydroxypregnenolone and then into DHEA (Gomez-Sanchez, Qi et al. 2014, Midzak and 
Papadopoulos 2016). 
  
Chapter 4 
67 
4.3 Aim 
 
This study main objective was to analyze the expression of four key proteins involved in the 
adrenal steroidogenesis, namely StAR, 11β-hydroxylase, aldosterone synthase and 17α-
hydroxylase, in different adrenocortical tumors in order to infer the potential utility of these 
molecular markers for diagnosis in the clinical setting. 
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4.4 Material and Methods 
 
Case Selection 
Adrenal tissue was obtained during elective surgical procedures from patients with adrenal 
cortical tumors (ACT) (n=30), comprising ACC (n=14) and adrenocortical adenomas (ACA) 
(n=26), including non-functioning adenomas (ACAn) (n=15) and cortisol secreting adenomas 
with clinical features of Cushing syndrome (ACAc) (n=11). The participants provided written 
informed consent for adrenal tissue deposit at our institutional Tumor Bank to be used for future 
research. The study was approved by the local Ethics Committee. 
 
Immunohistochemistry (IHC) and analysis  
CYP11B1, CYP11B2 and 17α-hydroxylase antibodies used in this study were developed by 
Professor Celso E. Gomez-Sanchez form the Medical Center, University of Mississippi, USA 
and the IHC protocol was performed as previously described (Gomez-Sanchez, Qi et al. 2014). 
Briefly, 3μm formalin-fixed paraffin embedded tissue sections mounted on adhesive 
microscope slides (StarFrost, Knittel Glass, Germany) were deparaffinized, rehydrated in 
graded alcohols and underwent 45 minutes heating in a temperature controlled water bath 
(99.9º C) with ethylenediaminetetraacetic acid (EDTA) (E5134, Sigma-Aldrich, St Louis, MO, 
USA) solution 1mM at pH 9 with Sodium dodecyl sulfate (SDS) 0.05%, for antigen retrieval. 
Endogenous peroxidase inhibition was performed using hydrochloric acid at 0.02N for 20 
minutes before overnight incubation with the primary antibodies: CyP11B1 (1:100), CyP11B2 
(1:500) or 17β-Hydroxylase (1:500) at 4ºC. The detection of the immune reaction was 
performed by incubation for 60 minutes with the commercial Dako REAL™ EnVision™ 
Detection System (ref.: K5007, Dako, Denmark), which includes a dextran backbone with 
peroxidase (HRP) molecules coupled to goat secondary antibody molecules against rabbit 
immunoglobulins. DAB (3,3'- Diaminobenzidine), also included in the same commercial Dako 
Kit, was used as chromogen and Mayer’s Hematoxylin (ref.: HX390929, MERK, Germany) was 
used for nuclear counterstaining. 
For StAR, antigen recuperation was performed by boiling in pressure cooker for 3 minutes in 
0.01 M-citrate buffer at pH 6.0 with 0.05% Tween 20. The endogenous peroxidase was blocked 
with 3% hydrogen peroxide in methanol, followed by normal serum pre-treatment for 30 
minutes and overnight incubation at 4° C with the primary rabbit anti-human polyclonal 
antibodies against StAR (HPA023644; 1:100; Atlas Antibodies). Slides were then incubated 
with the secondary antibodies at a 1:200 dilution (Polyclonal swine anti-rabbit, Dako Denmark), 
followed by avidin-biotin peroxidase complexes (1:100, Vector Laboratories, Inc.) for 30 
minutes. Diaminobenzidine (K3468, Dako, Denmark) was used as chromogen and 
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hematoxylin for nuclear counterstaining. Normal adrenal tissue was used as positive control 
and omission of primary antibody incubation was used as negative control. 
To evaluate the percentage of the stained area for each molecular marker a computerized 
image analysis was performed, for which slides were scanned using the image acquisition 
Olympus VS110 virtual slide scanning system and captured using the image acquisition 
software VS-ASW (version 2.3 for Windows). The images obtained were analyzed using the 
FIJI color deconvolution plugin (HDab) that allows the separation of the stained area from the 
initial image based in the RGB system. The percentage of the stained area for each marker 
was quantified in the total tumor area, as previously described (Pereira, Morais et al. 2013). 
 
Statistical analysis  
Continuous variables are represented as mean ± standard error (SE) of the mean. Normality 
was evaluated using the D’Agostinho & Pearson test. For variables that passed this test, the 
one-way ANOVA test with the post-hoc Tukey was used to compare the means of the three 
groups. For variables that did not pass the normality test, Kruskal Wallis with a Post-hoc Dunn’s 
was used. Statistical analysis was performed using the GraphPad Prism (version 7.00 for 
Windows). A p<0.05 was considered statistically significant. 
The area under the receiver operating characteristic (ROC) curve was used to determine 
diagnostic accuracy of the markers with significant results. Based on the area under the ROC 
curve (AUC), the test was considered excellent for values ranging between 0.90 to 1.00; good 
when between 0.80 to 0.90; fair if between 0.70 to 0.80; poor for values between 0.60 to 0.70 
and fail if below 0.60 (Fan, Upadhye et al. 2006). The analysis of ROC curves also allowed to 
obtain the best cut-off values for the differential diagnosis. 
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4.5 Results 
 
CYP11B1 expression in ACC is low 
IHC CYP11B1 expression is present in all ACAc adenomas and in the majority of ACAn 
(86.7%) and ACC (64.3%) (Table 4 and Figure 22). Staining for CYP11B1 was significantly 
higher in ACAc (17.99 ± 13.12%) when compared to ACAn (5.56 ± 1.35%, p<0.05) and ACC 
(1.04 ± 0.59%, p<0.001) (Figure 26A). ROC curve analysis showed that CYP11B1 is a marker 
with highly accuracy for the differential diagnosis between ACC and ACAc with an AUC of 0.99 
(Figure 26C) and a good accuracy for the differential diagnosis between ACC and total ACA 
(ACAt) (Figure 26D). 
 
 
Figure 22 - Immunohistochemistry staining for CYP11B1 (Scale = 50 µm). A- Adrenocortical carcinoma; 
B- Adrenocortical adenoma with Cushing syndrome; C- Non-functioning adrenocortical adenoma and 
D- Normal adrenal gland. 
 
CYP11B2 and CYP11B1 dual negativity is highly suggestive of malignant ACT 
CYP11B2 IHC staining was negative in the majority of ACC and in the rare tumors with positive 
staining expression was found to be low (Table 4, Figure 23 and 26A). After ROC curve 
analysis, CYP11B2 exhibited an insufficient accuracy for the differential diagnosis of ACT 
given the low AUC values observed (Figure 26B and C). However, CYP11B1 and CYP11B2 
dual negativity is highly suggestive of ACC, since it was only observed in ACC (28.6%) and in 
1 ACAn (6.7%). This pattern has a specificity of 100% or 96% for malignancy in functioning or 
non-functioning ACT, respectively.  
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Figure 23 - Immunohistochemistry staining for CYP11B2 (Scale = 50 µm). A- Adrenocortical carcinoma; 
B- Adrenocortical adenoma with Cushing syndrome; C- Non-functioning adrenocortical adenoma and 
D- Normal adrenal gland. 
 
17β-Hydroxylase expression in ACC is low 
The 17β-hydroxylase expression was positive in every ACC and ACAc, as well as in the 
majority of ACAn (93.3%) (Table 4 and Figure 24). 17β-Hydroxylase expression was 
significantly lower in ACC (16.44 ± 2.29) when compared with ACAc (26.19 ± 1.63, p<0.01) 
(Figure 26A). However, ROC curves depicted low AUC indicating that this enzyme has a poor 
accuracy to be used for differential diagnosis (Figure 26B, C and D).  
 
 
Figure 24 - Immunohistochemistry staining for 17α-Hydroxylase (Scale = 50 µm). A- Adrenocortical 
carcinoma; B- Adrenocortical adenoma with Cushing syndrome; C- Non-functioning adrenocortical 
adenoma and D- Normal adrenal gland. 
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StAR expression is decreased in ACC and ACAn 
Positivity for StAR antibody was present in every ACT (Figure 25 and Table 4). Significant 
differences in the stained area were only found between ACAc (18.12 ± 1.40%) and ACC (7.11 
± 1.95%, p<0.05). StAR expression was lower in ACAn (6.02 ± 1.40%) than in ACAc (18.12 ± 
1.40%, p<0.05) and similar to ACC (7.11 ± 1.95%) (Figure 26A). The ROC curve analysis to 
assess the accuracy of StAR for the differential diagnosis between ACA and ACC has yield 
AUC of 0.86 suggesting that StAR is a good molecular marker to distinguish ACC from ACAc 
(Figure 26B and 26C). 
 
 
 
Figure 25 - Immunohistochemistry staining for StAR (Scale = 50 µm). A- Adrenocortical carcinoma; B- 
Adrenocortical adenoma with Cushing syndrome; C- Non-functioning adrenocortical adenoma and D- 
Normal adrenal gland. 
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Table 4 - Frequency of CYP11B1, CYP11B2, 17α-Hydroxylase and StAR immunostaining positivity in 
the different adrenocortical tumors. 
  Negative Positive 
ACC (n=14) 
CYP11B1 5 (35.7%) 9 (64.3%) 
CYP11B2 11 (78.6%) 3 (21.4%) 
17α-Hydroxylase 0 (0.00%) 14 (100.0%) 
StAR 0 (0.00%) 14 (100.0%) 
ACAc (n=11) 
CYP11B1 0 (0.00%) 11 (100.0%) 
CYP11B2 5 (45.5%) 6 (54.5%) 
17α-Hydroxylase 0 (0.00%) 11 (100.0%) 
StAR 0 (0.00%) 11 (100.0%) 
ACAn (n=15) 
CYP11B1 2 (13.3%) 13 (86.7%) 
CYP11B2 7 (46.7%) 8 (53.3%) 
17α-Hydroxylase 1 (6.7%) 14 (93.3%) 
StAR 0 (0.00%) 15 (100.0%) 
ACC – Adrenocortical carcinomas; ACAc- Adrenocortical adenomas with Cushing syndrome; 
ACAn - non-functioning adrenocortical adenomas; CYP11B1- 11-beta-hydroxylase; CYP11B2 - 
Aldosterone synthase, StAR - Steroidogenic acute regulatory protein 
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Figure 26 - Graphic representation of the percentage of CYP11B1, CYP11B2, 17α-Hydroxylase and 
StAR in the studied groups (A), and the ROC curves to distinguish adrenocortical carcinomas (ACC) 
from non-functioning adrenocortical adenomas (ACAn) (B); ACC from adenomas with Cushing 
syndrome (ACAc) (C) and ACC from total adenomas (D) with the respective area under the curve (AUC). 
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4.6 Discussion 
 
 
Despite the fact that the majority of ACC are capable of autonomous steroid production, these 
tumors not always present as clinically functioning hormone secreting syndromes (Else, Kim 
et al. 2014). Steroidogenesis in ACC is known to be dysfunctional and the use of steroid 
metabolite levels as a tool for diagnosis was suggested specially using analysis of the urine 
metabolites. The utility of serum steroid routine analysis is more controversial (Grondal, 
Eriksson et al. 1990, Kikuchi, Yanaihara et al. 2000, Arlt, Biehl et al. 2011, Kerkhofs, Kerstens 
et al. 2015). In the most relevant study in this area, Arlt et al after performing steroid 
metabolomics by gas chromatography/mass spectrometry in the urine of ACT patients, 
observed that combined androgen and glucocorticoids excess was present in 69% of the 
analyzed ACC, while routine biochemistry analysis only identified 27% of the cases. Besides 
that 85% of ACC patients presented accumulation of steroids precursors rather than mature 
steroids confirming incomplete steroidogenesis (Arlt, Biehl et al. 2011). This hormonal profile 
could be due to an incomplete pattern of steroidogenic enzyme expression, which warrants to 
be characterized. Thus, we started this study with the aim to analyze the expression profile of 
four key proteins involved in the steroidogenesis cascade, namely StAR protein, CYP11B1, 
CYP11B2 and 17α-hydroxylase, in different types of adrenocortical tumors. 
Our results have shown that ACC depicted a decreased expression of CYP11B1, StAR and 
17α-hydroxylase when compared to ACAc. CYP11B1 was the steroidogenic enzyme with the 
highest discriminative power to distinguish ACC from ACAc with a sensitivity and specificity of 
100% and 92%, respectively, for a cut-off value of 4.44%. Besides that, 28.6% of ACC were 
negative for both CYP11B1 and CYP11B2, while this pattern was only found in one ACAn and 
in none of the ACAc. Although isolated CYP11B2 negativity was not useful for diagnosis, 
CYP11B1 and CYP11B2 dual negativity is highly suggestive of ACC, with a specificity of 100% 
in functioning and 96% in non-functioning ACT. When comparing the two subgroups of benign 
tumors, CYP11B1 and StAR were the steroidogenic proteins that were most discriminative 
between ACAn and ACAc, with lower levels of both proteins found in non-functioning ACA. 
Previous studies that focused on urine steroid metabolomics profile analysis of patients 
harboring ACC and ACA found that tetrahydro-11-deoxycortisol (THS), a metabolite of 11-
deoxycortisol, was the steroid with the highest discriminative power to differentiate ACA from 
ACC (Grondal, Eriksson et al. 1990, Kikuchi, Yanaihara et al. 2000, Arlt, Biehl et al. 2011, 
Kerkhofs, Kerstens et al. 2015). The abundance of THS suggests that CYP11B1a, the enzyme 
responsible for the conversion of 11-deoxycortisol into cortisol, is either dysfunctional or with 
decreased expression, as observed in the present study. The progesterone metabolite 
pregnanediol was also described to be increased in the urine of ACC patients (Kerkhofs, 
Kerstens et al. 2015). This finding corroborates our own observation of decreased expression 
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of 17α-Hydroxylase in ACC, since 17α-hydroxylase is responsible for the conversion of 
progesterone into 17α-hydroxypregnenolone. 
Few studies have analyzed the expression profile of the steroidogenic enzymes in ACC. 
Sasano et al described that ACC presented a disorganized pattern of steroidogenic enzymes 
expression, with non-functioning ACC being devoid of CYP11B1 and 17α-hydroxylase and 
having lower levels of expression of other enzymes (21-hydroxylase, 3-β-hydroxysteroid 
dehydrogenase and CYP11A1) as compared to functioning ACC presenting with Cushing 
syndrome (Sasano, Suzuki et al. 1993). Uchida et al reported a case of an ACC presenting 
with mild primary aldosteronism and subclinical Cushing’s syndrome, in which CYP11B1, 
CYP11B2 and 3-β-hydroxysteroid dehydrogenase was poorly expressed as detected by 
immunohistochemistry and variable across different areas of the tumor. Moreover, some 
CYP11B2-positive cells also expressed 17α-hydroxylase enzyme, a feature that does not 
occurs in normal adrenal cells, suggesting that the coordinated expression of enzymes 
involved in steroidogenesis is disturbed in ACC (Uchida, Nishimoto et al. 2017).  
 
In conclusion, our study provides significant evidence that CYP11B1, StAR and 17α-
hydroxylase expression is lower in ACC when compared to benign ACAc. The incomplete 
pattern of steroidogenic enzyme expression could justify the increased secretion of steroid 
metabolites precursors witnessed in ACC. CYP11B1 was shown to be a highly accurate 
molecular marker for the differential diagnosis between ACC and ACAc. Besides that 
CYP11B1 and CYP11B2 dual negativity was shown to be very specific for malignancy. Thus, 
the use of these molecular tools should be considered in the clinical setting for the differential 
diagnosis of ACT. 
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5.1 Abstract 
 
Adrenocortical tumors (ACT) are common adrenal tumors. The majority of ACT are non-
functioning and benign, while adrenocortical carcinomas (ACC) are rare, usually very 
aggressive and often metastasized when first diagnosed. Our aim was to assess whether 
blood and lymph vessel density within ACT correlate with the malignancy character or tumor 
functionality.  
For that, the microvascular distribution was evaluated by immunohistochemistry staining with 
D2-40 antibody, for lymph vessels and CD31 antibody, for blood vessels, in ACC (n=15), 
adenomas with Cushing syndrome (n=9) and non-functioning adenomas (n=10). The 
percentage of stained area was quantified by computerized morphometric analysis.  
D2-40 expression was significantly lower in ACC as compared to adenomas with Cushing 
syndrome (p<0.01) and correlated positively with the expression of the steroidogenic acute 
regulatory protein (StAR) (R2=0.553, p<0.001). CD31 expression was found to be significantly 
higher in ACC as compared to adenomas with Cushing syndrome (p<0.05)  
Our results show that angiogenesis is increased in ACC, suggesting that this phenomenon 
may have an important role in ACT biological behavior, while lymph vascular density seems to 
be more closely related to the tumor functional status than malignancy. 
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5.2 Introduction 
 
Adrenocortical tumors (ACT) are common tumors affecting 3% to 10% of the human 
population. The majority of ACT are benign, non-functioning and discovered incidentally during 
imaging studies performed for unrelated conditions (Allolio, Hahner et al. 2004). In contrast, 
adrenocortical carcinomas (ACC) are rare malignant tumors with an annual incidence of 1 to 
2 cases per million persons worldwide. The majority of ACC are in advanced stages when 
diagnosed, leading to a poor prognosis. The most common metastatic sites for ACC are the 
lung (46-79%),  the liver (44-93%) and the lymph nodes (18-73%) (Allolio, Hahner et al. 2004). 
Cancer cell dissemination occurs mostly through the vascular system, either through blood or  
lymph vessels (Paduch 2016).  Angiogenesis or lymphangiogenesis, are complex processes 
leading to the formation of new blood or lymph vessels, which are regulated by a high number 
of signal transduction pathways that were described to be altered in tumors and to contribute 
to their dissemination (Alitalo, Tammela et al. 2005, Paduch 2016). 
A diversity of molecular markers that allow the evaluation of the vascular system are now 
available.  Factor VIII-related antigen, CD31, and CD34 are the most commonly targeted 
antigens used to identify blood vessels by immunohistochemistry (Pusztaszeri, Seelentag et 
al. 2006), while lymphatic endothelial hyaluronan receptor-1 (LYVE-1) and podoplanin (D2-40) 
are specific markers for the lymphatic endothelium (Alitalo, Tammela et al. 2005, Pusztaszeri, 
Seelentag et al. 2006). 
  
Chapter 5 
81 
5.3 Aim 
 
Since angiogenesis and lymphangiogenesis have been poorly characterized in ACT 
particularly in correlation with the tumor functionality and malignant character (Bernini, Moretti 
et al. 2002, Browning, Bailey et al. 2008, Zhu, Xu et al. 2014), our aim was to assess whether 
blood and lymph vessel density within ACT were correlated with the biological behavior of 
these tumors.  
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5.4 Material and Methods 
 
Adrenal Tissues 
Adrenal tissues were obtained during elective surgical procedures from patients with ACT 
(n=34), comprising ACC (n=15) and adrenocortical adenomas (ACA) (n=19). Benign tumors 
included non-functioning adenomas (ACAn) (n=9) and cortisol secreting adenomas with 
Cushing syndrome (ACAc) (n=10). 
 
Immunohistochemistry analysis 
Immunohistochemistry was performed in 3μm formalin-fixed paraffin embedded tissue 
sections mounted on adhesive microscope slides. Antigen retrieval was performed by 
microwave treatment in 0.01 M-citrate buffer at pH 6.0, during 20 minutes. Endogenous 
peroxidase inhibition was performed with hydrogen peroxide (MERK, Germany) at 0.3%, for 
15 minutes, before incubation with the primary antibodies against D2-40 (rabbit, 1:200, ref.: 
M3619, Dako, Denmark) or CD31 (mouse, 1:100, ref. M0823, Dako, Denmark)  for 1 hour at 
room temperature. The detection of the immune reaction was performed by incubation for 60 
minutes with the commercial Dako REAL™ EnVision™ Detection System (ref.: K5007, Dako, 
Denmark), which includes a dextran backbone with peroxidase (HRP) molecules coupled to 
goat secondary antibody molecules against rabbit immunoglobulins. DAB (3,3'- 
Diaminobenzidine), also included in the Dako System, was used as chromogen. Normal 
thyroid tissue was used as positive control for D2-40 and normal tonsil tissue for CD31. The 
omission of primary antibody was used as negative control. 
To evaluate the percentage of the stained area for each marker a computerized image analysis 
was performed. First, slides were scanned using the image acquisition Olympus VS110 virtual 
slide scanning system and captured using the image acquisition software VS-ASW (version 
2.3 for Windows). Then, the images obtained were analyzed using the FIJI color deconvolution 
plugin (HDab), which allowed the separation of the stained area from the initial image, based 
in the RGB system. The stained area with the D2-40 or CD31 antibodies in the total tumor 
areas was quantified as previously described (Pereira, Morais et al. 2013). 
 
Statistical analysis  
The continuous variables are represented as mean ± standard error of the mean (SEM). The 
variables normality was evaluated using the D’Agostinho & Pearson test. For variables that 
passed this test, the one-way ANOVA test with the post-hoc Tukey was used to compare the 
means of the three groups. For the variables that did not pass the normality test, the Kruskal 
Wallis with a Post-hoc Dunn’s was used. The correlations between continuous variables were 
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evaluated using the Pearson Test.  Statistical analysis was performed using the GraphPad 
Prism (version 7.00 for Windows). A p<0.05 was considered statistical significant. 
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5.5 Results 
 
D2-40 expression 
Lymph vessels in ACT were immunohistochemistry stained for D2-40, an O-linked 
sialoglycoprotein found on the lymphatic endothelium (Figure 27 A-C). Lymph vessels density 
was significantly lower in the ACC (0.129 ± 0.046 %) compared with the ACAc (0.933 ± 0.268 
%, p<0.01) (Figure 27D).  No differences were observed between the two groups of adenomas 
and the ACC vs ACAn (0.557 ± 0.255 %).  
 
 
Figure 27 - Immunohistochemistry staining for D2-40 (Scale = 50 µm). A- Adrenocortical carcinoma 
(ACC); B- Adrenocortical adenoma with Cushing syndrome (ACAc); C- Non-functioning adrenocortical 
adenoma (ACAn); D-Graphic representation of the percentage of the stained area for D2-40 in the 
different studied groups (ANOVA: ** p<0.01). 
 
CD31 expression 
ACT tumoral blood vessel density was evaluated by immunohistochemistry staining for CD31. 
Blood vessel density was significantly higher in ACC than in ACAc (ACC: 1.927 ± 0.391 % vs 
ACAc: 0.698 ± 0.113 %, p<0.05) (Figure 28).  
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Figure 28 - Immunohistochemistry staining of CD31 (Scale = 50 µm). A- Adrenocortical carcinoma 
(ACC); B- Adrenocortical adenoma with Cushing Syndrome (ACAc); C- Non-functioning adrenocortical 
adenoma (ACAn); D-Graphic representation of the percentage of the CD31 in the studied groups 
(ANOVA: * p<0.05). 
 
Correlation between D2-40, CD31 expression with a steroidogenesis marker 
The steroidogenic acute regulatory protein (StAR) is responsible to the acute regulation of 
steroid hormone biosynthesis since it mediates the cholesterol transfer to the inner 
mitochondrial membrane. A significant correlation was observed between D2-40 expression 
StAR protein expression (R2=0.553, p<0.001) (data from the Chapter 4 of this Thesis) (Pereira, 
Morais et al. 2013). No correlation was found between the CD31 and StAR expression (Table 
5). 
 
Table 5 - Correlation results between the CD31, D2-40 and the marker of steroidogenesis StAR. 
Correlation Coefficient correlation (R2) p 
D2-40 and StAR expression 0.553 p<0.001 
CD31 and StAR expression 0.049 NS 
StAR – steroidogenic acute regulatory protein; NS- non-significant 
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5.6 Discussion 
 
Angiogenesis and lymphangiogenesis are complex processes of substantial importance in 
cancer biology as these mechanisms may contribute to nurturement of the tumoral cells, 
dissemination of their humoral secretions as well as to the spread of the neoplastic cells. The 
majority of the ACC are very aggressive tumors, most of them already being metastasized 
when first diagnosed (Allolio, Hahner et al. 2004). 
Our aim was to study the expression of the D2-40 lymph vessel marker and the CD31 blood 
vessel marker in the different ACT and to assess whether these were correlated with the 
malignant character of the tumors or their functionality. 
In our study, lymph vessel density was found to be lower in the ACC compared to ACAc. 
Besides that, as a positive correlation between D2-40 expression and StAR protein expression 
was found. So, we concluded that lymphangiogenesis in ACT seems to be more related to the 
production of steroids than to the carcinogenesis process. StAR is an enzyme involved in the 
transport of cholesterol to the inner mitochondrial membrane, which is the first and limiting step 
of steroidogenesis (Pereira, Morais et al. 2013). The association of StAR expression with 
lymph vessel density could be hypothetically related with the needs of cholesterol supplying to 
the adrenal or effluent distribution of secreted adrenal steroids from functioning tumors. These 
two hypothesis were not tested, although certainly deserve further consideration. 
Lymphangiogenesis in ACT is a poorly characterized phenomena. D2-40 immunostaining was 
reported to be strong, diffuse and similar in both adrenocortical adenomas (n=5) and 
carcinomas. No information about functionality was provided (Browning, Bailey et al. 2008).  
Blood vessel density was found to be significantly higher in ACC compared with functioning 
ACA. ACC are aggressive tumors that frequently metastasize to the lung and the liver, thus 
the high blood vessels density found in this type of tumors is not unexpected. Besides that, the 
lower blood vessels density found in ACAc could be due the prior described anti-angiogenic 
actions of cortisol (Logie, Ali et al. 2010). 
Nonetheless, previous studies addressing angiogenesis in ACT yielded inconsistent results. 
Bernini et al analyzed the vascular density in benign and malignant ACT by CD34 
immunostaining and showed that ACC had a significantly lower vascular density as compared 
with ACA (Bernini, Moretti et al. 2002). Contrarily, Zhu et al, using the same marker and the 
same methodologic approach to assess the angiogenesis in ACT demonstrated that CD34 
expression was higher in ACC than in ACA (Zhu, Xu et al. 2014). However, all previous studies 
have used the classical assessment method of semi-quantitative hotspot examination that 
restricts the analysis to representative tumor areas selected at the discretion of the observer 
to assess vascular density, in contrast to our current study in which the entire tumor tissue 
available was analyzed using a computerized morphometric method that is less prone to bias. 
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In support of our finding vascular endothelial growth factor (VEGF) plasma levels and VEGF 
immune staining of the tumors was also found to be significantly higher levels in ACC when 
compared to ACA (De Fraipont, El Atifi et al. 2000, Bernini, Moretti et al. 2002).  
 
In conclusion, blood vessel density is increased in ACC suggesting that angiogenesis could 
have an important role in the ACT biological behavior, while lymph vessel density seems to be 
more closely related to the tumor functional status than with malignancy. 
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6.1 Abstract 
 
Adrenocortical carcinomas (ACC) are frequently very aggressive tumors, although the 
molecular mechanisms driving the observed pathological features are still largely unknown. 
The aim of the present study was to assess the influence of telomerase reverse transcriptase 
(TERT) and cadherins in ACT biologic behavior and their potential utility as molecular 
biomarkers for the differential diagnosis of adrenal neoplasms.  
For that, adrenal cortex samples (n=48), comprising adrenal tumors (n=39) and normal adrenal 
glands (n=9) were used. TERT promoter mutations were searched in two hotspots positions (-
124 and -146) by PCR and Sanger sequencing, while telomerase, β-catenin and E-, P- and N-
cadherin expression in adrenal tissues were evaluated by immunohistochemistry. 
No TERT promoter mutations were detected in ACC or adrenocortical adenomas (ACA). 
Telomerase nuclear expression was present in 26.6% of ACC and in 45.5% of non-functioning 
adrenocortical adenomas, but absent in adenomas with Cushing syndrome and in normal 
adrenal glands. In contrast, N-cadherin expression in the cell membrane was always present 
in benign tumors and normal adrenals but was not detected in the majority of ACC. Nuclear 
telomerase and membrane N-cadherin expression were positively correlated in ACC. Ectopic 
β-catenin expression in the cell cytoplasm and/or nucleus, was observed both in ACC and ACA 
despite occurring in different proportions and thus was not specific of any tumor group. 
We conclude that the loss of N-cadherin cell membrane expression should be considered for 
differential diagnosis of ACT, as it is frequent phenomenon in both high and low proliferative 
ACC. While TERT promoter mutations and nuclear telomerase expression are absent or rarely 
found. The positive correlation between the loss of the N-cadherin expression and the absence 
of telomerase expression that was observed, also suggests the existence of a TERT non-
canonical function in cell adhesion. 
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6.2 Introduction 
 
ACC are rare tumors however highly aggressive having an extremely poor prognosis, mainly 
due to the advanced stages at which they are usually diagnosed (Lafemina and Brennan 2012, 
Zheng, Cherniack et al. 2016). Understanding of the adrenocortical tumors’ biology and 
identification of progression factors will contribute to a more correct and comprehensive tumor 
categorization and is certainly one of the most challenging areas in adrenal pathology (Lau 
and Weiss 2009).  
Telomeres play an essential role regulating genomic stability by allowing the cell to distinguish 
between chromosome ends and double-strand DNA breaks (Dewar and Lydall 2012). To 
maintain the telomeres, cells use a specialized enzyme complex called telomerase that is able 
to add TTAGGG repeats to the ends of chromosomes. This complex is formed by two core 
subunits: the catalytic telomerase reverse transcriptase (TERT) and the telomerase RNA 
component (TERC) (Martinez and Blasco 2011, Doksani, Wu et al. 2013). Telomerase and 
other molecules with key roles in the regulation of telomere length and end-protection, 
frequently have altered expression or are affected by somatic mutations in cancers conferring 
these malignant cells the ability to bypass senescence while promoting genomic instability.  
Many cancers display increased telomerase activity leading to sustained telomere 
maintenance (Cong, Wright et al. 2002, Kyo, Takakura et al. 2008, Vinagre, Almeida et al. 
2013).Germline mutation as well as somatically acquired mutations in the promoter of TERT 
increase the expression of TERT and have been reported to constitute a cancer-predisposition 
condition (Vinagre, Almeida et al. 2013, Vinagre, Pinto et al. 2014, Akincilar, Unal et al. 2016). 
Nevertheless, there are few studies that have analyzed their contribution to the development 
of adrenocortical tumors (Liu, Brown et al. 2014, Papathomas, Oudijk et al. 2014, Zheng, 
Cherniack et al. 2016). 
Telomerase activation has been related to cellular immortalization and cancer, having been 
described in 90% of human cancers (Cong, Wright et al. 2002, Kyo and Inoue 2002, Kyo, 
Takakura et al. 2008). However, the mechanisms leading to telomerase reactivation or re-
expression and its role in carcinogenesis are not yet completely understood (Kyo, Takakura et 
al. 2008, Donate and Blasco 2011). Mutations in the promoter of the telomerase catalytic 
reverse transcriptase subunit located in two hotspots at -124 and -146 bp upstream the ATG 
start site, were found to be the most important mechanism responsible for reactivation or re-
expression of telomerase in cancer cells (Vinagre, Almeida et al. 2013, Vinagre, Pinto et al. 
2014, Akincilar, Unal et al. 2016). This ATG start site is responsible for generating a consensus 
binding site for transcription factors of the E26 transformation-specific (ETS) family within the 
TERT promoter region that stimulate the TERT promoter activity and, consequently, TERT 
transcription and synthesis (Horn, Figl et al. 2013, Huang, Hodis et al. 2013, Patton and 
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Harrington 2013). These TERT promoter mutations have already been documented in several 
cancers, namely of the central nervous system, the bladder, thyroid (follicular cell-derived 
tumors) and in melanomas (Vinagre, Pinto et al. 2014). In the case of the adrenal cortex, 
however the Cancer Genomic Atlas (TCGA), a multinational project that analyzed the genomes 
of different human cancers only identified 4 cases of TERT promoter mutations at -124 bp 
upstream the ATG start site, in 91 Adrenal Cortex Cancers (Zheng, Cherniack et al. 2016). 
Besides to unregulated growth, cancer cells are also characterized by invasiveness. Part of 
the aggressiveness of cancers is highly dependent on the loss of cell to cell adherence and 
hence on changes in the function of cell adhesion molecules (CAM) that regulate the 
connection between the neoplastic cells, as well as, between cells and extracellular matrix 
(Cavallaro and Christofori 2004, Wheelock, Shintani et al. 2008). CAM have also been 
implicated in the control of cell proliferation and hence in neoplasia formation.  
Cadherins are among such molecules and their expression in several malignant tumors has 
been demonstrated to be reduced or at least inactivated (Hirohashi 1998, Cavallaro and 
Christofori 2004, Wheelock, Shintani et al. 2008). There are 3 main cadherin molecules E-, P- 
and N-cadherin, each one associated with different tissues and tumors. Changes in their level 
of expression have been associated with increased tumor aggressiveness (Angst, Marcozzi et 
al. 2001, Halbleib and Nelson 2006). Cadherins are linked to the actin cytoskeleton via binding 
to catenins, notably β-catenin, in adherens junctions (Nagafuchi 2001). Besides the adhesion 
function of β-catenin, its involvement in Wnt signaling pathway is already well described and it 
is appointed as a key protein in the ACC tumorigenesis (Wijnhoven, Dinjens et al. 2000, Tissier, 
Cavard et al. 2005, Komiya and Habas 2008). 
Cell adhesion molecules are considered to play a significant role in the reduction of 
connections of cancer cells and especially metastatic cancer cells: reduced expression of E-
cadherin on invasive neoplastic cells has been demonstrated in cancers of the stomach, liver 
and breast (Furukawa, Takigawa et al. 1994, Wheelock, Shintani et al. 2008). On the other 
hand, markedly elevated levels of soluble cadherins, like E-cadherin have been demonstrated 
in patient with metastatic cancer (Furukawa, Takigawa et al. 1994, Inge, Barwe et al. 2011). 
Other tumors, instead of losing the expression of a certain cadherin, switch the cadherin 
subtype (Wheelock, Shintani et al. 2008). This switch has been observed in various metastatic 
tumors such as breast and prostate cancers, suggesting that it apparently confers progression 
advantage to such tumors (Mariotti, Perotti et al. 2007, Wheelock, Shintani et al. 2008, Araki, 
Shimura et al. 2011). The adrenal cortex, despite being an epithelial tissue, is normally 
characterized by an absence of the E-cadherin and the presence of N-cadherin (Khorram-
Manesh, Ahlman et al. 2002, Tsuchiya, Sato et al. 2006, Pereira, Morais et al. 2013). Similarly 
to E-cadherin, N-Cadherin expression has been described to be altered in some types of 
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tumors namely in the adrenal cortex (Khorram-Manesh, Ahlman et al. 2002, Velazquez-
Fernandez, Laurell et al. 2005). 
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6.3 Aim 
 
The aim of this study was to evaluate cadherins and β-catenin expression in conjunction to 
telomerase promoter mutation and telomerase nuclear expression in adrenocortical tumors 
(both benign and malignant, secretory and non-secretory), as well as in normal adrenal tissue 
in order to try to identify a pattern of molecular markers that may be useful in the differential 
diagnosis of adrenocortical tumors and also possible targets for therapeutical drugs 
development.  
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6.4 Material and Methods  
 
Case Selection 
The study was approved by the Ethics Committee of the Centro Hospitalar São João - Porto, 
Portugal. The participants provided their written informed consent to accept that a tumor 
sample is stored in the tumor bank of the Department of Pathologic Anatomy - Centro 
Hospitalar São João, Porto, to posteriorly be used in research. 
Samples from adrenal tumors were obtained from 39 patients, with adrenocortical carcinoma 
(ACC) (n=15) and adrenocortical adenomas (ACA) (n=24), including non-functioning 
adenomas (ACAn) (n=11) and cortisol secreting lesions presenting as Cushing syndrome 
(ACAc) (n=13). Nine specimens of normal adrenal glands obtained in nephrectomy procedures 
for the treatment of kidney tumors (N-AG) (n= 9) were also used. 
 
DNA extraction 
DNA was extracted from 10 μm sections of paraffin-embedded tissues after careful micro-
dissection. The extraction was performed using the Ultraprep Tissue DNA Kit (AHN 
Biotechnologie, Nordhausen, Germany) following the manufacturer’s instructions. 
 
PCR and Sanger sequencing for TERT  
Screening of TERT promoter mutations was performed in two hotspots located at -124bp and 
-146bp upstream from the ATG start site previously identified by PCR followed by Sanger 
sequencing. TERT promoter mutation analysis was performed with the pair of primers 
FwTERT: CAGCGCTGCCTGAAACTC and RwTERT: GTCCTGCCCCTTCACCTT. 
Amplification of genomic DNA was performed by PCR using the commercial kit Qiagen 
Multiplex PCR (Qiagen, Hilden, Germany) following the manufacturer instructions. Sequencing 
reaction was performed with the ABI Prism BigDye Terminator Kit (Perkin-Elmer, Foster City, 
California) and the fragments were run in an ABI prism 3100 Genetic Analyser (Perkin-Elmer).  
 
Telomerase, β-catenin and cadherins Immunohistochemistry (IHC) 
IHC was performed in 3μm formalin-fixed paraffin embedded tissue sections mounted on 
adhesive microscope slides. Sections were deparaffinized, rehydrated in graded alcohols and 
underwent antigen retrieval performed by microwave treatment in 0.01 M-citrate buffer at pH 
6.0.  Then, the samples were incubated overnight at 4° C with the primary antibody for hTERT 
(polyclonal, rabbit, 1:500, Rockland Immunochemicals Inc., Gilbertsville, PA), N-cadherin 
(1:900, ab18203, Abcam, Cambridge, UK), E-cadherin (1:200, EP700Y, Cell Marque, Rocklin, 
CA, USA), P-cadherin (1:200, HPA001767, Atlas Antibodies, Stockholm,Sweden) or β-catenin 
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(1:500; 424A-14; Cell Marque).  The detection of the immune reaction was performed using 
the streptavidin-biotin immunoperoxidase method (Thermo Scientific/Lab Vision,Fremont, 
USA). DAB (3,3'- Diaminobenzidine) was used as chromogen and hematoxylin as nuclear 
counterstaining. A previously tested liver cancer case was used as positive control for hTERT, 
normal liver for N-cadherin, lung adenocarcinoma for E-cadherin, normal human tonsil for P-
cadherin and breast cancer for β-catenin, while the omission of primary antibody incubation 
was used as negative control. 
Cytoplasmic and nuclear telomerase expression, membrane cadherin expression and β-
catenin expression were recorded in all tissue samples and evaluated independently by two 
observers. An IHC score for telomerase was established, 0 for no staining; 1 for staining 
present in 20%-50% of nuclei; and 2 for staining present in 50%-100% of nuclei. In the 
statistical comparisons only TERT nuclear expression was considered. For E-, N- and P-
cadherin, the membrane expression was considered 0 if there was no expression or 1 if the 
tissues presented membrane expression. The staining of β-catenin was analyzed in different 
localization: in the cell membrane, in the cytoplasm and in the nucleus. 
 
Statistical analysis 
The IHC scores for telomerase nuclear expression and for N-cadherin membrane expression 
were compared among the different groups, through the X2 test. The correlations were 
performed through the Spearman Test. Statistical analysis was carried out using the SPSS 
software (version 20.00) for Windows and a value of p<0.05 was considered statistically 
significant. 
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6.5 Results 
 
No TERT promoter mutations were detected in ACT 
TERT promoter mutations in the hotspots located at -124bp and -146bp upstream from the 
ATG start site were not observed in any of the studied cases, including in ACC. 
 
Telomerase nuclear expression was absent in the majority of ACT  
Contrarily to the absence of TERT promoter mutations, telomerase expression, as assessed 
by immunohistochemistry, was observed both in the cytoplasm and in some cases in the 
nucleus. Significant differences between the groups were present (p<0.05). 
 
Cytoplasmic expression - Telomerase cytoplasmic expression was present in all types of 
adrenocortical tumors studied (Figure 29). It was also observed in the cytoplasm of normal 
adrenal glands. Cytoplasmic expression did not differ, in statistical terms, between the different 
types of tumor. The only difference that was observed was that tissue areas with higher lipid 
droplet’s content apparently displayed lower telomerase staining. This was especially 
noticeable in the normal adrenal tissue where the Fasciculata layer apparently had lower 
cytosol staining (Figure 29). 
 
Nuclear expression - The IHC score for nuclear expression was significantly different between 
the studied groups (p<0.05). The majority (73,4%) of the ACC were negative for telomerase 
nuclear staining (Figure 29A). The staining was positive in 26.6% of ACC being that 13.3% of 
those presented less than 50% of nuclei stained and 13.3% presented more than 50% of the 
nuclei stained (Figure 29B) (Table 6). 
Non-functioning adenomas presented positive staining in 45.5% of the cases. Of these, 27.3% 
presented less than 50% of nuclei stained and 18.2% presented more than 50% of the nuclei 
stained (Figure 29C and 29D) (Table 6).  
On the contrary, none of the cortisol secreting adenomas presented nuclear staining for 
telomerase (Figure 29E) (Table 6). 
Finally, none of the analyzed normal adrenal glands presented telomerase nuclear staining 
(Figure 29F) (Table 6).  
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Figure 29 - Immunohistochemistry staining of telomerase reverse transcriptase (Scale = 20 µm). A- 
Adrenocortical carcinoma negative for nuclear staining; B- Adrenocortical carcinoma with nuclear 
positive staining; C- Non-functioning adrenocortical adenoma without nuclear staining; D- Non-
functioning Adrenocortical adenoma with nuclear positive staining; E- Adrenocortical adenoma with 
Cushing syndrome without nuclear staining; F-  Normal adrenal gland without nuclear staining. Arrow 
heads are showing cells of glomerulosa layer that present low levels of lipid droplets and the arrows are 
pointing cells of fasciculata layer that present high levels of lipid droplets. 
 
 
Table 6 - Telomerase reverse transcriptase’ nuclear expression in adrenocortical carcinoma, 
adrenocortical adenoma and normal adrenal gland. 
 Score 
Groups n Zone 0 1 2 
ACC 15  11 (73.4%) 2 (13.3%) 2 (13.3%) 
ACAn 11  6 (54.5%) 3 (27.3%) 2 (18.2%) 
ACAc 13  13 (100.0%) 0 (0.0%) 0 (0.0%) 
N-AG 
9 Z Glomerulosa 9 (100.0%) 0 (0.0%) 0 (0.0%) 
9 Z Fasciculata 9 (100.0%) 0 (0.0%) 0 (0.0%) 
9 Z Reticularis 9 (100.0%) 0 (0.0%) 0 (0.0%) 
ACC- Adrenocortical carcinoma; ACAn- non-functioning adrenocortical adenomas; ACAc- adrenocortical 
adenomas with Cushing syndrome; N-AG- Normal Adrenal glands;  
Scoring explanation: 0-No staining; 1- Staining present in 20%-50% of nuclei; 2- Staining present in 50%-
100% of nuclei 
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N-cadherin membrane expression is absent in the majority of ACC  
E-, N- and P-cadherin expression in the membrane was assessed by immunohistochemistry 
in all tissue samples. The E- and P-cadherin were not expressed in any of the studied cases 
(Figures 30 and 31). On the contrary generalized immunostaining for N-cadherin was clearly 
present. However, the IHC score for N-cadherin membrane expression was significantly 
different between the studied groups (p<0.001). The majority of the adrenocortical carcinomas 
(67%) did not present N-cadherin at the membrane, while the adrenocortical adenomas, and 
normal adrenal glands always presented N-cadherin membrane expression (Table 7 and 
Figure 32). A negative significant correlation between the N-cadherin and Ki-67 expression 
was verified (R2= -0.6102; p<0.001). Contrarily, in the ACC group, no correlation was found 
between N-cadherin and Ki-67 (p>0.05) (Ki-67 data used was from the results of the Chapter 
3, Figure 19). 
 
 
Figure 30 - Immunohistochemistry staining of E-cadherin (Scale = 50 µm). A- Adrenocortical carcinoma; 
B- Non-functioning adrenocortical adenoma; C- Adrenocortical adenoma with Cushing syndrome and 
D- Normal adrenal gland. 
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Figure 31 - Immunohistochemistry staining of P-cadherin (Scale = 50 µm). A- Adrenocortical carcinoma; 
B- Non-functioning adrenocortical adenoma; C- Adrenocortical adenoma with Cushing syndrome and 
D- Normal adrenal gland. 
 
 
Figure 32 - Immunohistochemistry staining of N-cadherin (Scale = 50 µm). A- Adrenocortical carcinoma; 
B- Non-functioning adrenocortical adenoma; C- Adrenocortical adenoma with Cushing syndrome and 
D- Normal adrenal gland. 
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Table 7 - N-cadherin membrane expression in adrenocortical carcinoma, adrenocortical adenoma and 
normal adrenal gland. 
 Score 
Groups n 0 1 
ACC 15 10 (66.7%) 5 (33.3%) 
ACAn 11 0 (0.0%) 11 (100.0%) 
ACAc 13 0 (0.0%) 13 (100.0%) 
  N-AG 9 0 (0.0%) 9 (100.0%) 
ACC- Adrenocortical carcinoma; ACAn- non-functioning adrenocortical adenomas; ACAc- adrenocortical 
adenomas with Cushing syndrome; N-AG- Normal Adrenal glands;  
Scoring explanation: 0- No N-cadherin membrane staining; 1- N-cadherin staining in the membrane. 
 
β-catenin nuclear expression was present in both ACC and non-functioning ACA. 
The staining of β-catenin showed different distributions, namely in the cell membrane, in the 
cytoplasm and in the nucleus (Figure 33). The distribution of the β-catenin immunostaining 
was significantly different between the groups (p<0.01). However the abnormal location of the 
staining, i.e., cytoplasm and/or nucleus, was not a marker for any specific group as it was 
observed in ACC and ACA in spite of in different proportions (Table 8). 
 
 
Figure 33 - Immunohistochemistry staining of β-catenin (Scale = 20 µm). A- Adrenocortical carcinoma; 
B- Non-functioning adrenocortical adenoma; C- Adrenocortical adenoma with Cushing syndrome and 
D- Normal adrenal gland. 
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Table 8 - β-catenin staining localization distribution in the different study groups. 
 Localization 
Groups n Only membrane 
Membrane + 
cytoplasm 
Membrane + 
cytoplasm + 
nucleus 
ACC 15 4 (26.7%) 9 (60.0%) 2 (13.3%) 
ACAn 11 0 (0.0%) 6 (54.5%) 5 (45.5%) 
ACAc 13 0 (0.0%) 13 (100.0%) 0 (0.0%) 
N-AG 9 3 (33.3%) 6 (66.7%) 0 (0.0%) 
ACC- Adrenocortical carcinoma; ACAn- non-functioning adrenocortical adenomas; ACAc- 
adrenocortical adenomas with Cushing syndrome; N-AG- Normal Adrenal glands.  
 
Nuclear telomerase and membrane N-cadherin expression were positively correlated in ACC 
The majority of the ACC without N-cadherin expression in the membrane did not present 
nuclear telomerase expression (87.5%), while 75% of the carcinomas with N-cadherin 
presented nuclear telomerase expression (p<0.001) (Figure 34). 
 
 
Figure 34 - Relation between the N-cadherin and telomerase expression in the adrenocortical 
carcinomas (ACC). 
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6.6 Discussion 
 
Adrenocortical carcinomas are generally highly aggressive tumors and the understanding of 
its molecular pathogenesis is still limited. In consequence, the differential diagnosis between 
adenomas and carcinomas is sometimes difficult and the progress towards newer therapeutic 
tools still very limited (Ragazzon, Libe et al. 2010, Lafemina and Brennan 2012, Pereira, Morais 
et al. 2013).  
In the present study we investigated the frequency of TERT promoter hotspot mutations in 
adrenocortical tumors, while at the same time we analysed the molecular distribution of 
telomerase, cadherins and β-catenin in the same tumoral cells, to understand the roles played 
by these molecules in the biology of these tumors and the possible use of these proteins as 
therapeutic targets or at least as biomarkers for the differential diagnosis between benign and 
malignant adrenal tumors. 
Tumors that have high frequency of TERT promoter mutations originate mainly from tissues 
with low rates of self-renewal such as glioblastomas, melanomas and thyroid carcinomas 
(Killela, Reitman et al. 2013, Vinagre, Almeida et al. 2013). In contrast, the adrenal cortex is 
an exceptionally dynamic endocrine organ with a high rate of self-renewal (Pihlajoki, Dorner et 
al. 2015). Mutations in the promoter region of the TERT gene are among the most common 
somatic genetic lesions in human cancers, but knowledge about their frequency in adrenal 
cortex tumors has been limited because of the heterogeneity of these tumors. In our study, 
none of the cases presented TERT promoter mutations, which agrees with the presence of 
those mutations in no more than 12% of adrenocortical carcinomas formerly reported by other 
authors (Liu, Brown et al. 2014, Papathomas, Oudijk et al. 2014) and, more recently, in 4% of 
the cases of the multinational project of TCGA (Zheng, Cherniack et al. 2016). All of the 
mutations found in these studies were at-124 bp upstream the ATG start site (Liu, Brown et al. 
2014, Papathomas, Oudijk et al. 2014, Zheng, Cherniack et al. 2016). The low prevalence of 
TERT promotor mutations might imply that other mechanisms could be active leading to the 
maintenance of the telomeric function by alternative pathways. TERF2 is a gene that is related 
to one of such mechanisms. TERT and TERF2, were amplified respectively in 15% and 7% of 
the ACC analyzed in the TCGA study (Zheng, Cherniack et al. 2016). Since our study had an 
absolute number of ACC cases that was smaller than for instance that of TCGA, these results 
may not be considered significantly different. Taking together all of the studies that have 
addressed the presence of TERT promotor mutations in ACC cancer we have to conclude that 
the presence these mutations in these carcinomas (12 positive cases in 178 samples of ACC) 
has to be considered infrequent.  
On the other hand, our study is the first to evaluate the immunohistochemical expression of 
telomerase in adrenocortical tumors. And in fact telomerase expression occurred in 26.6% of 
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the ACC. An interesting possibility is that these may be carcinomas in initial phases of 
development when the prolonging of cellular viability may be crucial to the occurrence of 
cellular modifications that lead to more aggressive forms of ACC. Taking into account that the 
majority of ACC did not have increased telomerase expression (as well as TERT promoter 
mutations), telomerase over-expression does not seem to be crucial for the malignant 
adrenocortical tumors.  
 A completely different situation was observed concerning the expression of N-Cadherin during 
tumorigenesis. Changes in cadherin expression were observed in various types of tumors and 
have been associated with increased tumor aggressiveness because cells lose their 
interaction with neighbor cells and intercellular matrix and can more easily invade the 
neighboring organs or migrate (Cavallaro and Christofori 2004, Mariotti, Perotti et al. 2007, 
Wheelock, Shintani et al. 2008). 
In the normal adrenal glands and in adrenal cortex adenomas the cadherin that is normally 
expressed is N-cadherin and our study confirmed that. There was, however, a significant loss 
of N-cadherin expression in malignant tumors. Loss of N-cadherin membrane expression was 
found in the majority of the adrenocortical carcinomas suggesting that this phenomenon is 
involved in the aggressiveness of these cases, possibly by being responsible for a reduction 
of cell adhesion thus facilitating the process of cellular migration and invasion that could lead 
to metastization.  
In the current study we could not associate the abnormal expression of β-catenin with the 
malignant character of the tumors, since we found nuclear expression in both ACC and non-
functioning ACA. Previously, Tissier et al that was the first author to demonstrate that Wnt 
signaling activation was frequent in adrenocortical tumors, verified that the abnormal 
expression was observed in both ACA and  ACC, and most adrenocortical adenomas showing 
an abnormal β-catenin immunostaining were non-functioning adrenocortical tumors, 
corroborating with our results (Tissier, Cavard et al. 2005, Ragazzon, Libe et al. 2010).Besides 
that, no association was demonstrated between the expression of abnormal β-catenin and N-
cadherin.   
The evidence of the existence of TERT non-canonical functions such as roles in apoptosis, 
DNA damage response, inflammation and gene expression regulation has been reported 
(Perrault, Hornsby et al. 2005, Li and Tergaonkar 2014, Liu, Liu et al. 2016).  
According to our results a significant relationship between telomerase nuclear expression and 
N-cadherin membrane expression does exist, since the majority of the carcinomas with 
telomerase expression, presented intact N-cadherin in the membrane. Curiously, in a study 
using a hTERT-transfected prostate tumor cell line the authors observed a concomitant 
overexpression of N-Cadherin and suggested that telomere elongation might affect the 
cadherin expression (Hirashima, Migita et al. 2013). More recently, Liu et al generated two cell 
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lines with TERT overexpression expression and observed that TERT expression significantly 
increased the cell adhesion (Liu, Liu et al. 2016). Our study, together with these studies seems 
to support another non-canonical function of TERT: a TERT role in cell adhesion.  
Besides that, our results support the hypothesis that different tumors use distinctive molecular 
approaches in order to reach advantage that may promote tumor progression, depending on 
the endogenous proliferative rate of the tissues where those tumors originate. Since the 
adrenal cortex has a high rate of self-renewal (Pihlajoki, Dorner et al. 2015) and the ACC are 
characterized by having an increased rate of proliferation, as we observed before  through the 
Ki-67 immunohistochemistry, these tumors do not need an increased telomerase expression 
to maintain the survival of cells. In this case, what seems to be more important is space to 
expand and the loss of cell adhesion that allows the cells to invade and metastasize is the 
most important.  
As a general rule we postulate that there is telomerase re-expression in carcinomas with slow 
proliferative capacity in order to prolong their cell's lifespan allowing them to accumulate 
somatic cancerigenic mutations. These carcinomas usually maintain the cadherins expression 
at their membranes at least in the first phases of their transformation, while in carcinomas 
without increased telomerase expression the cells have an elevated proliferation rate and tend 
rather to loose cadherin adhesion at their membranes to facilitate the tumor expansion.  
Finally, no correlation was observed between N-cadherin and Ki-67 in the ACC group, meaning 
that the loss of N-cadherin expression is observed in both high and low grade ACC, reinforcing 
the idea that this marker may in the future have a great importance for diagnostic application.  
 
In conclusion, our study shows that TERT promoter mutations and nuclear telomerase 
expression are not very frequent in adrenocortical carcinomas and are not likely to be useful 
molecular markers for differential diagnosis or treatment target. In contrast, the loss of the N-
cadherin membrane expression is frequent in adrenocortical malignant tumors and may 
represent a useful marker for diagnosis and/or treatment. TERT may have a non-canonical 
function in the cell adhesion.  
  
 
 
 
 
 
Chapter 7 
IGF2 role in adrenocortical carcinoma biology 
 
  
Chapter 7 
108 
  
Chapter 7 
109 
7.1 Abstract 
 
Clinical outcomes of adrenocortical carcinomas (ACC) could be improved by using novel 
treatment targets based on the recent advances of tumor biology knowledge. Insulin-like 
growth factor 2 (IGF2) protein expression is usually 8 to 80 fold higher in ACC when compared 
to normal adrenal glands (N-AG) or adrenocortical adenomas (ACA), despite the fact that the 
biological features of high versus low IGF2 expressing ACC have not yet been well 
characterized. Our goal was to understand the IGF2 role in ACC biology by focusing in several 
cancer hallmarks, including cell proliferation, viability, invasion and metabolism. 
IGF2 immunohistochemistry expression was evaluated in non-functioning adenomas (ACAn) 
(n=14), ACA with Cushing`s syndrome (ACAc) (n=9), ACC (n=13) and N-AG (n=9). The effects 
of IGF2 (0, 50, 100 ng/mL) in cell proliferation, viability, invasion and metabolism, as well as in 
MAPK/ERK pathway activation and N-cadherin and p27 expression were evaluated in the ACC 
human cell line H295R.   
IGF2 expression was increased in ACC and ACAc compared to ACAn and N-AG. Exposure to 
100ng/mL of IGF2 increased H295R cell proliferation, viability and phospho-ERK expression. 
IGF2 triggered cell proliferation but not cell viability was reverted by MEK/MAPK/ERK 
inhibition. IGF2 at a 50ng/mL concentration increased the glycolytic flux and decreased 
glutamine consumption. 
In conclusion, IGF2 is an excellent molecular marker to differentiate ACC from ACAn.  In 
addition, IGF2 dose-dependently increased cell proliferation and viability, while IGF2 at 
different concentrations also modulates cell metabolism. These data support the conclusion 
that different IGF2 concentrations in ACC can be responsible for different biological behaviors 
of ACC.  
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7.2 Introduction 
 
Detailed knowledge of the molecular alterations that underlie the malignant transformation of 
benign cells, as well as the identification of the specific cell cycle alterations found in cancer 
cells that are associated with enhanced survival, will not only allow the identification of new 
diagnostic and prognostic tools but also have the potential to disclose novel treatment targets. 
The Insulin-like growth factor 2 (IGF2) system is one of the key molecular mechanisms that 
was recurrently described to be involved in adrenocortical carcinoma (ACC) pathophysiology 
(Soon, McDonald et al. 2008, Lehmann and Wrzesinski 2012, Fassnacht, Kroiss et al. 2013). 
IGF2 is a growth factor secreted mainly by the liver but also in many other tissues where it acts 
in an autocrine or paracrine way. IGF2 actions are mediated by tyrosine kinase receptors: the 
IGF1 receptor (IGF1R), insulin receptor (IR) and IGF2 receptor (IGF2R) (Ribeiro and Latronico 
2012, Iams and Lovly 2015). Tyrosine kinase receptors activation in turn lead to mitogen-
activated protein kinase (MAPK) or phosphatidylinositol 3-kinase (PI3K)/Akt pathways 
activation. Activated Akt is then able to trigger the subsequent activation of the mammalian 
target of rapamycin (mTOR) pathway. MAPK, PI3K/Akt and mTOR pathways are well 
described mechanisms involved in proliferation, survival and metastasis of cancer cells 
(Ribeiro and Latronico 2012, Livingstone 2013, Iams and Lovly 2015). 
IGF2 overexpression was previously described as responsible for increased proliferation of 
ACC cells (Guillaud-Bataille, Ragazzon et al. 2014). However, despite being increased in the 
majority of the tumors, IGF2 expression can be highly variable in ACC cells. IGF2 mRNA 
expression was found to be 10 to 20 fold higher in ACC compared to normal adrenal glands 
or ACA, while IGF2 protein expression was described to be 8 to 80 fold greater in ACC than in 
normal adrenal glands or ACA (Ilvesmaki, Kahri et al. 1993, Boulle, Logie et al. 1998, Erickson, 
Jin et al. 2001, Schmitt, Saremaslani et al. 2006, Soon, Gill et al. 2009, Guillaud-Bataille, 
Ragazzon et al. 2014).  
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7.3 Aim 
 
Our aim was to extend the understanding of the IGF2 role in ACC evaluating the expression 
of IGF2 in the adrenocortical tumors and the paracrine effects of IGF2 in the proliferation, 
viability, invasion and metabolism of ACC cells. 
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7.4 Material and Methods 
 
Adrenal tissue  
Adrenal tumor samples were obtained from patients with ACT (n=36), comprising 13 ACC and 
23 ACA, including non-functioning adenomas (ACAn) (n=14) and cortisol secreting lesions 
presenting as Cushing syndrome (ACAc) (n=9). Normal adrenal glands (N-AG) (n=9) retrieved 
during nephrectomy performed for urologic conditions from patients without adrenal pathology 
were used as controls. 
 
IGF2 Immunohistochemistry (IHC) and data analysis 
IHC was performed in 3μm formalin-fixed paraffin embedded tissue sections mounted on 
adhesive microscope slides. Sections were deparaffinized, rehydrated in graded alcohols and 
underwent antigen retrieval performed by microwave treatment in 0.01 M-citrate buffer at pH 
6.0, during 9 minutes.  The sections were then incubated overnight at 4° C with the primary 
antibody against IGF2 (Table 9). The detection of the immune reaction was performed using 
the avidin-biotin peroxidase method (1:100; Vector Laboratories, Inc., Peterborough, UK). DAB 
(3,3'- Diaminobenzidine) was used as chromogen and hematoxylin as nuclear counterstaining. 
Placental tissue was used as positive control, while omission of the primary antibody from 
incubation was used as negative control.  
From each section slide, a minimum of 10 microphotographs were taken (Leica EC3 camera, 
Leica, Germany) and images were analyzed using the software ImageJ (originated at the 
National Institutes of Health, USA) that allows to separate the stained area from the total area 
in order to calculate the percentage of the area stained for IGF2.  
 
Cell Culture 
Human adrenocortical carcinoma cell line (H295R) obtained from CLS Cell Lines Service 
GmbH (Eppelheim, Germany) was cultured in Dulbecco's Modified Eagle Medium: Nutrient 
Mixture F-12 (DMEM/F12; Sigma-Aldrich, St Louis, MO, USA) supplemented with 0.365 g/L of 
L-Glutamine (Sigma-Aldrich, St Louis, MO, USA), 10 mL/L of Penicillin-Streptomycin (Sigma-
Aldrich, , St Louis, MO, USA), 2.5% of NuSerum (BD Bioscience, San Jose, CA) and 1% of 
ITS + Premix (Corning, NY, USA). The medium was changed three/four times per week and 
the cells were detached for sub-culturing with a 0.25% trypsin- Ethylenediaminetetraacetic acid 
(EDTA) solution (Sigma-Aldrich, St Louis, MO, USA). Cell cultures were handled in a laminar 
flow chamber and maintained at 37°C in an incubator (Heracell 150i, Thermo scientific, 
Waltham, MA USA) with 5% CO2. Cells were then incubated with 2 different IGF2 
concentrations (50ng/mL and 100 ng/mL) for 24 hours, except when the aim was to evaluate 
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MAPK/ERK pathway activation in which case the incubations were performed for 5, 10 and 20 
minutes. 
 
Cell proliferation assay 
H295R cells (0.4x106 cells/well) were cultured in 24 well-plates with complete medium for 22 
hours followed by a 2 hours period with serum depleted medium (NuSerum). H295R cells were 
then incubated for 24 hours in the presence of IGF2 with or without a MEK inhibitor - PD184352 
(Sigma-Aldrich, St Louis, MO, USA). H295R cell proliferation was monitored by 5-bromo-2-
deoxyuridine (BrdU, 10µM, Sigma-Aldrich) incorporation over a 2 hours period. Cultured cells 
were harvested by cyto-spinning, fixed in 4% paraformaldehyde (Merck Millipore, Darmstadt, 
Germany) followed by  immunofluorescence for BrdU staining (Table 9). A minimum of 500 
cells were counted at a 400x magnification.  
 
Cell viability assay 
H295R cells (0.05x106 cells/well) were cultured in 96 well-plates with complete medium for 22 
hours followed by a 2 hour period with serum depleted medium. H295R cells were then 
incubated with IGF2 at different concentrations, with or without a MEK inhibitor - PD184352 
(Sigma-Aldrich, St Louis, MO, USA), in the presence of 10% Alamar Blue (Bio-Rad AbD 
Serotec, Oxford, UK). Absorbance was measured at wavelengths of 570 nm and 595 nm, at 
0, 12 and 24 hours. The % of resazurin reduction was calculated using the following equation:  
%𝑅𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 = (
𝐸𝑜𝑥𝜆2𝑥 𝐴𝜆1−𝐸𝑜𝑥𝜆1𝑥 𝐴𝜆2
𝐸𝑟𝑒𝑑𝜆1𝑥 𝐴𝑏𝑙𝑎𝑛𝑘 𝜆2−𝐸𝑟𝑒𝑑𝜆2𝑥 𝐴𝑏𝑙𝑎𝑛𝑘 𝜆1
) 𝑥100 , being λ1 = 570 nm, λ2 = 595 nm, Eox1 
= 80,573, Eox2 = 117,216, Ered1 = 155,667 and Ered2 = 14,652.  
 
Invasion Assay 
To evaluate the invasion capacity of H295R cells incubated with different IGF2 concentrations, 
cell culture inserts with an 8.0μm pore size membrane (BD Biocoat 24-well Matrigel Chambers, 
BD Bioscience Bedford, MA, USA) were used according to the manufacturer’s protocol. 
Matrigel-coated inserts were pre-incubated for 1 h with serum-free DMEM-F12, before H295R 
cells (0.1x106 cells) were seeded in the upper chamber of the well and cultivated in the 
presence of IGF2. Cells cultured with media supplemented with 30% Nu-serum were used as 
positive controls. After 24 hours, the medium was collected, the membranes of the inserts were 
fixed with 70% ethanol and the cells were stained with 0.2% crystal violet for 10 minutes, as 
previously described (Justus, Leffler et al. 2014). The membranes were then mounted in slides 
using entellan and the cells that invaded the membrane were observed using an optical 
microscope (Zeiss AxioPlan microscope, Zeiss, Germany). 
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N-cadherin immunofluorescence (IF) 
The H295R cell (0.4 x106 cells) were incubated in coverslips imersed in 24 well-plates, with 
complete medium for 22 hours followed by 2 hour period with serum depleted medium 
(NuSerum). H295R cells were then exposed to IGF2 for 24 hours, after which cells were fixed 
in 4% paraformaldehyde for 15 min before immunofluorescence was performed. The 
coverslips were incubated overnight at 4°C with the primary antibody for N-cadherin (Table 9), 
followed by the secondary antibody incubation for 2 hours to allow N-cadherin detection (Table 
9). The slides were then mounted and counterstained with Vectashield hardset with Dapi (ref. 
H1500, Vector Laboratories, UK). 
 
Western Blot 
After IGF2 incubation, cell proteins were extracted using RIPA buffer (ref: 20-188, Sigma-
Aldrich, USA) with protease inhibitor (ref: 4693124001, Roche, Switzerland) and phosphatase 
inhibitor (ref: 4906845001, Roche). Extracted proteins were quantified using the Pierce™ BCA 
Protein Assay Kit (ref: 23225, ThermoFisher Scientific, USA). A total of 20 µg of protein was 
heated at 95ºC for 10 minutes, fractionated on a 12% sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride membranes. The 
membranes were blocked in a Tris-buffered saline solution with 0.05% Tween 20 containing 
5% BSA (ref: A7906, Sigma- Aldrich) and incubated overnight at 4ºC with the primary 
antibodies, separately (Table 9). Mouse β-actin was used as protein loading control for p27 
and N-cadherin quantification. Immune-reactive proteins were detected separately using the 
respective secondary antibody (Table 9). Membranes were reacted with ECL detection (ref. 
32209, GE Healthcare) system and read with the ChemiDoc™ XRS+ System (Bio-Rad, UK). 
The densities of each band were obtained using the Quantity One Software (Bio-Rad, UK). 
 
Nuclear magnetic resonance (NMR) spectroscopy  
1H NMR spectroscopy (VNMRS 600 MHz, Varian, Inc. Palo Alto, CA) was used to determine 
metabolite concentrations in H295R cell culture media after IGF2 incubation. Sodium fumarate 
was used as internal reference (6.50 ppm) to quantify the following metabolites (multiplet, 
ppm): lactate (doublet, 1.33); alanine (doublet, 1.45); pyruvate (singlet, 2.36); glutamine (triplet, 
3.75) and H1-α glucose (doublet, 5.22) as previously described (Alves, Oliveira et al. 2011). 
The relative areas of 1H NMR resonances were quantified using the curve-fitting routine 
supplied with the NUTSpro™ NMR spectral analysis program (Acorn, Fremont, CA, USA) and 
the results were normalized to the number of cells present at the time when the media was 
collected. 
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Table 9 – Antibodies used in this chapter. 
Antibodies Source Reference and Vendor Dilution 
Primary antibody used in Immunohistochemistry 
IGF2 Rabbit 
Ref. ab9574; Abcam, Cambridge, United 
Kingdom 
1:100 
Primary antibody used in Immunofluorescence 
BrdU Mouse 
Ref. sc-32323; Santa Cruz Biotechnology, 
Heidelberg, Germany 
1:200 
N-cadherin Rabbit 
Ref. ab18203; Abcam, Cambridge, United 
Kingdom 
1:200 
Primary antibodies used in Western Blot 
Phospho-ERK 1/2 Rabbit 
Ref. 4370S; Cell Signaling Technology, Danvers, 
USA 
1:2000 
Total-ERK 1/2 Mouse 
Ref. 4696S; Cell Signaling Technology, Danvers, 
USA 
1:2000 
p27 Mouse 
Ref. ab193379; Abcam, Cambridge, United 
Kingdom 
1:500 
N-cadherin Rabbit 
Ref. ab18203; Abcam, Cambridge, United 
Kingdom 
1:1000 
β-actin Goat 
Ref. sc1616; Santa Cruz Biotechnology, 
Heidelberg, Germany 
1:250 
Secondary antibody used in Immunohistochemistry  
Biotinylated anti-rabbit Swine Ref. EO35301-2; Dako, Glostrup, Denmark 1:200 
Secondary antibody used in Immunofluorescence  
Anti-mouse IgG 
(H+L), Alexa Fluor® 
488 
Goat 
Ref. 4408; Cell Signaling Technology, Danvers, 
USA 
1:1000 
Anti-rabbit IgG (H+L), 
Alexa Fluor® 555 
Goat 
Ref. 4413; Cell Signaling Technology, Danvers, 
USA 
1:1000 
Secondary antibodies used in Western Blot 
Anti-goat IgG-HRP Donkey 
Ref. sc-2020; Santa Cruz Biotechnology, 
Heidelberg, Germany 
1:1000 
Anti-mouse IgG-HRP Goat Ref. 12-349; Merck-Millipore, California, USA 1:2000 
Anti-rabbit IgG-HRP Goat 
Ref. ab6721; Abcam, Cambridge, United 
Kingdom 
1:2500 
IGF2- Insulin-like Growth Factor 2; BrdU- of 5-bromo-2-deoxyuridine; ERK- extracellular signal-regulated 
kinase; HRP - horseradish peroxidase; Ig- immunoglobulin 
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Statistical analysis 
All results are presented as Mean ± Standard Error (SE). D’Agostinho & Pearson test was 
used to evaluate variables normality. For continuous variables that passed this test, one-way 
ANOVA test with the post-hoc Tukey was used to compare the means of three groups. For the 
variables that did not pass the normality test, the Kruskal Wallis with a Post-hoc Dunn’s was 
used. The correlations between continuous variables were evaluated using the Pearson Test. 
The diagnostic accuracy of IGF2 was evaluated using the receiver operating characteristic 
(ROC) curve. The significance level was defined by a value of p<0.05. 
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7.5 Results 
 
IGF2 in tumor and normal human adrenocortical tissues 
 
The expression of IGF2 is significantly higher in ACC and ACAn 
The percentage of stained area for IGF2 was significantly higher in ACC (35.97 ± 1.38) and 
ACAc (31.85 ± 2.92) compared to ACAn (16.79 ± 2.09) and N-AG (13.45 ± 1.94), p<0.001 
(Figure 35 A-E). ROC Curve analysis showed an AUC of 1.00 for discrimination between ACC 
and ACAn, while for distinguishing ACC from ACAc and ACC from total adrenocortical 
adenomas (ACAt), AUC were only 0.64 and 0.86, respectively (Figure 35F). 
 
Figure 35 - Immunohistochemistry staining for IGF2 (Scale = 20 µm) in adrenocortical carcinoma (ACC) 
(A), adrenocortical adenoma with Cushing syndrome (ACAc) (B), non-functioning adrenocortical 
adenoma (ACAn) (C) and normal adrenal gland (N-AG) (D). Graphic representation of the percentage 
of the area staining for IGF2 in the studied groups (E) and ROC curves with the respective area under 
the curve (AUC) to compare carcinomas and adenomas (F) (ANOVA: ***p<0.001). 
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Besides that, we correlated IGF2 expression with the expression of previously markers 
analyzed in this thesis and we observed a significant positive correlation between IGF2 
expression and p27 expression (p<0.01). 
 
In vitro analysis of the influence of IGF2 in the H295R proliferation, viability, 
invasion and metabolism  
 
A high IGF2 concentration increases H295R proliferation and viability 
H295R incubation with the highest IGF2 concentration tested (100ng/mL) led to a significant 
increase in cell proliferation (111.6 ± 2.56 %) after 24 hours when compared to the cells 
incubated with the 50ng/mL concentration (100.2 ± 3.93 %) and to the cells that were not 
supplemented with IGF2 (100.0 ± 1.61 %; p<0.05; Figure 36A). Besides that IGF2 (100ng/mL) 
significantly increased cell viability (150.8 ± 15.40 %) when compared to the control (100.0 ± 
6.11 %; p<0.05; Figure 36B).  
 
Figure 36 - H295R cells proliferation (A) and viability (B) after incubation without or with IGF2 at the 
concentrations of 50 and 100ng/mL for 24 hours (ANOVA: *p<0.05). 
 
MEK inhibition reverts IGF2 triggered proliferation  
Incubation with both concentrations of IGF2 led to a rapid increase of the phospho-ERK 
expression (5 minutes: 50ng/mL: 266.6 ± 138.8; 100ng/mL: 198.2 ± 18.78) (Figure 37A). The 
IGF2 concentration of 50ng/mL led to similar levels of phospho-ERK during the study time (5, 
10 and 20 minutes), while the concentration of 100 ng/mL led to higher levels of phospho-ERK 
expression after 10 minutes of incubation (584.7 ± 212.3) followed by a subsequent decrease 
after this time point (20 minutes:296.2 ± 35.76) (Figure 37A). Co-incubation of IGF2 with a 
MEK inhibitor led to a significant increase in proliferation and viability (100ng/mL), which was 
able to revert almost totally the IGF2 triggered proliferation (IGF2 100ng/mL: 111.8 ± 4.16; 
IGF2 100ng/mL + PD184532 10µM: 102.7 ± 4.43) (Figure 37B). Co-incubation of IGF2 with a 
MEK inhibitor did not interfere in cell viability as compared to IGF2 alone (Figure 37C). 
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Figure 37 - Relative phospho-ERK expression after IGF2 incubation at the concentrations of 50 and 
100ng/mL for 5, 10 and 20 minutes (A). Cell proliferation (B) and viability (B) after IGF2 incubation 
(100ng/mL) with and without a MEK inhibitor (PD185352) at 10µM (ANOVA: *p<0.05; **p<0.01). 
 
IGF2 increases p27 expression  
IGF2 incubation lead to a non-significant increase of p27 expression (0 ng/mL: 100.00 ± 26.67; 
50 ng/mL: 169.2 ± 24.11; 100ng/mL: 157.9 ± 53.4) (Figure 38). 
 
 
Figure 38 - Relative p27 expression after 24 hours incubation with IGF2 at concentrations of 50 and 
100ng/mL. 
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IGF2 does not influence cell invasion capacity 
H295R cells depicted a low invasion capacity (Figure 39A) that was not influenced by IGF2 
incubation. IGF2 did not influence H295R cells N-cadherin expression (Figure 39B and C).  
 
Figure 39 - Matrigel membrane invaded with H295R cells (A). N-cadherin expression after 24 hours 
incubation with IGF2 at the 50 and 100ng/mL concentrations evaluated by Western Blot (B) and 
immunofluorescence (C). 
 
IGF2 incubation at a concentration of 50ng/mL decreased glutamine consumption 
Glutamine consumption by H295R cells was significantly decreased after IGF2 incubation at a 
concentration of 50ng/mL (0.03 ± 0.01 µmol/106 cells) compared to control (0.07 ± 0.01 
µmol/106 cells, p<0.01) or to cells incubated with the IGF2 concentration of 100ng/mL (0.06 ± 
0.01 µmol/106 cells, p<0.05, Figure 40B). Glucose consumption and pyruvate, lactate and 
alanine production were not significantly influenced by IGF2 incubation (Figure 40). 
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Figure 40 - Glucose (A) and glutamine (B) consumption; pyruvate (C), lactate (D) and alanine (E) 
production; lactate/glucose ratio (F) and lactate/alanine (G) after IGF2 incubation at the concentrations 
of 50 and 100ng/mL (ANOVA: *p<0.05; **p<0.01). 
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7.6 Discussion 
 
The IGF2 system represents a crucial pathway in the tumor biology of ACC and thus is 
considered an attractive target for the treatment of these tumors (Ribeiro and Latronico 2012). 
IGF2 protein expression was found to be 8 to 80 fold higher in ACC when compared to the N-
AG or ACA, although the biological differences between high and low IGF2 expressing ACC 
have not yet been well characterized (Ilvesmaki, Kahri et al. 1993, Boulle, Logie et al. 1998, 
Erickson, Jin et al. 2001, Schmitt, Saremaslani et al. 2006, Soon, Gill et al. 2009, Guillaud-
Bataille, Ragazzon et al. 2014). In order to gain further insight into the role of IGF2 in ACC 
pathogenesis, after having analyzed the IGF2 expression in different ACT, we have evaluated 
the effects of IGF2 in some important hallmarks of cancer, including cell proliferation, viability, 
invasion and metabolism in vitro in a human adrenocortical cancer cell line. 
As previously reported, IGF2 expression was found to be significantly higher in ACC compared 
with ACA (Schmitt, Saremaslani et al. 2006, Soon, Gill et al. 2009, Pereira, Morais et al. 2013). 
Besides that, IGF2 presented a 100% of specificity and sensibility to distinguish ACC from 
ACAn. However, IGF2 expression was found to be similar when ACC and ACAc were 
compared. A possible link between IGF2 and steroid production was demonstrated by showing 
that IGF2 alone was able to enhance the expression of enzymes involved in steroid synthesis 
and to increase the steroids levels in prostate cancer cells (Comstock and Knudsen 2013). 
The results observed in our study also suggest that IGF2 may have an additional role in adrenal 
steroidogenesis besides the well-known role in ACC tumorigenesis. Overall, our results 
support that IGF2 is a good tumor marker for the differential diagnosis between ACA and ACC, 
as previously reported by several authors (Gicquel, Boulle et al. 2001, Schmitt, Saremaslani 
et al. 2006, Soon, Gill et al. 2009, Guillaud-Bataille, Ragazzon et al. 2014). However, our data 
further indicates that IGF2 use as a tumor marker should be limited to the differential diagnosis 
between ACAn and ACC. 
Furthermore, we observed that IGF2 expression was positively correlated with p27 expression, 
a cell cycle regulator, in ACT. Then we confirmed that these molecular markers are indeed 
correlated since both concentrations of IGF2 used were able to increase the p27 expression, 
although no statistic difference was reached. Despite p27 being known to be a cyclin 
dependent kinase inhibitor, its role in the adrenocortical tumorigenesis is not yet well-
established, as in contrast to what would be expected, p27 expression is increased in ACC 
(Stojadinovic, Brennan et al. 2003, Pereira, Morais et al. 2013). p27 expression in ACC 
triggered by IGF2 should be unrelated MAPK/ERK pathway activation, since ERKs are known 
to be able to phosphorylate and degrade p27 protein (Zhang and Liu 2002). 
The high variability in IGF2 protein expression observed in ACC by several authors, raises the 
hypothesis whether this could be reflected in distinct biological behaviors. To test this 
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hypothesis a human adrenocortical carcinoma cell line (H295R) was used to assess the 
influence of IGF2 in several cancer hallmarks.  
IGF2 at the higher concentration tested increased H295R cell proliferation and viability. Since 
the same IGF2 concentration also increased phospho-ERK expression, suggesting 
MAPK/ERK signaling pathway activation, we decided to underscore whether this pathway 
could be the one responsible for the increased proliferation and viability. For that, we have 
used a MEK inhibitor reported to successfully suppress phospho-ERKs (Allen, Sebolt-Leopold 
et al. 2003, Wang, Boerner et al. 2007).  The use of this MEK inhibition was only able to revert 
IGF2 triggered cell proliferation, while cell viability was virtually unaltered. These data supports 
that MAPK/ERK pathway is not involved in mediating the IGF2 effects in cell viability and thus 
PI3K/Akt pathway may be the most logical possibly as its activation is also triggered by IGF2 
binding to IGF1R (Ribeiro and Latronico 2012).   
Besides that, IGF2 influence in cell adhesion and invasion were also tested. For that, N-
cadherin expression that is the main protein responsible for cell to cell adhesion in the adrenal 
gland was studied (Pereira, Maximo et al. 2016). Nevertheless, our results showed that IGF2 
does not influence N-cadherin expression in adrenocortical cancer cells and so invasibility 
seems to be not effected by IGF2. These results corroborate the data from a previous study 
showing that ACC patients presented similar overall and disease free survival, regardless IGF2 
expression levels, suggesting that IGF2 overexpression should not be used as a predictive 
marker in ACC (Guillaud-Bataille, Ragazzon et al. 2014).  
Finally, our data shows that IGF2 is able to interfere in ACC cell metabolism by increasing the 
lactate/glucose ratio that is correlated with an increase of glycolytic flux, being higher after 
incubation with the IGF2 concentration of 50ng/mL. Besides that, different IGF2 concentrations 
influenced differentially the glutamine consumption. Glutamine is known to enter the cell 
through the Alanine-Serine-Cysteine transporter (ASCT2). When inside the cell, glutamine by 
itself can contribute to nucleotide biosynthesis or it can suffer glutaminolysis, a metabolic 
pathway in which glutamine is catabolized to generate ATP and lactate. For that glutamine is 
initially converted by glutaminase, into glutamate which is then converted to α‐ketoglutarate, a 
tricarboxylic acid (TCA) cycle intermediate, to produce both ATP and anabolic carbons for the 
synthesis de novo of amino acids, nucleotides and lipids (Altman, Stine et al. 2016, Jin, Alesi 
et al. 2016). IGF2 at a lower concentration (50ng/mL) seems to lead to a compensatory 
balance between the glycolytic flux and glutamine consumption, as the glycolytic flux is 
increased while glutaminolysis decreases. IGF2 at a higher concentration (100ng/mL) leads to 
similar levels of glycolytic flux with increased levels of glutamine consumption as compared to 
the lower concentration (50ng/mL), suggesting that at a higher concentration IGF2 leads to 
cumulative effects on glycolytic and glutaminolysis pathways instead of compensatory. These 
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two metabolic pathways are well-known to be involved in the biosynthesis of molecular 
precursors that are needed to boost cellular proliferation. 
 
In conclusion, IGF2 arises as an excellent molecular marker to be used in the clinical setting 
for the differential diagnosis between adrenocortical carcinomas and non-functioning 
adenomas.  Moreover, IGF2 was demonstrated to influence adrenocortical cancer cell 
proliferation and viability, as well as to modulate the cellular metabolism status. Altogether, 
these data suggests that different IGF2 concentrations in ACC can be responsible for different 
biological behaviors of ACC. 
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8.1 Abstract 
 
Unraveling molecular mechanisms that regulate tumor development and proliferation is of the 
utmost importance in the quest to decrease the high mortality rate of adrenocortical 
carcinomas (ACC). Our aim was to evaluate the role of two of the MAPK signaling pathways 
(ERKs 1/2 and p38) in ACC tumor development, as well as the therapeutic potential of 
MAPK/ERK inhibition.   
ERKs 1/2 and p38 activation were evaluated in non-functioning adrenocortical adenomas 
(ACAn) (n=10), adrenocortical adenomas with Cushing syndrome (ACAc) (n=12), 
adrenocortical carcinomas with Cushing syndrome (ACCc) (n=6) and normal adrenal glands 
(N-AG) (8).  Adrenocortical carcinoma cell line (H295R) was used to evaluate the ability of 
PD184352 (0.1, 1 and 10 µM), a specific MAPK/MEK/ERK pathway inhibitor, to modulate cell 
proliferation, viability, metabolism and steroidogenesis. 
ERKs 1/2 activation was significantly higher in ACCc (3.18 ± 0.28) compared with N-AG (1.13 
± 0.18 “arbitrary units”), ACAn (1.71 ± 0.22) and ACCc (2.33 ± 0.21). Phospho-p38 expression 
was absent in all the ACCc analyzed. MEK inhibition with PD184352 significantly decreased 
proliferation as well as steroidogenesis and also increased the redox state of the H295R cells. 
This data suggests that MAPK/ERK signaling has a role in adrenocortical tumorigenesis that 
could be potentially used as a diagnostic marker for malignancy and targeted treatment in 
ACC.  
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8.2 Introduction 
 
The molecular mechanisms that underlie the transformation of normal adrenocortical cells into 
malignant tumor cells, are still largely unknown. Several genes involved in the tumorigenesis 
of malignant, as well as the benign lesions of the adrenal cortex have already been identified 
(Bertagna 2015, Drougat, Omeiri et al. 2015, Espiard and Bertherat 2015), such as the Armc5 
gene mutations in adrenocortical macronodular hyperplasias (Assie, Libe et al. 2013, Albiger, 
Regazzo et al. 2016) and the PKA catalytic fraction mutations in adenomas with Cushing 
syndrome (Calebiro, Hannawacker et al. 2014, Berthon, Szarek et al. 2015). Molecular studies 
in ACC, highlighted the overexpression of the insulin-like growth factor 2 (IGF2) in sporadic 
tumors (Boulle, Logie et al. 1998, Pereira, Morais et al. 2013, Nielsen, How-Kit et al. 2015), 
the TP53 mutations (Ragazzon, Libe et al. 2010, Herrmann, Heinze et al. 2012) and the genetic 
alterations conditioning abnormal expression of molecules of the Wnt signaling pathway as the 
predominant findings (Tissier, Cavard et al. 2005, Ragazzon, Libe et al. 2010, Mitsui, 
Yasumoto et al. 2014). 
The mitogen-activated protein kinases (MAPKs) family represents a group of highly conserved 
protein kinases that play a crucial role in cell signal transduction in response to a range of 
extracellular and intracellular stimuli (Kim and Choi 2010, Kyriakis and Avruch 2012). The 
extracellular signal-regulated protein kinases (ERK1 and ERK2), p38 MAPKs (p38α, p38β, 
p38ɣ) and c-Jun N-terminal kinases (JNK1, JNK2 a JNK3) (Pearson, Robinson et al. 2001, 
Keshet and Seger 2010) are the most widely studied MAPKs. Each MAPK cascade is 
composed of at least three kinase components: a MAPK, a MAPK kinase (MAP2Ks, also called 
MEKs or MKKs) and a MAPK kinase kinase (MAP3Ks) (Keshet and Seger 2010, Kim and Choi 
2010) . 
MAPK/MEK/ERK pathway activation requires ERK (ERK1 and ERK2) phosphorylation by MEK 
(MEK1 or MEK2), which in turn needs to be phosphorylated by Raf to become active (Figure 
41)  (Pearson, Robinson et al. 2001).  
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Figure 41 – MAPK/ERK Signaling Pathway. The binding of growth factors to tyrosine kinase receptors 
(TK receptor) activates two distinct signal transduction pathways: MAPK responsible for cell proliferation 
and PI3K-AKT that promotes anti- apoptotic effects. This figure only shows the MAPK signaling and 
simplifies complex interacting regulatory networks. The activation of TK receptor leads to the Ras 
activation that directly interacts with Raf and activates it. Raf phosphorylates and activates MEK, which 
in turn phosphorylates and activates ERKs. ERKs, in turn, is translocated to the nucleus, with resultant 
mitogenic response: progression of the cell cycle and cell proliferation.  
  
Activation of upstream signaling components that activate ERKs, by overexpression or 
mutations, is observed in the majority of human cancers (Dhillon, Hagan et al. 2007, Roberts 
and Der 2007). Thus, MAPK/MEK/ERK pathway is a promising anti-tumor target, while Raf 
and MEK inhibitors are being profusely investigated as targeted therapies to stop tumor 
progression (Roberts and Der 2007).  A high frequency of RAS and BRAF mutations has been 
described in several different tumors, such as melanoma (Goldinger, Murer et al. 2013), 
papillary thyroid cancer (Soares, Trovisco et al. 2003, Tavares, Melo et al. 2016), colorectal 
cancer (Arcila, Lau et al. 2011) and pancreatic cancer (Ishimura, Yamasawa et al. 2003, 
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Dhillon, Hagan et al. 2007, Roberts and Der 2007). In contrast, RAS and BRAF mutations have 
been described to be infrequent in adrenocortical tumors (Ocker, Sachse et al. 2000, Kotoula, 
Sozopoulos et al. 2009, Masi, Lavezzo et al. 2009, Rubin, Monticelli et al. 2015). 
The p38s are MAPK family members that can be activated by a diversity of inflammatory 
cytokines and environmental factors, such as oxidative stress, UV irradiation and hypoxia 
(Zarubin and Han 2005). Dual phosphorylation of Thr180 and Tyr182 p53 residues mediated 
by upstream MKK4, MKK3 and MKK6 is required for their activation, while MKKs are in turn 
activated by a diverse range of MAP3Ks that include TAK1 and MEKK4 (Zarubin and Han 
2005). Dysregulation of p38 MAPK expression in patients with prostate, breast, bladder, liver 
and lung cancer is associated with advanced tumor stages and decreased patient survival 
(Koul, Pal et al. 2013). The p38 MAPKs activation also contribute to the expression of 
epithelial-mesenchymal transition (EMT) transcription factors of primary tumor cells leading to 
acquisition of invasion and migrating capacities (Bhowmick, Zent et al. 2001, Koul, Pal et al. 
2013). 
The p38 MAPK role in adrenocortical cells was only evaluated in a few studies focusing on 
their influence in steroidogenesis, which described their action as negative regulators of 
steroidogenic acute regulatory (StAR) gene transcription and in mediating inhibition of the 
steroid production induced by oxidative stress (Abidi, Zhang et al. 2008, Zaidi, Shen et al. 
2014). Exploring the consequences of these pathway’s alterations in ACC is needed in order 
to identify more effective treatments that can target the cancer features.  
Besides to the presence or absence of ERKs and p38, there is also increased evidence that 
cell metabolism is a core hallmark of cancer directly involved in cell proliferation and survival 
makes this an important marker of tumor aggressiveness and thus, its modulation can be an 
important therapeutic approach (Hay 2016, Pavlova and Thompson 2016).  
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8.3 Aim 
 
Our aim was to assess the putative role of MAPK/MEK/ERK pathway activation in tumor 
progression and the potential of its inhibition as a therapeutic target for ACT that may lead to 
major consequences in the cell proliferation, steroidogenesis, as well as the influence of 
cellular metabolism in these processes. 
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8.4 Material and methods 
 
Adrenal tissue samples 
Adrenal tissue pertaining to patients with adrenocortical adenomas with Cushing`s syndrome 
(ACAc) (n=12), adrenocortical carcinomas with Cushing`s syndrome (ACCc) (n=6), non-
functioning adrenocortical adenomas (ACAn) (n=10) and normal adrenal glands (N-AG) (n=8) 
retrieved during nephrectomy for urologic conditions without adrenal pathology were used.  
 
Study of the adrenal hormonal secretion 
All patients harboring adrenal tumors were submitted to routine endocrine investigation to 
determine their secretory pattern prior to surgery. This included measurement of 
adrenocorticotropic hormone (ACTH) plasma levels, cortisol circadian rhythm with 
measurement of cortisol levels at 8.00h and 16.00h, as well as an overnight suppression test 
with 1mg of oral Dexamethasone (Dxm) given at 23.00h and assessment of serum cortisol at 
8.00h of the following day. 
 
Immunohistochemistry (IHC) procedures and analysis 
IHC was performed in 3μm formalin-fixed paraffin embedded tissue sections mounted on 
adhesive microscope slides. Sections were deparaffinized, rehydrated in graded alcohols and 
incubated for 10 min with 3% hydrogen peroxide in methanol. After thorough washing, the 
slides were incubated in citrate buffer and boiled for 5 minutes for antigen retrieval. After 
cooling down, adrenal sections were placed in a 5% Normal Goat Serum solution for 1 hour at 
room temperature and then incubated overnight at 4º C with specific (ref. 4370; 1:200; Cell 
Signalling Technologies, UK) or with specific anti-phospho-p38 antibody (ref. 4511; 1:400; Cell 
Signalling Technologies, UK). After adequate washing, tissue sections were incubated with a 
biotin conjugated secondary antibody for 30 minutes, followed by the incubation with the Avidin 
Biotin Complex (DAKO, Dakopatts, Denmark). 3,3’-diaminobenzidine (DAB, Sigma Chemicals, 
USA) was used as chromogen and the nuclei were contrasted with haematoxylin. 
Two observers, unaware of the clinical and pathologic diagnosis, analyzed all sections. 
Evaluation of immunoreactivity was performed using a Nikon microscope (Optiphot model) 
with the 20x objective lens, both for phospho-ERKs and phospho-p38. An arbitrary 
classification score system was used for the quantification of the immunostaining. Briefly, cells 
were classified according to the intensity and extension of the immune staining, varying from 
0 (no immunostaining), 1 (few cells positive/weak positivity), 2 (groups of positive cells) to 3 
(intense and generalized immunostaining). 
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Cell Culture 
Human adrenocortical carcinoma cell line (H295R) obtained from CLS Cell Lines Service 
GmbH (Eppelheim, Germany) was cultured in Dulbecco's Modified Eagle Medium: Nutrient 
Mixture F-12 (DMEM/F12; Sigma-Aldrich, St Louis, MO, USA) supplemented with 0.365 g/L of 
L-Glutamine (Sigma-Aldrich, St Louis, MO, USA), 10 mL/L of Penicillin-Streptomycin (Sigma-
Aldrich, , St Louis, MO, USA), 2.5% of NuSerum (BD Bioscience, San Jose, CA) and 1% of 
ITS + Premix (Corning, NY, USA). The medium was changed three/four times per week and 
the cells were detached for sub culturing with a 0.25% trypsin- Ethylenediaminetetraacetic acid 
(EDTA) solution (Sigma-Aldrich, St Louis, MO, USA). Cell cultures were handled in a laminar 
flow chamber and maintained at 37°C in an incubator (Heracell 150i, Thermo scientific, 
Waltham, MA USA) with 5% CO2. 
 
MEK Inhibitor treatment 
The MEK inhibitor PD184352 (Sigma-Aldrich) (also known as CI-1040) was chosen since it is 
described to be highly selective for MEK compared with other kinases that induces a specific 
conformational change in MEK leading to a closed and catalytically inactive form. The inhibitor 
is also a non-competitive MEK inhibitors with respect to ATP, so it is not affected by the 
changes in the intracellular ATP concentration (Wang, Boerner et al. 2007). This MEK inhibitor 
leads to a successful phospho-ERK suppression and it has a great efficacy in inhibiting cell 
growth particularly in breast, colon and pancreatic tumors (Allen, Sebolt-Leopold et al. 2003, 
Wang, Boerner et al. 2007). The concentrations of the MEK inhibitor used in this study were 
0.1, 1 and 10 µM and DMSO was used as control. These concentrations were already 
demonstrated to have great anti-proliferative effect in other types of tumors (Sebolt-Leopold, 
Dudley et al. 1999, Squires, Nixon et al. 2002). 
 
Cell proliferation assay 
H295R cells (0.4x106 cells/well) were cultured in 24wells-plates with complete medium for 22 
hours followed by 2 hour period with serum depleted medium (NuSerum). H295R cells were 
then incubated with the inhibitor PD184352 during 12 or 24 hours. H295R cell proliferation was 
monitored by the incorporation of 5-bromo-2-deoxyuridine (BrdU, 10µM, Sigma-Aldrich) over 
2 hours. Cultured cells were harvested by cyto-spinning, fixed in 4% paraformaldehyde (Merck 
Millipore, Darmstadt, Germany) and immunofluorescence stained using mouse anti-BrdU (sc-
32323, 1:200; Santa Cruz Biotechnology, Inc; Heidelberg, Germany) and goat anti-mouse-
AlexaFluor488 (1:1000; Cell Signalling Technologies, UK). Minimums of 500 cells were 
counted in a 400x of magnification. Cell culture medium was retrieved and stored for steroid 
quantification. 
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Cell viability assay 
H295R cells (0.05x106 cells/well) were cultured in 96wells plates with complete medium for 22 
hours followed by 2 hour period with serum depleted medium. H295R cells were then 
incubated with a MEK inhibitor (PD184352, Sigma-Aldrich) at different concentrations (0.1, 1 
and 10 µM) or vehicle (DMSO, Sigma-Aldrich) in the presence of 10% Alamar Blue (Bio-Rad 
AbD Serotec, Oxford, UK). Absorbance was measured at wavelengths of 570 nm and 595 nm, 
at 0, 12 and 24 hours. The % of resazurin reduction was calculated using the following 
equation:  
%𝑅𝑒𝑑𝑢𝑐𝑡𝑖𝑜𝑛 = (
𝐸𝑜𝑥𝜆2𝑥 𝐴𝜆1−𝐸𝑜𝑥𝜆1𝑥 𝐴𝜆2
𝐸𝑟𝑒𝑑𝜆1𝑥 𝐴𝑏𝑙𝑎𝑛𝑘 𝜆2−𝐸𝑟𝑒𝑑𝜆2𝑥 𝐴𝑏𝑙𝑎𝑛𝑘 𝜆1
) 𝑥100 , being λ1 = 570 nm, λ2 = 595 nm, Eox1 
= 80,573, Eox2 = 117,216, Ered1 = 155,667 and Ered2 = 14,652.  
 
Nuclear magnetic resonance (NMR) spectroscopy  
1H NMR spectroscopy (VNMRS 600 MHz, Varian, Inc. Palo Alto, CA) was used to determine 
metabolite concentrations in H295R cell culture media after MEK inhibitor incubation. Sodium 
fumarate was used as internal reference (6.50 ppm) to quantify the following metabolites 
(multiplet, ppm): lactate (doublet, 1.33); alanine (doublet, 1.45); acetate (singlet, 1.9), H1-α 
glucose (doublet, 5.22), as previously described (Alves, Oliveira et al. 2011). The relative areas 
of 1H NMR resonances were quantified using the curve-fitting routine supplied with the 
NUTSpro™ NMR spectral analysis program (Acorn, Fremont, CA, USA) and the results were 
normalized to the number of cells present  at the time the medium was collected. 
 
Mitochondrial membrane potential assay 
The mitochondrial membrane potential was evaluated using the 5,5´,6,6´-tetrachloro-1,1´,3,3´-
tetraethylbenzimidazolcarbocyanine iodide (JC-1) dye (Molecular Probes, Eugene, OR, USA). 
H295R cells incubated with MEK inhibitor, as previously described for the viability analysis, 
were treated with 1.5 mM JC-1 dye (diluted in DMEM: Ham’s F12 with 1% Nu-Serum) for 30 
minutes at 37 ºC. JC-1 forms aggregates detected at an excitation wavelength of 535 nm and 
at an emission wavelength of 595 nm in functional mitochondria, while in non-functional 
mitochondria, JC-1 forms monomers that are detected at excitation wavelength 485 nm and 
emission wavelength 530 nm. The energized mitochondria membrane potential was calculated 
using the ratio between the fluorescent intensity of the JC-1 aggregates and the fluorescent 
intensity of the JC-1 monomers. 
 
Western Blot 
After incubation with MEK inhibitor, cell proteins were extracted using RIPA buffer (ref: 20-188, 
Sigma-Aldrich, USA), with protease inhibitor (ref: 4693124001, Roche, Switzerland) and 
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phosphatase inhibitor (ref: 4906845001, Roche). Extracted proteins were quantified using the 
Pierce™ BCA Protein Assay Kit (ref: 23225, ThermoFisher Scientific, USA). A total of 30 µg of 
proteins was heated at 37ºC for 30 minutes, fractionated on a 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride 
membranes. The membranes were blocked in a Tris-buffered saline solution with 0.05% 
Tween 20 containing 5% dried milk and incubated overnight with Total OXPHOS (1:1000)  
(ab110413 Abcam, UK) or with β-actin (1:5000) ( MA5-15739, Thermo Fisher, USA),  at 4ºC. 
Immune-reactive proteins were detected separately using an anti-mouse secondary antibody 
at 1:5000 (A3562, Sigma-Aldrich, USA). Membranes were reacted with ECF detection (GE 
Healthcare) system and read with the BioRad FX-Pro-plus (Bio-Rad, UK). The densities of 
each band were obtained using the Quantity One Software (Bio-Rad, UK). 
 
Steroids quantification 
Cortisol, dehydroepiandrosterone sulfate (DHEA-S) and androstenedione were measured in 
the medium, after H295R incubation with the MEK inhibitor, by Electrochemiluminescence 
immunoassay (ECLIA) using Cobas®, e411 analyzer (Roche, Switzerland), a fully automated, 
random access system for immunoassay analysis.  
The results were normalized to cells number present when the medium was collected and the 
results are expressed as fold change relative to the vehicle control. 
 
Statistical analysis 
All results are presented as Mean ± Standard Error (SE). D’Agostinho & Pearson test was 
used to evaluate variables normality. For continuous variables that passed this test, one-way 
ANOVA test with the post-hoc Tukey was used to compare the means of three or more groups. 
For the variables that did not pass the normality test, the Kruskal Wallis with a Post-hoc Dunn’s 
was used. The correlations between continuous variables were evaluated using the Pearson 
Test. The significance level was defined by a value of p<0.05. 
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8.5 Results 
 
Analysis of the ERKs 1/2 and p38 activation in tumoral and normal adrenal tissue 
 
Adrenal weight and hormonal secretion 
ACCc weight and diameter were significantly higher when compared to the other types of 
tumors (p<0.01) (Table 10). ACAc patients presented a lower age at diagnosis when compared 
to normal patients (p<0.05).  
 
Table 10 - Patients age and adrenal features (ANOVA: *p<0.05 compared with normal adrenal glands; 
** p<0.01 compared with all the other tumors). 
 n 
Age 
(years) 
Tumor weight 
(g) 
Tumor 
diameter (cm) 
ACCc 6 59.1 ± 10.1 916.1 ± 953.2** 19.92 ± 6.5** 
ACAn 10 55.4 ± 12.5 15.33 ± 7.0 3.79 ± 2.3 
ACAc 12 35.1 ± 11.4* 15.88 ± 5.1 3.08 ± 0.6 
N-AG 8 53.2± 10.7 
10.30 ± 1.5 
(adrenal 
weight) 
_____ 
ACCc- Adrenocortical carcinoma with Cushing syndrome; ACAn- non-functioning adrenocortical adenomas; ACAc- 
adrenocortical adenomas with Cushing syndrome; N-AG- Normal Adrenal glands. 
 
 
Morning cortisol levels of patients with ACAc and ACCc were significantly higher when 
compared to normal subjects and ACAn patients (p<0.001). Besides, normal subjects and 
patients with ACAn depicted a normal cortisol circadian rhythm with normal morning peak and 
afternoon nadir that was significantly attenuated in patients with ACAc and ACCc. The 
overnight dexamethasone test also failed to supress morning cortisol (cortisol <1.8 µg/dL) in 
patients with benign or malignant Cushing ´s syndrome, thus confirming the autonomous 
cortisol secretion (Figure 42)  
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Figure 42- Serum cortisol levels at 8.00h and 16.00h measured to assess the circadian rhythm and 
serum cortisol levels at 8.00h after the overnight 1mg Dexamethasone (Dxm) suppression test. 
Overnight dexamethasone test also failed to supress morning cortisol (cortisol < 1.8 µg/dL) in patients 
with benign or malignant Cushing ´s syndrome confirming autonomous cortisol secretion. 
 
Phospho-ERK expression is increased in ACCc 
In N-AG, 7 out of 8 (7/8) presented basal activation of ERKs 1/2, with a mean intensity 
immunostaining score of 1.13±0.18 (Figure 43). This activation was more evident in Zona 
Glomerulosa (ZG) and Zona Reticularis (ZR), although a few disperse cells were also detected 
in Zona Fasciculata (ZF) (Figure 43A and 43B). In ACAc, the presence of phospho-ERKs was 
detected in all studied cases (12/12) (Figure 43D). In these situations, the intensity score of 
phospho-ERKs was significantly higher than in normal adrenals (2.33±0.21; p<0.001; Figure 
43F). ACCc depicted ERKs 1/2 activation (mean score of 3.18±0.28) in all studied samples 
(6/6) (Figure 43E and 43F), with an intensity score also significantly higher than in N-AG 
(p<0.001), ACAn (p<0.001) and ACAc (p<0.05). 
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Figure 43 - Immunohistochemistry staining for phospho-ERK (Scale bar = 100 µm) in normal adrenals 
(N-AG) (A and B), non-functioning adrenocortical adenomas (ACAn) (C), adrenocortical adenomas with 
Cushing syndrome (ACAc) (D), adrenocortical carcinomas with Cushing syndrome (ACCc) (E) and the 
respective graphic representation of the phospho-ERKs staining score (F) (ANOVA: *** p<0.001; 
*p<0.05). 
 
 
Phospho-p38 expression is absent in ACCc 
Phospho-p38 staining indicating basal activation of the protein was present in 7/8 N-AG 
(1.04±0.11; Figure 44A, 44B and 44F). The highest intensity staining was again found in ZG 
and ZR, while in ZF it was scarce and disperse. Phospho-p38 expression was found in all 
ACAn nodules (10/10), with an intensity staining score similar (0.97±0.10) to what was 
observed in N-AG (Figure 44C and 44F). Phospho-p38 staining was present in 3 out of the 12 
ACAc studied cases and in these only one presented p38 activation. The staining intensity for 
phospho-p38 was significantly decreased in ACAc (0.08±0.08) when compared with ACAn and 
N-AG (p<0.001, Figure 44D and 44F). In what concerns to the ACCc cases, none (6/6) 
presented any phospho-p38 staining (p<0.001, when compared to N-AG; Figure 44E and 44F). 
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Figure 44 - Immunohistochemistry staining for phospho-p38 (Scale bar = 100 µm) in in normal adrenals 
(N-AG) (A and B), non-functioning adrenocortical adenomas (ACAn) (C), adrenocortical adenomas with 
Cushing Syndrome (ACAc) (D), adrenocortical carcinomas with Cushing Syndrome (ACCc) (E) and the 
respective graphic representation of the phospho-p38 staining score (F) (ANOVA: ** p<0.01; *** 
p<0.001). 
 
In vitro analysis of the influence of the MEK inhibition in the H295R proliferation, 
viability, metabolism and steroidogenesis 
 
MEK inhibitor significantly decreased H295R proliferation  
H295R incubation with the highest MEK inhibitor concentration tested (10 µM) led to a 
significant decrease in cell proliferation (77.74 ± 4.96 % after 12 hours when compared with 
the vehicle 100.00 ± 2.28 %; p<0.05; Figure 45A). At 24 hours, the H295R cell proliferation 
was also significantly decreased after MEK inhibitor incubation at the concentrations of 1µM 
(81.57 ± 3.11 %) and 10 µM (80.23 ± 6.15 %) when compared to vehicle (100.00 ± 2.23 %; 
p<0.05; Figure 44A). MEK inhibitor (1µM) significantly decreased cell viability at 12 hours, 
(77.74 ± 4.96 %) when compared to vehicle (94.63 ± 3.63 %; p<0.05; Figure 45B) however, 
no significant differences were observed after 24 hours. Besides that, no differences were 
observed for cell viability and proliferation using the other MEK inhibitor concentrations. 
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Figure 45 - H295R cells proliferation (A) and viability (B) after the incubation with a MEK inhibitor 
(PD184352), at concentrations of 0.1, 1 and 10 µM or with the vehicle (DMSO), during 12 and 24 hours 
(ANOVA: * p<0.05). 
 
Incubation of H295R cells with the highest concentration of MEK inhibitor increased glycolytic 
flux 
Incubation of H295R cells with the highest MEK inhibitor concentration (10µM)  for  12 and  24 
hours significantly increased their glucose consumption from 384.70 ± 45.95 nmol/106 cells at  
12 hours to 646.90 ± 109.80 nmol/106 cells at  24 hours) when compared with lower MEK 
inhibitor concentrations (12 hours: 0.1µM: 163.50 ± 23.84 nmol/106 cells; 1µM: 141.20 ± 25.24 
nmol/106 cells, p<0.001;  24 hours: 0.1µM: 276.20 ± 37.16 nmol/106 cells; 1µM: 310.50 ± 42.90 
nmol/106 cells, p<0.01) and the vehicle ( 12 hours: 177.30 ± 30.44 nmol/106 cells, p<0.001;  24 
hours: 384.40 ± 57.03 nmol/106 cells, p<0.05) (Figure 46A). As expected, lactate production 
was positively correlated with glucose consumption (R2=0.72, p<0.001). H295R cells 
incubated with the higher MEK inhibitor concentration for 12 or 24 hours, significantly 
increased lactate production (12 hours: 10µM: 1038.00 ± 85.80 nmol/106 cells vs  vehicle: 
517.40 ± 24.35 nmol/106 cells, 0.1µM: 469.70 ± 33.26 nmol/106 cells, 1µM: 473.30 ± 41.57 
nmol/106 cells, p<0.001;  24 hours: 10µM: 1522.00 ± 270.50 nmol/106 cells vs  0.1µM: 645.80 
± 80.35 nmol/106 cells, p<0.01; 1µM: 810.80 ± 113.80 nmol/106 cells, p<0.05) (Figure 46B).  
The concentration of 1µM (4.55 ± 0.59), led to an increase of lactate/glucose ratio at 12 hours, 
compared with the vehicle (2.53 ± 0.11), which is correlated with an increased glycolytic flux. 
The lactate/alanine ratio, which is associated with the cellular redox state, was significantly 
increased after the incubation with the higher MEK inhibitor concentration for 12 or 24 hours 
(12 hours: 10µM: 36.58 ± 3.29 vs  vehicle: 18.2 ± 0.54, 0.1µM: 16.63 ± 0.54, 1µM: 15.74 ± 
0.45, p<0.001;  24 hours: 10µM: 58.17 ± 3.08 vs  vehicle: 24.04 ± 1.25, 0.1µM: 20.17 ± 1.21, 
p<0.01; 1µM: 18.73 ± 1.13, p<0.001) (Figure 46E and 46F). 
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Figure 46 - Glucose (A) consumption and lactate production (B), acetate consumption (C), alanine 
production (D), lactate/glucose ratio (E) and lactate/alanine ratio (F)  after the incubation with a MEK 
inhibitor (PD184352) at concentrations of 0.1, 1 and 10 µM or with the vehicle (DMSO), during 12 and 
24 hours.  (ANOVA: *p<0.05, **p<0.01, ***p<0.001). 
 
 
Treatment with the lowest MEK inhibitor concentration increased acetate consumption while 
higher doses decreased it dose-dependently 
At 12 hours, the concentration of 0.1µM of MEK inhibitor led to a higher consumption of acetate 
(42.82 ± 3.04 nmol/106 cells) compared with the other MEK concentrations (1µM: 31.79 ± 2.98 
nmol/106 cells, p<0.05; 10µM: 20.75 ± 2.00 nmol/106 cells, p<0.001) and vehicle (27.56 ± 1.99 
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nmol/106 cells, p<0.01). Besides that, at 12 hours the cells incubated with 1µM of MEK inhibitor 
led to a significantly higher consumption of acetate then was observed for higher concentration 
used (p<0.01) (Figure 46D). At 24hours, the concentration of 10µM of MEK inhibitor also lead 
to a significantly decrease of acetate consumption (25.51 ± 3.79 nmol/106 cells) compared with 
the concentration of 0.1µM (45.18 ± 2.55 nmol/106 cells, p<0.05). The values of acetate 
consumption using the concentration of 10µM of MEK inhibitor were similar to the control 
values.  
 
 
Mitochondrial complexes analysis 
JC1 ratio, a measure of mitochondrial membrane potential, increased significantly in H295R 
cells after 12 hours incubation with the highest MEK inhibitor concentration (8.26 ± 1.13) when 
compared with the lower MEK concentrations tested (0.1µM: 4.57 ± 0.78; 1µM: 4.95 ± 0.68, 
p<0.05) or vehicle (4.31 ± 0.49) (Figure 47A).  JC1 ratio was also significantly higher (5.76 ± 
0.36; p<0.01)), after 24 hours of incubation with the highest concentration when compared with 
the other MEK inhibitors concentrations (Figure 47A). To further evaluate mitochondrial 
functionality, mitochondrial complexes III (cytochrome c reductase) and V (mitochondrial ATP 
synthase) levels were measured  due their involvement in the electron transport chain and in 
adenosine triphosphate (ATP) synthesis (Kuhlbrandt 2015). Our results revealed no 
differences in the mitochondrial complexes III and V after the incubation with all concentrations 
of MEK inhibitor as compared to vehicle (Figure 47B and 47C). 
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Figure 47 - JC1 ratio (A) and expression of the mitochondrial complexes III and IV (B and C) after the 
incubation with a MEK inhibitor (PD184352) at concentrations of 0.1, 1 and 10 µM or with the vehicle 
(DMSO), during 12 hours (B) and 24 hours (C) (ANOVA: * p<0.05). 
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MEK inhibition decreased steroids secretion by H295R 
MEK inhibitor significantly decreased H295R cortisol (vehicle: 1.00 ± 0.03 vs 1µM: 0.77 ± 0.05, 
p<0.05); (vehicle: 1.00 ± 0.03 vs 10µM: 0.55 ± 0.06, p<0.001) and DHEA-S secretion (vehicle: 
1.00 ± 0.08 vs 1µM: 0.72 ± 0.09, p<0.05); (vehicle: 1.00 ± 0.08 vs 10µM: 0.21 ± 0.05, p<0.001) 
compared to the vehicle. Also, the concentration of 10µM significantly decreased the 
androstenedione secretion (vehicle: 1.00 ± 0.01 vs 10µM: 0.55 ± 0.02, p<0.001) (Figure 48).  
 
 
Figure 48 - Cortisol, dehydroepiandrosterone sulfate (DHEA-S) and androstenedione secretion by 
H295R, after the incubation with a MEK inhibitor (PD184352) at concentrations of 1 and 10 µM or with 
the vehicle (DMSO), during 24 hours (ANOVA: *p<0.05; **p<0.01; ***p<0.001). 
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8.6 Discussion 
 
Surgery is the most important treatment for adrenocortical carcinoma being a complete 
surgical resection (R0), the only potential curative approach (Fassnacht, Johanssen et al. 
2009, Libe 2015). However, a high rate of adrenocortical carcinoma recurrence has still been 
described after R0 surgery (Libe 2015). Mitotane is the only drug available with the specific 
indication for adjuvant treatment of ACC to reduce the risk of recurrence and control excess 
hormone production. It is occasionally also used in combination with radiotherapy or 
chemotherapy (Allolio and Fassnacht 2006, Terzolo, Angeli et al. 2007, Fassnacht, Libe et al. 
2011, Berruti, Baudin et al. 2012, Fassnacht, Terzolo et al. 2012). However, the benefits of 
mitotane as an adjuvant therapy for ACC have been questioned due to the lack of data from 
controlled clinical trials or large prospective studies with consistent assessment of drug dosing 
(Kopf, Goretzki et al. 2001, Pignatelli 2011, Berruti, Baudin et al. 2012). Thus, there is an 
unquestionable need to identify alternative drug targets to improve ACC treatment and 
prognosis. For that, our aim was to assess the putative role of MAPK/MEK/ERK pathway 
activation in tumor progression and the potential of its inhibition as a therapeutic target for ACT 
through modulation of cell proliferation, metabolism and steroidogenesis. 
To achieve this aim we have first focused our studies on characterizing the expression of 
phospho-ERK and phospho-p38, in adrenocortical tumors and normal adrenal tissue. 
Phospho-ERK expression was found to be higher in malignant tumors compared to benign 
tumors or normal adrenal glands, suggesting that MAPK/ERK pathway activation could have 
an important role in driving adrenocortical tumorigenesis and growth in ACC. Indeed, Rubin et 
al analyzed the presence of mutation in key components of MAPK pathway (BRAF, HRAS, 
KRAS, NRAS, EGFR) in adrenal tissue and peripheral blood DNA of 24 patients with 
adrenocortical tumors. Only BRAF mutations in 2 ACC and HRAS mutations in other 2 ACC 
and 2 adrenocortical adenomas were identified, while no mutations were found in the 
peripheral blood DNA of the patients (Rubin, Monticelli et al. 2015). Moreover, Kotoula et al 
compared the phospho-MEK, phospho-ERK and phospho-AKT expression in the BRAF and 
EGFR mutant tumor with the wild-type ACC and verified that tumors harboring these mutations 
also presented a stronger immunostaining for phospho-MEK, phospho-ERK, suggesting that 
MAPK/ERK pathway inhibitors could represent candidate targeted therapies for patients with 
adrenocortical carcinomas carrying these mutations (Kotoula, Sozopoulos et al. 2009). In 
another study comparing phospho-ERK and total-ERK expression in 1 mutated and 3 non-
mutated BRAF ACC, it was observed that these tumors had a similar expression pattern, 
although it was higher in ACC than in normal adrenal glands (Rubin, Monticelli et al. 2015), 
suggesting that despite this pathway is frequently activated in ACC it is rarely secondary to 
mutational alteration in MAPK signaling. 
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Our results show that phospho-p38 expression is absent in adrenocortical carcinomas 
suggesting that it is the MAPK/ERK pathway activation that may have an important role in 
driving tumorigenesis and cell growth. To further confirm the role of MAPK/ERK pathway 
activation in adrenal carcinoma cell growth and to study the molecular mechanisms by which 
this may occur, we used the ACC cell line H295R.  This cell line has been described as wild-
type for the MAPK/ERK pathway by genotyping (Kotoula, Sozopoulos et al. 2009, Rubin, 
Monticelli et al. 2015) and thus likely to respond positively to the MEK inhibitor used in the 
present study. Cells were treated with a MEK inhibitor to evaluate its efficacy in inhibiting 
crucial characteristics associated with cancer progression and malignancy such as cell 
proliferation, metabolism and steroidogenesis. H295R cells treatment with MEK inhibitor at a 
concentration of 1µM only decreased cell proliferation after 24 hours, while the 10 µM 
concentration led to a 20% decrease in cell proliferation after 12 and 24 hours. Notably at this 
later time point, both concentrations showed similar efficacy. However, cell viability was only 
negatively affected by treatment with the inhibitor at 1 µM concentration after 12 hours by 
approximately 20%. These effects are similar to what was observed by previous studies 
exposing H295R cells to high concentrations of mitotane that at a 100 µM concentration 
inhibited cell growth by 15% with a minimal effect on cell viability (Stigliano, Cerquetti et al. 
2008), while in another study using 62.5 µM of mitotane a decrease in cell viability by 20% was 
observed (Lehmann, Wrzesinski et al. 2013).  
H295R cell treatment with a MEK inhibitor was also associated with concentration-dependent 
metabolic effects. The concentration of 1µM, led to an increase of lactate/glucose ratio at 12 
hours, which is correlated with an increased glycolytic flux. At 24 hours, this effect is not 
observed highlighting that this is a transient effect that may need the reinforcement of the 
inhibition to be sustained.  However, after exposure to 10 µM of MEK inhibitor, H295R cells 
presented a similar lactate/glucose ratio and a significantly higher lactate/alanine ratio and a 
higher mitochondrial membrane potential after 12 and 24 hours of treatment. The increased 
lactate/alanine ratio is associated with cellular redox state reflecting the intracellular 
NADH/NAD+ equilibrium. The redox system is essential in maintaining cellular homeostasis 
and when a redox imbalance occurs, due to higher production of reactive oxygen species 
(ROS) or a decrease in endogenous protective antioxidants, cells become vulnerable to 
apoptosis and necrosis. In cancer, a redox imbalance can be beneficial or unfavorable since 
ROS can lead to cellular tissue damage but it also plays a role in the development of resistance 
mechanisms (Jorgenson, Zhong et al. 2013). Thus, further studies will be needed to unveil the 
real role of MEK inhibitor in H295R cells that leads to decreased cell proliferation at higher 
concentrations. Thus, the higher concentration of the MEK inhibitor, can lead to a cellular tissue 
damage due the increased ROS production which is then reflected in the lower H295R 
proliferation rate or the tumor cell redox state changes in order to acquire resistance to this 
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therapy and activate other survival signaling pathway, such as PI3K/Akt pathway. The 
existence of “escape” mechanisms were already described in other types of cancer, such as 
breast cancer, and it suggests that a superior efficacy may be observed if both pathways are 
targeted (Saini, Loi et al. 2013). 
The MEK inhibitor dose-dependently decreased the acetate consumption, an effect that is 
lower with the concentration of 10 µM that presented similar values to the control condition. 
Acetate is a precursor of cholesterol production for cellular membrane biosynthesis and thus, 
inhibition of its consumption with the highest MEK inhibitor concentrations may be related to 
the decrease in cell proliferation reported for that concentration. On the other hand, acetate-
derived cholesterol is a precursor of steroids synthesis and thus, the decreased consumption 
of acetate may also be associated with the reduction of steroids secretion by H295R cells. In 
addition, phospho-ERK expression was higher in cortisol production tumors compared with 
non-functioning adenomas. These results reinforce the previous reports, that MAPK pathway 
is an important steroidogenesis regulator (Manna and Stocco 2011).  
The observed decrease in cortisol and testosterone secretion elicited by MEK inhibition, was 
higher than the previously reported 10% decrease after 24 hours mitotane incubation(100 µM), 
suggesting that MEK inhibition could be more efficient in suppressing steroidogenesis and 
control their clinical manifestations (Stigliano, Cerquetti et al. 2008). Patients with ACT that 
produce high levels of cortisol have an increased cardiovascular risk due not only by metabolic 
complications, such as obesity, but also to vascular and cardiac alterations, such as 
atherosclerosis (De Leo, Pivonello et al. 2010). This is an important treatment target, also in 
patients with cortisol secreting ACT that have an increased risk of mortality form cardiovascular 
complications (De Leo, Pivonello et al. 2010). 
Furthermore, phospho-p38 expression was found to be absent in ACCc and decreased in 
ACAc as compared with ACAn and N-AG. Activated p38 is associated with a decrease of StAR 
gene expression (Zaidi, Shen et al. 2014), which encodes a protein responsible for an 
important and limiting step of adrenal steroidogenesis, the cholesterol transport from the outer 
to the inner mitochondrial membrane (Miller 2007, Miller 2011). So, retention of activated p38 
in the ACAn could also explain the preservation of regulated steroid production by these 
tumors, opposite to what is observed in both malignant and benign functional tumors 
presenting with Cushing’s syndrome where p38 seems to be inactivated. As p38 inactivation 
is similarly observed in malignant and benign tumors, p38 does not seems to play a role in the 
adrenocortical malignancy. 
 
In conclusion, our results show that the MAPK/ERK signaling pathways is important for 
adrenocortical tumorigenesis. Moreover, ACC with Cushing’s syndrome have increased 
phospho-ERK expression that could be used as diagnosis marker for malignancy in adrenal 
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tumors.  In addition, MAPK/ERK pathway inhibition through MEK inhibition decreases adrenal 
tumor cell proliferation and negatively modulated the cell metabolism increasing the cellular 
redox state. Thus, MEK inhibitors also arise as an alternative targeted treatment for ACC. 
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The work presented in this dissertation focuses on the identification of molecular patterns that 
characterize and are specific of adrenal malignancy, potentially useful to establish an accurate 
diagnosis in the clinical setting. After recognizing the pathologic features that are rather unique 
for adrenocortical malignancy we have concentrated our research efforts into understanding 
how malignant adrenocortical tumors (ACT) molecular fingerprints could be translated into 
different biological behaviors as insights into the perspective of disclosing novel targets for 
adrenocortical carcinoma (ACC) treatment. 
 
Molecular markers for differential diagnosis of adrenocortical tumors 
 
Malignant ACT are rare but highly aggressive tumors with a poor prognosis. The clinical 
outcome of ACC is mostly related to the fact that these tumors are usually diagnosed at an 
advanced clinical and pathological stage (Lafemina and Brennan 2012). After surgical removal, 
the differential diagnosis between benign and malignant ACT is currently based on the Weiss 
scoring system according to several histological parameters, in which, a tumor scoring equal 
or below 2 is classified as benign and a tumor scoring equal or above 4 is classified as 
malignant, while a score of 3 translates insufficient morphological signs to allow a reliable 
discrimination between ACC and adrenocortical adenomas (ACA) (Tissier 2010). Therefore, 
there is a consensual agreement that specific molecular markers are needed to support an 
accurate pathologic diagnosis, which would most probably lead improved prognosis by 
allowing the identification of malignant tumors at earlier stages.  In this research work, we have 
characterized, mostly by immunohistochemistry techniques, several molecular markers 
involved in cell cycle regulation, cell proliferation, cell adhesion, steroidogenesis, tumor 
progression and cell signaling pathways in the normal adrenal gland and different ACT tumors. 
Moreover, a computerized evaluation method was used to analyze the immunohistochemistry 
staining, a methodology that not only allows to remove the subjectivity of the observer but that 
is also less time consuming than the traditional manual cell counting currently used. Besides, 
the use of this technical approach could be replicated in the future studies to characterize 
additional molecular markers that were recently suggested by genomic studies (Zheng, 
Cherniack et al. 2016), which once appropriately confirmed could also become useful in clinical 
practice. 
Among the studied molecules, Ki-67 and p27 were demonstrated to have the highest power to 
discriminate ACC from ACA (Chapter 3), in addition the insulin-like growth factor 2 (IGF2) 
proved very useful to differentiate ACC from non-functioning adrenocortical adenomas (ACAn) 
(Chapter 7) whereas 11β-hydroxylase (CYP11B1) demonstrated to be very accurate for the 
distinction between ACC and adrenocortical adenomas with Cushing syndrome (ACAc) 
(Chapter 4). The Ki-67 and p27 molecular markers have an excellent accuracy for avoiding 
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false positive ACC, when considering the cut-off values of 0.50% for Ki-67 and 7.23% for p27, 
as all ACA present lower levels of these markers. Ki-67 is a well-stablish marker of malignancy 
in several cancers that has also been reported to be useful tool for the differential diagnosis of 
ACT. In contrast, the utility of p27 for the pathological diagnosis of ACC had not been 
previously identified. So, we have demonstrated for the first time, that p27 could even be a 
more powerful diagnostic tool than Ki-67, since it is able to exclude all ACA and diagnose more 
cases of ACC when compared to Ki-67 (Chapter 3). 
IGF2 expression had already been reported to be increased in the ACC and thus suggested 
to be a good marker for the differential diagnosis between ACA and ACC (Gicquel, Boulle et 
al. 2001, Schmitt, Saremaslani et al. 2006, Soon, Gill et al. 2009, Guillaud-Bataille, Ragazzon 
et al. 2014). Soon et al performed a characterization IGF2 expression in ACT, whose ROC 
curve analysis showed an area under the curve (AUC) of 0.863 for the differential diagnosis 
between total ACA and ACC (Soon, Gill et al. 2009), which was similar to the AUC observed 
in our own study (AUC=0.86) (Chapter 7). However, when we performed separate ROC curve 
analysis according to ACA functionality, our data further indicates that IGF2 is not a good 
marker to distinguish ACC from ACA with Cushing Syndrome, yet it is extremely accurate to 
distinguish ACC from non-functioning ACA. Thus, based on our findings we suggest that the 
use of IGF2 as a tumor marker should be limited to the differential diagnosis between ACAn 
and ACC (Chapter 7). Considering functioning ACT, our results showed that CYP11B1, 
steroidogenic acute regulatory protein (StAR) and 17α-hydroxylase expression is lower in ACC 
when compared to ACAc. Furthermore, CYP11B1 is the steroidogenic enzyme with the highest 
power to discriminate ACC from ACAc, with for a cut-off value of 4.44%, a sensitivity and 
specificity of 100% and 92%, respectively. Besides that, 28.6% of ACC were negative for both 
CYP11B1 and aldosterone synthase (CYP11B2), while this pattern was only found in one 
ACAn and in none of the ACAc. Although isolated CYP11B2 negativity was not found to be 
useful for pathological diagnosis, CYP11B1 and CYP11B2 dual negativity was found to be 
highly suggestive of ACC, with a specificity of 100% or 96% in functioning or non-functioning 
ACT, respectively (Chapter 4). And finally, another molecular fingerprint that was identified to 
be potentially useful to distinguish between ACT was the pattern of expression of the adhesion 
molecule N-cadherin, due to the fact that the majority of the ACC depict a loss of N-cadherin 
membrane expression while all ACA retain N-cadherin membrane expression (Chapter 6).  
 
Molecular targets for ACC treatment  
 
The only treatment approach with curative potential for ACC is complete surgical resection 
(R0) (Fassnacht, Johanssen et al. 2009, Libe 2015), nevertheless even R0 surgery is still 
associated with a high recurrence rate (Libe 2015). After surgery, the only drug currently 
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available with an indication for ACC adjuvant treatment to reduce the risk of recurrence and to 
control excess hormone production is mitotane (Allolio and Fassnacht 2006, Terzolo, Angeli 
et al. 2007, Fassnacht, Libe et al. 2011, Berruti, Baudin et al. 2012). However, mitotane 
benefits as adjuvant therapy for ACC have been questioned due to the lack of data from 
controlled clinical trials or large prospective studies with consistent assessment of drug dosing 
(Kopf, Goretzki et al. 2001, Pignatelli 2011, Berruti, Baudin et al. 2012). Thus, pharmacological 
treatment of ACC is a well-recognized unmet need, which, however could be achievable if 
targeted therapies based on the advances in the knowledge of adrenal tumor biology were 
developed. After having demonstrated that phospho-ERK expression was frequently increased 
in ACC, a feature that translates MAPK/ERK pathway activation, we have tested the 
hypothesis that MAPK/ERK pathway could be a good target for ACC treatment (Chapter 8). 
Indeed, after MAPK/ERK pathway inhibition trough MEK blockade, the adrenal tumor cell 
proliferation decreased and the cell metabolism was negatively modulated by increasing the 
cellular redox state. Besides that, MEK inhibition was shown to affect cell proliferation to a 
similar extent as mitotane and to suppress steroidogenesis and control the clinical 
manifestations of cortisol excess more efficiently way than mitotane (Stigliano, Cerquetti et al. 
2008). 
Despite the fact that IGF2 system has been repeatedly demonstrated to be a crucial pathway 
in ACC tumor biology and thus considered an attractive treatment target, clinical trials using 
IGF1R inhibitors alone or combined with insulin receptor and mTOR inhibitors, have failed to 
achieve the satisfactory endpoints in order to be recommended for the treatment of these 
tumors (Cohen, Baker et al. 2005, Haluska, Worden et al. 2010, Fassnacht, Berruti et al. 2015). 
Nonetheless, the previously reported 8 to 80 fold variation in the increment of the IGF2 protein 
expression in ACC compared to ACA, highlights that there must be a high degree of 
heterogeneity among these malignant tumors, which could  be responsible for a lack of 
significant results. We tested this hypothesis by studying whether different IGF2 levels could 
influence some important hallmarks of cancer (Chapter 7). The studies undertaken have 
allowed us to confirm that different IGF2 concentrations in ACC could be responsible for 
different biological behaviors of ACC cells that would necessarily result in distinct responses 
to targeted treatment.  
 
New insights into the biology of adrenocortical carcinomas 
  
Understanding the molecular mechanisms that underlie adrenocortical tumor cell expansion 
arises as the most promising approach to unravel invaluable molecular keys for the 
identification of efficacious targeted treatments.  
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In Chapter 3 we described that p27, a cyclin-dependent kinase inhibitor (CDKi) involved in the 
regulation of cyclin E-CDK2 and cyclin D-CDK4/6 complexes in the G1-S transition was 
overexpressed in ACC, contrarily to what was expected, since p27 up-regulation results in cell 
cycle arrest and apoptosis (Lee and Duh 2009). p27 was recently described as a 
multifunctional protein involved in the regulation of several cellular processes in a CDK-
independent manner that involves cytoplasmic retention and/or nuclear export. Cytoplasmic 
p27 is described to confer a pro-tumorigenic advantage since it is implicated in the control of 
cell migration, transcriptional repression, autophagy, stem cell specification, differentiation and 
apoptosis (Chu, Hengst et al. 2008, Serres, Zlotek-Zlotkiewicz et al. 2011, Jeannot, Nowosad 
et al. 2017). The multi-functionality could justify the high levels of p27 expression in ACC. Once 
only nuclear expression was observed in ACC it suggests that nuclear p27 may have an 
unknown function in ACC tumorigenesis, such that cancer cells could eventually develop 
tolerance to the inhibition of the cell cycle progression mediated by p27 or develop the ability 
to repress p27 activity, as an important step in tumor progression. Thus, despite the presence 
of p27 nuclear expression, it would be unable to arrest the cell cycle. The fact that no co-
localization of p27 and Ki-67 was found in the same cell, suggests that nuclear p27 might have 
an additional role unrelated to proliferation in the adrenocortical tumorigenesis still unidentified. 
As adrenal cortex cells depict a high rate of self-renewal (Pihlajoki, Dorner et al. 2015) finding 
a high frequency of telomerase reverse transcriptase (TERT) promoter mutations in ACC is 
unlikely, since these were predominantly described in tumors originating from tissues with low 
rates of self-renewal, such as glioblastomas, melanomas and thyroid carcinomas (Killela, 
Reitman et al. 2013, Vinagre, Almeida et al. 2013). Taking into account that we did not find 
TERT promoter mutations in any of the ACT analyzed and nuclear telomerase expression 
occurred only in a few percentage of ACC (26.6%) (Chapter 6), these findings suggest that 
telomerase overexpression does not seem to be crucial in malignant adrenocortical tumors. 
Nevertheless, a significant relationship between telomerase nuclear expression and N-
cadherin membrane expression was observed, since the majority of the carcinomas with 
telomerase expression, presented intact N-cadherin in the membrane. Previously, in a study 
using a hTERT-transfected prostate tumor cell line the authors found a concomitant 
overexpression of N-Cadherin and suggested that telomere elongation might affect the 
cadherin expression (Hirashima, Migita et al. 2013), while Liu et al generated two cell lines 
with TERT overexpression and observed that TERT expression significantly increased the cell 
adhesion (Liu, Liu et al. 2016). Our studies, in accordance to the previous findings also support 
this non-canonical role for TERT, which is cell adhesion. Besides that, our results support the 
hypothesis that different tumors use distinctive molecular pathways depending on the 
endogenous proliferative rate of the tissues where the tumors originate in order to achieve 
biological features that could be translated into a survival advantage. Since the adrenal cortex 
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has a high rate of self-renewal (Pihlajoki, Dorner et al. 2015) and the ACC are characterized 
by having an increased rate of proliferation, as we confirmed by showing that these tumors 
depict a high Ki-67 immunohistochemistry expression (Chapter 3), an increased telomerase 
expression is not needed to warrant cell survival. In this biological scenario, the loss of cell 
adhesion to allow the cells to invade, metastasize and tumor to expand seems to be a most 
important feature.  
ACC are very aggressive tumors since most are already metastasized when first diagnosed 
(Allolio, Hahner et al. 2004, Pignatelli 2011). In addition, to characterizing cell adhesion in ACT, 
the putative role of angiogenesis and lymphangiogenesis in tumor expansion were also 
explored. Research work focusing in the evaluation of lymph and blood vessel densities in 
different ACT, allowed us to verify that ACC have a higher density of blood vessels when 
compared with benign ACT (Chapter 5). Nevertheless, previous studies addressing 
angiogenesis in ACT yielded inconsistent results. Bernini et al analyzed the vascular density 
in benign and malignant ACT and showed that ACC had a significantly lower vascular density 
when compared with ACA (Bernini, Moretti et al. 2002). Contrarily, Zhu et al demonstrated that 
vascular density was higher in ACC than in ACA (Zhu, Xu et al. 2014). However, in contrast to 
our study in which the entire tumor tissue available was analyzed using a computerized 
morphometric method which is less prone to bias, all previous studies shared in common the 
use of classical morphometric assessment methods by semi-quantitative hotspot examination 
to assess vascular density that restricts the analysis to representative tumor areas selected at 
the observer discretion.   
 
What have we learned about steroidogenesis in the ACT? 
 
Adrenocortical tumors can be classified according to their biological behavior in benign or 
malignant, and according to their functionality in non-functioning or functioning tumors (Lee 
and Duh 2009). The majority of the ACA are non-functioning and discovered incidentally during 
imaging for unrelated clinical reasons, while the majority of the ACC are functional, with 
Cushing’s syndrome alone being the most frequent clinical presentation among adults (45%) 
(Ng and Libertino 2003, Allolio and Fassnacht 2006, Pignatelli 2011). Although the majority of 
ACC are able of autonomous overproduction of steroids, this is not always clinically apparent 
(Else, Kim et al. 2014). Steroidogenesis in ACC is described to be dysfunctional with a 
predominance of steroids precursor secretion (Grondal, Eriksson et al. 1990, Kikuchi, 
Yanaihara et al. 2000, Arlt, Biehl et al. 2011, Kerkhofs, Kerstens et al. 2015). In this thesis, we 
postulated that this could be due to an incomplete pattern of steroidogenic enzyme expression, 
and this was confirmed through immunohistochemistry analysis of some key enzymes of the 
adrenal steroidogenic cascade (Chapter 4). We have shown that CYP11B1 and 17α-
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Hydroxylase are lower in ACC, justifying the high levels of the precursor metabolites 
tetrahydro-11-deoxycortisol (THS) and pregnanediol observed in the urine of ACC patients as 
previously reported (Gomez-Sanchez, Qi et al. 2014, Midzak and Papadopoulos 2016). 
Our results also suggest that IGF2 has a role in ACT cortisol production, since a significantly 
higher expression of IGF2 was observed in ACAc when compared with ACAn (Chapter 7). 
IGF2 influence in steroidogenesis may be due the activation of the MAPK/ERK pathway 
triggered by IGF2 binding to its receptors, since MAPK/ERK pathway was described to be 
involved in steroidogenesis regulation. This MAPK/ERK role was also confirmed by us since 
phospho-ERK expression was found to be higher in functioning ACT and the in vitro inhibition 
of the MAPK/ERK pathway also led to a decrease in steroids levels (Chapter 8). How is the 
MAPK pathway involved in the steroidogenesis cascade remains a matter of debate, as our 
data does not allows us to discard a putative the role for IGF2 in mediating steroidogenesis in 
ACT presenting with Cushing syndrome, which could occur either through activation of the 
MAPK/ERK pathway or by targeting other steps in the steroidogenesis cascade. However, 
given the lack of correlation found between IGF2 and StAR the former hypothesis arises as 
the most likely one. 
Besides that, lower phospho-p38 levels were observed in cortisol producing ACT compared to 
non-producing ACT (Chapter 8). This is due to the negative correlation between MAPK/p38 
pathway activation and the high levels of StAR gene expression, already described (Manna 
and Stocco 2011, Zaidi, Shen et al. 2014).  
The cortisol producing ACT also showed high density of lymph vessels as displayed by the 
expression of the D2-40 molecular marker, moreover these were correlated with the StAR 
protein expression (Chapter 5). Thus, it could be hypothetically related with the needs of 
cholesterol supplying to the adrenal or effluent distribution of secreted adrenal cortisol from 
functioning tumors.  
 
The two major limitations that are responsible for the poor prognosis in ACC patients are the 
difficulty of identification of malignant tumors at earlier stages and the non-existence of 
effective therapies. Our studies were able to bring novel insights on the ACC pathology and to 
provide translational results that could be useful in the clinical practice to answer some of these 
key problems. We showed that p27, IGF2, CYP11B1 and CYP11B2 can be good markers for 
an accurate diagnosis of ACC that should be differentially used according to ACT functionality. 
In addition, specific cut-off values for each marker were provided whose accuracy should be 
tested by other centers and in larger multicenter tumor series in order to validate our results 
and to render possible the implementation of these tools in the clinical practice. Besides that, 
MAPK/ERK pathway inhibition emerged as a possible target for ACC that if successfully 
achieved could lead to better clinical outcomes than the currently available therapy.  
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The case series in which our studies were performed included a rather small number of tumors, 
yet representative given the relative rarity of ACC. The lack of availability of large tumor series 
to perform studies such as these is a natural consequence of the rarity of these tumors. 
Throughout the world and particularly in Europe a number of research groups dedicated to 
ACT have put together their efforts to increase the numbers of available cases for research 
and especially clinical trials. Portugal has to necessarily follow their examples, overcoming the 
traditional isolated practice of medicine. Some good signs are already identifiable like the 
collaboration between two hospitals, two faculties and I3S in Porto that allowed this study to 
be done up to a conclusion. 
The number of tumors that support our findings is clearly the major limitation to the 
generalization of our results, which could be outreached if confirmed over a large multicenter 
study. Moreover, the unavailability of frozen tumor tissue in the past has further limited our 
studies, since we were not able to perform genetic characterizations to validate some of the 
results obtained by immunohistochemistry or to perform an enlarged profile analysis to identify 
genes that could be involved in ACC pathology. These are the constraints that we hope to 
overcome in the near future, as during the work period of this thesis, ethical approvals for tumor 
bio bank to store frozen and paraffin embedded ACT were requested and granted, so that we 
are now able to increase our local series and participate in large scale and more 
comprehensive studies. To achieve this aim we will rely on several collaborations that have 
now been establishing with other research groups, namely Professor Gavin Vinson at Queen 
Mary (London), Professor André Lacroix from Centre de Recherche du Centre Hospitalier de 
l’Université de Montréal (Canada) and Professor Gomez-Sanchez from University of 
Mississippi Medical Center (USA). In the future and consequently to getting international 
recognition, we expect to be able to include Porto in the multicenter randomized clinical trials, 
some of which are already advanced but some other still being designed, a fact per se may 
improve the prognosis of some (or many) of our patients.  
The existence of a single human adrenocortical carcinoma cell line, the H295R used in our 
studies, represents another limitation to the performance of in vitro studies aiming to disclose 
the role of molecular pathways driving tumor expansion or to test drug response, as despite 
well-established this cancer cell line does not necessarily reflects the in vivo response. To 
overcome this pitfall, we expected to gain access to ACC to carry over primary cell cultures or 
ex-vivo studies during the course of this PhD project, which was not possible to perform in a 
timely manner due to the need to seek for ethical and legal authorizations and due to the rarity 
of the pathology. So, in the near future and now that the necessary conditions have been 
gathered we expect to pursue our studies in order to perform ex-vivo assays using primary 
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patient tumors. Patient-derived xenografts are also very attractive research models, although 
considerably more expensive and time consuming as compared to the ex-vivo assays. 
And at last but not the least, our studies have raised additional questions that we were not yet 
able to answer, such as: What leads to the p27 overexpression in the ACC? What is the role 
of p27 in ACC tumorigenesis? Does IGF2 has a role in the steroidogenesis of ACC? What is 
the role of lymphatics in ACC related steroidogenesis? These are some of the questions that 
most definitely we would like to see clarified in the future to come. And also to create conditions 
to start a clinical trial with an inhibitor of the MAPK pathway. 
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Appendix Table 1 - G1/S phase regulators altered in adrenocortical carcinoma (ACC) compared with 
adrenocortical adenoma (ACA) 
 
 ACC ACA Ref. 
CDK4 
↑ 64.7% cases were 
strongly positive 
↓ 13.6% cases were 
strongly positive 
(Schmitt, 
Saremaslani et al. 
2006) a 
 
Cyclin E 
↑ 2 fold ↓ 2 fold 
(Giordano, Kuick et 
al. 2009) a 
↑ labeling index median 
of 15% 
↓ labeling index median 
of 0% 
(Tissier, Louvel et 
al. 2004) a 
CCNE1 
↑ 10.4 fold ↓ 10.4 fold 
(Giordano, Thomas 
et al. 2003) b 
↑ 3.56 fold ↓ 3.56 fold 
(de Reynies, Assie 
et al. 2009) b 
Cyclin D1 
↑ 1.27% of stained 
area 
↓ 0.1% of stained area 
(Pereira, Morais et 
al. 2013) a 
= 5.4% of positive 
cases 
= 0% of positive cases 
(Stojadinovic, 
Brennan et al. 
2003) a 
CCND1 ↑ 1.5 fold ↓ 1.5 fold 
(Lombardi, Raffaelli 
et al. 2006) b 
p53 
↑ 59% of positive cases ↓ 0% of positive cases 
(Arola, Salmenkivi 
et al. 2000) a 
 
↑ 52.4% of positive 
cases 
 
↓ 11.8% of positive 
cases 
(McNicol, Nolan et 
al. 1997) a 
=  5.4% of positive 
cases 
= 0% of positive cases 
(Stojadinovic, 
Brennan et al. 
2003) a 
= 7.39% of stained 
area 
= 2.99% of stained area 
(Pereira, Morais et 
al. 2013) a 
CDKN1C 
↓ 26.3 % of positive 
cases 
↑ 100.0% of positive 
cases 
(Bourcigaux, 
Gaston et al. 2000) 
c 
p21 
↑ 69.4 % of positive 
cases 
↓ 36.4 % of positive 
cases 
 
(Stojadinovic, 
Brennan et al. 
2003) a 
= 1.59% of stained 
area 
= 1.25% of stained area 
(Pereira, Morais et 
al. 2013) a 
p27 
↓ labeling index 
of 48.9% 
↑ labeling index 
of 59.4% 
(Nakazumi, Sasano 
et al. 1998) a 
↑ 94.4 % of positive 
cases 
↓ 68.8 % of positive 
cases 
(Stojadinovic, 
Brennan et al. 
2003) a 
↑ 9.37 % of stained 
area 
↓ 3.89 % of stained area 
(Pereira, Morais et 
al. 2013) a 
CCNA2 ↑ 3.36 fold ↓ 3.36 fold 
(de Reynies, Assie 
et al. 2009) b 
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CDKN3 
↑ 6.84 fold ↓ 6.84 fold 
(Giordano, Thomas 
et al. 2003) b 
↑ 5.28-fold ↓ 5.28 fold 
(de Reynies, Assie 
et al. 2009) b 
↑ higher than 5-fold ↓ lower that 5-fold 
(Giordano, Kuick et 
al. 2009) b 
↑ 2.69 fold ↓ 2.69 fold 
(Soon, Gill et al. 
2009) b 
E2F ↑ ↓ 
(Tombol, Szabo et 
al. 2009) b 
pRB1 
=  100% of positive 
cases 
=  100% of positive 
cases 
(Vargas, Vargas et 
al. 1997) a 
↓ 13.3% of cases with 
abundant staining 
↑ 73.3% of cases with 
abundant staining 
(Gupta, Shidham et 
al. 2001) a 
c-myc ↓ ↑ 
(Tombol, Szabo et 
al. 2009, Szabo, 
Racz et al. 2011) b 
Smad4 
↑ 92 % of positive 
cases 
↓ 40 % of positive cases 
(Wang, Sun et al. 
2014) a 
Smad3 ↓ ↑ 
(Parviainen, 
Schrade et al. 
2013) a 
 
 ↑- higher; ↓ - lower, = - similar; a Immunohistochemistry analysis; b Genome microarray analysis;  
  c  Northern Blot analysis 
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Appendix Table 2 - G2/M phase regulators altered in adrenocortical carcinoma (ACC) compared with 
adrenocortical adenoma (ACA) 
 
 ACC ACA Ref. 
CDC2 
↑ 7.70 fold ↓ 7.70 fold 
(Giordano, 
Thomas et al. 
2003) b 
↑ higher than 5-fold ↓ lower that 5-fold 
(Giordano, Kuick 
et al. 2009) b 
↑ ↓ 
(Tombol, Szabo 
et al. 2009) b 
↑ 3.76 fold ↓ 3.76 fold 
(Soon, Gill et al. 
2009) b 
↑ 5.85 fold ↓ 5.85 fold 
(de Reynies, 
Assie et al. 2009) 
b 
Cyclin B1 
↑ 43 % of positive 
cases 
↓ 0 % of positive cases 
(Soon, Gill et al. 
2009) a 
CCNB1 
↑ higher than 8-fold ↓ lower than 8-fold 
(Fernandez-
Ranvier, Weng et 
al. 2008) b 
↑ 7.05 fold ↓ 7.05 fold 
(de Reynies, 
Assie et al. 2009) 
b 
↑ ↓ 
(Tombol, Szabo 
et al. 2009) b 
↑ 2.88 fold ↓ 2.88 fold 
(Soon, Gill et al. 
2009) b 
CCNB2 
↑ 8.88 fold ↓ 8.88 fold 
(Giordano, 
Thomas et al. 
2003) b 
↑ higher than 8-fold ↓ lower than 8-fold 
(Fernandez-
Ranvier, Weng et 
al. 2008) b 
↑ 5.61 fold ↓ 5.61 fold 
(de Reynies, 
Assie et al. 2009) 
b 
↑ higher than 14-fold ↓ lower than 14-fold 
(Tombol, Szabo 
et al. 2009) b 
CDC25B ↑ 1.79 fold ↓ 1.79 fold 
(de Reynies, 
Assie et al. 2009) 
b 
CDC25C 
↑ 2.22 fold ↓ 2.22 fold 
(de Reynies, 
Assie et al. 2009) 
b 
↑ ↓ 
(Tombol, Szabo 
et al. 2009) b 
PlK1 ↑ ↓ 
(Tombol, Szabo 
et al. 2009) b 
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RPRM 
↓ 2.33 fold ↑ 2.33 fold 
(Soon, Gill et al. 
2009) b 
= = 
(Tombol, Szabo 
et al. 2009) b 
GADD45 
↑ ↓ 
(Szabo, Tamasi et 
al. 2010) b 
= = 
(Tombol, Szabo 
et al. 2009) b 
WEE1 ↑ 5.49 fold ↓ 5.49 fold 
(Giordano, 
Thomas et al. 
2003) b 
CDK7 ↑ 1.62 fold ↓ 1.62 fold 
(de Reynies, 
Assie et al. 2009) 
b 
TOP2A 
↑ labeling index mean 
of 6.13 
↓ labeling index mean of 
0.72 
(Iino, Sasano et 
al. 1997) a 
↑ labeling index mean 
of 37.5 
↓ labeling index mean of 
1.4 
(Gupta, Shidham 
et al. 2001) a 
↑ ↓ 
(Jain, Zhang et al. 
2013) a 
↑ ↓ 
(Ip, Pang et al. 
2015) a 
TOP2A 
↑ 6.86 fold ↓ 6.86 fold 
(Giordano, 
Thomas et al. 
2003) b 
↑ higher than 5-fold ↓ lower that 5-fold 
(Giordano, Kuick 
et al. 2009) b 
↑  3.54 fold ↓ 3.54 fold 
(de Reynies, 
Assie et al. 2009) 
b 
↑ higher than 9-fold ↓ lower that 9-fold 
(Tombol, Szabo 
et al. 2009) b 
↑ ↓ 
(Jain, Zhang et al. 
2013) c 
 
↑- higher; ↓ - lower, = - similar; a Immunohistochemistry analysis; b Genome microarray analysis; c Real-
time quantitative RT-PCR 
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Appendix Table 3- SAC regulators altered in adrenocortical carcinoma (ACC) compared with 
adrenocortical adenoma (ACA) 
 
 
 ACC ACA Ref. 
BUB1 ↑ 2.19 fold ↓ 2.19 fold 
(de Reynies, 
Assie et al. 2009) 
b 
BUB1B ↑ 2.47 fold ↓ 2.47 fold 
(de Reynies, 
Assie et al. 2009) 
b 
MAD2L1 
↑ 74% of positive 
cases 
↓ 5% of positive cases 
(Soon, Gill et al. 
2009) a 
MAD2L1 ↑ 3.28 fold ↓ 3.28 fold 
(Soon, Gill et al. 
2009) b 
 
  ↑- higher; ↓ - lower, = - similar; a Immunohistochemistry analysis; b Genome microarray analysis 
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